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Diabetic nephropathy is characterised. by increased glomerular penneability 
to protein and mesangial matrix deposition. Haemodynamic abnormalities are 
important in the pathogenesis of the kidney damage and strategies that reduce 
glornerular capillary pressure have potent reno-protective and anti-proteinuric 
effects. The haemodynamic insult can be mimicked in vitro by subjecting mesangial 
cells to mechanical stretch. In this work I have studied the effect of human mesangial 
cell stretching on: a) the production of extracellular matrix molecules b) the 
expression of potentially deleterious cytokines, membrane receptors, and 
transporters, c) the activity intracellular signalling molecules. 
The realisation. of this research has required the setting up of various 
techniques such as isolation of glomeruli from nephrectomy specimens, culture and I 
stretching of human mesangial cells in vitro, direct and indirect 
immunofluorescence, RNA and protein extraction, competitive RT-PCR, Western 
Blotting and in vitro kinase assay. 
Relevant findings from my work include: 1) stretch induces Vascular 
Endothelial Growth Factor (VEGF) gene expression and protein secretion in human 
mesangial cells via a Protein Kinase C (PKQ- and Src-dependent mechanism, 2) 
angiotensin II induces VEGF expression in human mesangial cells and stretch 
enhances the VEGF response to angiotensin 11,3) Insulin Growth Factor-I induces 
VEGF gene expression and protein secretion, 4) stretch induces expression of 
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fibronectin, Transforming Growth Factor (TGF)-Pl, and TGF-P type II receptor in 
human mesangial cells 5) stretch-induced fibronectin and TGF-01 production in 
human mesangial cells is p38 Mitogen Activated Protein Kinase-dependent. 6) the 
haernodynamic stress induces upregulation of the GLUT-I glucose transporter both 
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Diabetic nephropathy, a chronic complication of diabetes that affects around 
30% of diabetic patients, is the commonest cause of renal replacement therapy in the 
Western World and is associated with an increased risk for cardiovascular disease. 
Both increased glomerular permeability to protein and mesangial matrix 
expansion, due to an excess of matrix component deposition, are characteristic 
features of the disease. 
Both metabolic and haernodynamic abnormalities have been implicated in the 
pathogenesis of this complication and increasing evidence suggests a pivotal role of 
cytokines in translating these external noxae in the specific functional and structural 
abnormalities seen in the diabetic kidney. 
1.1. Epidemiology of Diabetic Nephropathy 
The annual incidence of end stage renal disease (ESRD) has increased 
worldwide and diabetic nephropathy has become the most common single cause of 
ESRD in the United States and Europe. This is due to various factors: increase 
prevalence of type 2 diabetes, longer survival of diabetic patients, and less restrictive 
criteria for including diabetic patient in ESRD treatment programmes (1 -5). 
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Between 1982 and 1992, the number of patients with diabetic ESRD rose 
from 27 % to 36 % in the United States and from II% to 17 % in Europe (3). More 
recent data indicate that in the United States diabetic nephropathy accounts for about 
44% of new cases of ESRD (5). Furthermore, there has been a remarkable increase 
in diabetes-related ESRD in countries that previously had a relatively low incidence 
of the disease (3). 
About 20-30% of patients with diabetes develop evidence of nephropathy, 
but in type 2 diabetes, a considerably smaller proportion of these patients progress to 
ESRD. However, because of the much greater prevalence of type 2 diabetes, such 
patients constitute about 43% of the patients entering renal replacement treatment 
(RRT) programs in Europe and 80% in the Unites States. There is, however, 
considerable racial/ethnic variability in this regard, with Native Americans, 
Hispanics (especially Mexican-Americans), and African-Americans having much 
higher risks of developing ESRD than non-Hispanic whites with type 2 diabetes. 
Furthermore, it has to be taken into account that a significant proportion of type 2 
diabetic patients develop ESRD for causes other than diabetes, while ESRD is 
almost exclusively due to diabetic nephropathy in type I diabetic subjects. Both the 
increased prevalence of type 2 diabetes in the general population and the improved 
survival of type 2 diabetic patients, mainly due to better antihypertensive and 
coronary heart disease treatment, have contributed to increase the number of type 2 
diabetic patients progressing to ESRD (2-5). 
The prognosis of patients who have diabetes and are receiving RRT has 
greatly improved in the last decade. Nevertheless survival and medical rehabilitation 
17 
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rates continue to be significantly worse than those of nondiabetic patients, mainly 
because of pre-existing severely compromised cardiovascular conditions (2,3). 
Treating kidney failure by dialysis or transplantation is expensive. The 
average annual Medicare payment for ESRD with diabetes as primary cause has 
been reported to be $63,100 per patient. In 1999,350,000 individuals in the United 
States suffered from ESRD and the Medicare ESRD program incurred $12.7 billion 
in costs. This cost is expected to increase to $28 billion a year by 2010 (2,6-8). 
1.2 Natural History and Clinical Course of Diabetic Nephropathy 
An increase in the glomerular filtration rate (GFR) of up to 15% rapidly 
develops after the onset of hyperglycaemia in diabetic patients. The mechanisms 
involved in increasing GFR involve glucose-dependent effects on arteriolar 
dilatation, mediated by a range of vasoactive factors and cytokines. Experimentally, 
this hyperfiltration is secondary to afferent arteriolar dilatation. Therefore, 
glomerular hyperfiltration appears to be a haemodynamic renal abnormality related 
to hyperglycaemia rather than an early predictor for the future development of 
diabetic nephropathy (1,2). 
The earliest clinical evidence of nephropathy is the appearance of low, but 
abnormal, levels of albumin in the urine (albumin excretion rate AER 30 mg/day or 
20 pg/min), referred to as microalbuminuria (2). Transition from normo- to micro- 
albuminuria is seen in 2-4% of cases per year and is associated with poor metabolic 
control, initial AER in the upper normal range, elevated blood pressure, and, in some 
series, elevated total cholesterol and smoking (2,9-11). The prevalence of 
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microalbuminuria is 16-22% in type I diabetes and 3040% in type 2 diabetes, 
respectively. Several longitudinal studies have demonstrated that diabetic patients 
with microalburninuria are at high risk of developing clinical nephropathy with a 
yearly AER percentage increase of about 10-20%, markedly affected by systemic 
blood pressure levels (I 1- 14). 
Several abnormalities have been documented in diabetic patients with 
microalbuminuria: the GFR is often elevated above nonnal (9), blood pressure levels 
are 10-15% higher than in control subjects and norynoalbuminuric patients (15,16), 
and diabetic retinopathy as well as other chronic diabetic complications are more 
common than in normoalbuminuric subjects (2). The increased glomerular 
permeability to albumin mirrors a widespread enhancement in vascular permeability 
to proteins (17,18) and this may contribute to explain the increased risk for 
cardiovascular disease associated to microalbuminuria (19). An increased AER is 
associated with 24-fold increases in both cardiovascular and all-cause mortality 
independently of other risk factors, such as hypertension, dyslipidaemia, and 
smoking, and the relationship between AER and cardiovascular risk is linear (20). 
Progression to overt nephropathy or clinical albuminuria (200 pg/min or 300 
mg/24 hours) characteristically occurs over a period of years with the development 
of heavier proteinuria, hypertension, and subsequent fall in GFR (9). The 
progression rate of diabetic nephropathy has a high interindividual variability and is 
affected by intervention, most notably reduction of blood pressure and inhibition of 
the renin angiotensin system (1,11,2 1). 
19 
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1.3 Structural and Biochemical Abnormalities in Diabetic Nephropathy 
Both glomerular and kidney hypertrophy are structural renal abnormalities 
that develop early after the onset of diabetes and in parallel with the rise in the GFR. 
The increase in renal size results primarily from renal hypertrophy. An increase in 
mesangial cell number has been reported in both human and experimental diabetic 
nephropathy, but hyperglycaeniia-induced hypertrophy appears to be the 
predominant mechanism of both tubular and renal enlargement (22). 
1.3.1 Diabetic Glomerulopath 
Glornerulopathy, characterised by thickening of the glornerular basement 
membrane (GBM) and mesangial matrix expansion, is the most important renal 
structural change in type I diabetic patients with diabetic nephropathy (23). The 
histology of advanced diabetic glomerulopathy consists of either diff-use or nodular 
glomerulosclerosis. The diff-use lesion is a uniform widening of the mesangial 
regions. As the volume of the mesangial matrix increases, some mesangial regions 
become more prominent than others and may take on the globular shape of the 
periodic acid-Schiff (PAS)-positive nodular lesions pathognomonic of the disease 
(Kimmelsteil-Wilson). Several nodules can be present in each glomerulus, usually 
distributed in the peripheral areas. Small nodules contain evenly distributed 
mesangial. cells; in medium-sized or large nodules the central areas are almost a- 
cellular, while the periphery contains either one or few layers of mesangial cells 
(24). 
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The progressive accumulation of matrix in the mesangial areas and the 
associated encroachment on neighbouring capillaries with loss of filtration surface 
areas is considered as the main structural lesion responsible for the relentless decline 
in glomerular function. Accordingly, mesangial fractional volume [Vv(mes/glom)], 
an estimate of mesangial expansion, is the structural parameter that best correlates 
with GFR and it is also closely related to the presence of proteinuria and 
hypertension (23,25). In a study on sequential renal biopsies of type I diabetic 
patients perfonned 5 years apart, the only structural change associated with 
increasing albinninuria was mesangial expansion; whereas GMB width, interstitial 
expansion and the number of globally sclerotic glomeruli did not change over 5 
years in this group of patients, several of whom were studied while in transition from 
normo to microalburninuria or from micro to macroalbuminuria (26). 
In type 2 diabetes, glomerular structural parameters are also altered, but 
glomerular lesions are more heterogeneous than in type I diabetes and only a subset 
of type 2 diabetic patients has typical diabetic glornerulopathy. A substantial 
proportion of type 2 diabetic patients has more advanced tubulo-interstitial and 
vascular rather than glomerular lesions and several patients have normal glomerular 
structure despite the development of persistent microalbuminuria or proteinuria. 
Furthermore, the relation between mesangial expansion and renal function, although 
significant, is less precise than in type I diabetes (23). 
Both mesangial matrix expansion and enhanced GBM thickness are present 
in diabetic patients with microalbuminuria (27-30). An abnonnal deposition of 
extracellular matrix components is, thus, a characteristic feature of an early stage of 
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the disease. The GBM is composed of a filamentous network of collagen type IV 
fibrils, structural glycoproteins, such as laminin and fibronectin, and heparan 
sulphate proteoglycan (HSPG). Mesangial matrix contains essentially the same 
components but in different distributions. In addition, collagen type IV a I, a2 chains 
are primarily detected in the mesangial matrix, whereas the a3, a4 chains are 
exclusively found in the GBM (29). A glomerular increase in fibronectin, laminin, 
collagen (type IV and VI) and a reduction in HSPG have been demonstrated in both 
human and experimental diabetic nephropathy (31,32). In diffuse glomerulosclerosis, 
an increased in the normal extracellular matrix components, such as laminin and 
collagen. (IV), and a reduction in HSPG is observed in both the GMB and the 
mesangial area. In contrast, in nodular glornerulosclerosis there is a marked 
reduction in laminin, HSPG, collagen IV (al, a2) and an increase in fibronectin and 
other types of collagen (111, VI, IV a3, a4). Nodules consist mostly of type VI 
collagen and their peripheral areas are positive for collagen type 111, which is not 
detected in earlier lesions. In the GMB, laminin and collagen type IV are increased, 
while HSPG is reduced (31,32). 
Studies performed in both diabetic animals and patients at various stages of 
diabetic nephropathy have clarified that extracellular matrix accumulation results 
from both increased synthesis and reduced degradation of extracellular matrix 
components. Gene expression and protein secretion of collagen type IV, laminin (B I 
and B2), and fibronectin are significantly enhanced in the diabetic kidney. This is 
associated with a decreased degradation of matrix components (32-34). Mesangial 
cells are the glomerular cell type responsible for the doubling in collagen al(IV) 
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messenger ribonucleic acid (mRNA) levels as shown by in situ hybridisation in rats 
with long duration of diabetes (35). 
1.3.2 Podo! ayes Abnormalities 
The glomerular filtration barrier comprises capillary endothelium; glomerular 
basement membrane; and specialised visceral epithelial cells, the podocytes, which 
are located on the outer surface of the barrier (36). The observation that diabetic 
glornerulopathy accounts for only 30-50% of the variability in AER and GFR, has 
suggested that other factors may be involved (37). Podocytes play a key role in the 
maintenance of the glomerular size-selective filtration barrier and podocyte structure 
abnormalities are present in several proteinuric; glomerular diseases (36,38). This has 
led to the hypothesis that podocytes may be implicated in the pathogenesis of 
diabetic proteinuria. 
In Pima Indians with type 2 diabetes and overt nephropathy there is a 
decrease in the number of podocytes per glomerulus as well as a broadening of the 
podocyte foot processes (39). Furthermore, longitudinal studies suggest that both 
podocytopcnia and podocyte damage may contribute to the progression of diabetic 
nephropathy in these subjects (40). Studies in Caucasian type 2 diabetic patients with 
early diabetic nephropathy show abnormalities in both podocyte structure and 
density that correlate with AER (37,41,42). Finally, podocyte loss and structural 
abnonnalities have also been reported in type I diabetic patients with overt 





Podocytes have limited capacity to replicate. Studies in rats with reduced 
nephron number and glomerular hypertrophy have demonstrated that podocytes 
suffer progressive injury in the attempt to cover a larger surface area and this results 
in foot process widening, proteinuria and subsequently glomerular sclerosis (45). 
Similarly, in diabetic nephropathy, loss of podocytes may lead to an expansion of 
foot processes in the remaining podocytes, which, in turn, widens the filtration slit 
diaphragm with consequent development of proteinuria. In addition, expansion of 
foot processes may reduce their ability to anchor to the GBM, with consequent 
formation of areas of bare GBM, which are potential starting points for 
glomerulosclerosis (41,42). 
The slit diaphragm between the podocyte foot processes contains, among 
others, a protein, named nephrin, whose absence causes the development of 
proteinuria in the congenital nephrotic syndrome of the Finnish type (46). The link 
between alterations in nephrin expression and proteinuria has been shown in animal 
models by using neutralizing antibodies or studying mice with inactivation of the 
nephrin gene. Moreover, the expression of nephrin is reduced in various animal 
models of proteinuric renal disease, including diabetic nephropathy (46). Human 
studies, in both type I and type 2 diabetes, show down-regulation of nephrin 
expression in the diabetic kidney. In experimental diabetes, there is a reduction in 
nephrin expression associated with increasing proteinuria. In vitro, angiotensin II 
induces a rapid reduction in the expression of nephrin. In vivo both angiotensin 11 
receptor antagonists and angiotensin converting enzyme (ACE)-inhibitors normalise 
the reduced nephrin expression that occurs in diabetes (46-48) and the 
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antiproteinuric effects of ACE inhibition may partially relate to the effects of these 
agents on nephrin expression (47). 
. 
1.3.3 Tubulo-interstitium Patho 
The most important structural changes of diabetic kidney disease occur in the 
glomeruli, however arterioles, tubules, and interstitium. also develop morphological 
alterations. Pathological changes that have been described in association with 
diabetic nephropathy include thickening of the tubular basement membrane (TBM), 
tubular atrophy, interstitial fibrosis, and arteriosclerosis (23). 
In both type I and type 2 diabetes interstitial volwne expansion correlates 
closely with the magnitude of renal dysfunction, albuminuria and mesangial. 
enlargement (49-52). In contrast, the relationship between TBM width and kidney 
function is uncertain and changes in TBM appear to reflect glycaernic exposure 
rather than evolving nephropathy (53). The biochemical abnormalities underlying 
the expansion of the interstitial volume in humans are poorly known, but studies in 
experimental diabetes have demonstrated both type IV collagen overexpression in 
the proximal tubule (53) and appearance of non-classic collagen chains in the 
interstitium (54,55). 
Excessive protein overload is believed to be the major determinant of the 
tubulo-interstitial damage. Specifically, the excessive tubular reabsorption of 
proteins and the consequent accumulation of proteins in tubular epithelial cells 
induce the release of vasoactive and inflammatory cytokines, such as endothelin-1, 
osteopontin, and macrophage chernotactic protein-1, triggering inflammatory/fibrotic 
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cytokine overexpression, mononuclear cell infiltration, and ultimately 
tubulointerstitial injury with renal scarring and insufficiency. A vicious cycle is then 
established in which changes in renal haemodynamics, either primitive or in 
response to nephron loss, induce ftu-ther proteinuria perpetuating a mechanism of 
interstitial scarring and loss of more nephrons (56). Accordingly, proteinuria is a 
strong and independent predictor of renal function decline in diabetic and other 
progressive glornerulopathies (57). 
In addition, the tubulointerstitial pathology may be not simply an aftermath 
of glomerular injury, but tubular cells may be primary targets for diabetes-related 
noxae. Indeed, in diabetes, perturbations in glucose-dependent metabolic pathways 
and vasoactive hormone systems may directly influence both tubular and interstitial 
cell behaviour and ultimately lead to interstitial fibrosis and rcnal dysfunction caused 
by glomerular independent mechanisms (59). Accordingly to this hypothesis, in 
some studies a predominant tubulointerstitial disease is the most common 
histological pattern in type 2 diabetic patients (58) and, in multivariate analysis, 
interstitial and mesangial expansion appear to be independent and additive 
determinants of renal function (50). 
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1.4 Pathogenesis of Diabetic Nephropathy 
1.4.1 The Role of Genetic Factors 
'Me abnormal glycaemic milieu of diabetes closely relates with the 
development of microvascular complications. However, in humans the evidence of a 
straightforward causal relationship between hyperglycaernia and renal disease is less 
compelling than in animal models. The development of clinically overt nephropathy 
affects only about 30% of patients (1). The majority of subjects with diabetes 
escapes renal failure, and although some histological damage occurs in their kidneys, 
their renal function remains essentially normal until death. Therefore, in humans 
hyperglycaemia. is necessary, but not sufficient to cause the renal damage in 
diabetes. The risk of developing kidney disease is not linearly correlated to the 
duration of diabetes, the incidence peaks after 17 years of type I diabetes and then 
sharply declines, a phenomenon likely due to exhaustion of the subgroup of 
susceptible subjects (1). It thus appears that some diabetic patients are susceptible to, 
while others are protected from renal disease. A diabetic sibling of a person with 
type I diabetes and nephropathy has approximately a 72% cumulative risk of 
developing renal disease, whereas a diabetic sibling of a person with type I diabetes 
but without nephropathy only has a 25% risk (60). In type 2 diabetic patients the 
evidence of a genetically determined susceptibility to develop diabetic nephropathy 
is less compelling than in type I diabetes. However, there is evidence of a familial 
clustering of diabetic nephropathy in type 2 diabetes (60-63) and affected sib-pair 
linkage analyses have identified loci associated with diabetic nephropathy in type 2 
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diabetes (64-66). Altogether these data indicate that inherited factors play an 
important role in determining susceptibility to diabetic nephropathy. 
A considerable effort has been invested in clarifying potential genetic 
markers, both for those with nephropathy and those who escape the complication 
using both candidate gene and whole genome approach. Polymorphisms of several 
genes, potentially involved in the genetic predisposition to diabetic nephropathy, 
have been investigated. However, most studies of candidate genes have been by and 
large inconclusive or have only shown weak associations (67-71). A strong 
association between a polymorphism in the 5'-end of the aldose reductase gene and 
the development of diabetic nephropathy has been reported (72). This association 
has been replicated in patients with either type I or type 2 diabetes as well as across 
ethnic groups (73). Overall the genes responsible for diabetic nephropathy as well 
their interaction with other genes and the environment currently represents an area of 
uncertainty. 
1.4.2 The Role ofHypeMlycaem 
Poor glycaemic control is associated with the development of diabetic 
nephropathy (74,75). Primary prevention studies have demonstrated the 
renoprotective effect of an optimum glycaemic control in both human (76-78) and 
experimental diabetes (79-81). Of interest, in a small study in 8 type I diabetic 
patients, pancreas transplantation and near normoglycaemia for ten years reverted 
kidney structural abnormalities (82). 
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Some of the mechanisms that link hyperglycaemia to the functional/structural 
abnormalities of diabetic kidney disease have been elucidated. Within the cells high 
glucose can react nonenzimatically with primary arnines of proteins, forming 
glycated compounds; it can exert direct toxic effects by altering intracellular 
signalling pathways; finally it can be metabolised either to sorbitol via the polyol 
pathway or to glucosamine via the hcxosamine biosynthetic pathway. These four 
pathways are believed to be important in hyperglycaemia-induced cellular damage. 
Recent studies suggest that increased production of superoxide by the mitochondrial 
electron transport chain is the unifying mechanism that integrates the above 
pathways of hyperglycaemia-induced cell damage. 
1.4.2.1 Nonenzymatic Glycosylation 
Sustained hyperglycaernia leads to non-enzymatic protein glycation, a post- 
translation modification that occurs physiologically, but is greatly enhanced in 
hyperglycaernic conditions. Glycation results from condensation of reducing sugars 
with c-amino groups of lysine residue of proteins. The resulting Schiff base 
undergoes rearrangement to fonn relatively stable ketoamines, the Amadori 
products. These glycated proteins undergo progressive dehydratation, cyclization, 
and rearrangement to form advanced glycation end products (AGEs). Once formed, 
the reaction is not reversible, and it gradually accumulates over the lifetime of the 
protein (83). AGEs were originally thought to arise from non-enzymatic reactions 
between extracellular proteins and glucose. However, the rate of AGEs formation 
from glucose is orders of magnitude slower than the rate of AGEs formation from 
29 
CHAPTER I INTRODUCTION 
-b- -- - -- __w 
glucose-derived dicarbonyl precursors generated intracellularly, and it now seems 
likely that intracellular hyperglycaemia is the primary initiating event in the 
fonnation of both intracellular and extracellular AGEs (84) 
The hypothesis that AGEs are involved in diabetic kidney disease is based on 
several observations. In both human and experimental diabetes, AGEs accumulate in 
renal glomeruli and tubuli. This phenomenon is specific, as it does not occur in 
non-nal kidneys or in kidneys from patients with glomerulonephritis and without 
diabetes (85). In normal animals, injection of AGEs-modified albumin results in 
matrix molecule overexpression, albuminuria and glomerulosclerosis (86). In 
diabetic animals, AGEs accumulation in the kidney is paralleled by the development 
of albuminuria, mesangial expansion, and glomerular basement membrane 
thickening. Furthermore, administration of arninoguanidine (AGN), an AGEs 
fon-nation inhibitor, attenuates renal AGEs accumulation and reduces both 
albuminuria, and mesangial expansion (87). 
Production of intracellular AGEs precursors damages target cells by three 
general mechanisms. Firstly, intracellular proteins modified by AGEs have altered 
function. Secondly, extracellular matrix components modified by AGEs precursors 
interact abnormally with other matrix components and with the receptors for matrix 
proteins (integrins) on cells. Thirdly, plasma proteins modified by AGEs precursors 
bind to AGEs receptors on mesangial cells inducing receptor-mediated deleterious 
effects (84). 
AGEs directly alter the structural and functional properties of extracellular 
matrix proteins. AGEs-mediated protein cross-linking increases matrix rigidity, 
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reduces susceptibility of protein to enzymatic digestion, thus inducing accumulation 
and thickening, and favours trapping of plasma proteins, such as LDL and IgG. 
AGN normalises the defect in matrix degradation that occurs when matrix is 
incubated in a high glucose medium, suggesting that the AGN effect in preventing 
mesangial expansion, is in part due to its capacity to normalise mesangial matrix 
digestion (88). In addition, AGEs can elicit a variety of cellular responses by binding 
to AGEs-specific receptors present on many cell types, including mesangial cells 
(89). Interaction of AGEs-modified proteins with the AGEs receptors serves to clear 
AGEs-proteins, but also induces the synthesis and release of deleterious cytokines 
and results in enhanced collagen, laminin and fibronectin production (90-92). The 
importance of AGEs receptors has been recently underpinned by the observation that 
diabetic animals overexpressing the AGEs receptor RAGE rapidly develop 
glomerular lesions similar to those seen in advanced diabetic nephropathy (93). The 
AGEs receptors are also expressed on tubular epithelial cells and it has been recently 
reported that RAGE activation can induce tubular epithelial cell trans-differentiation 
to myofibroblasts, a key event in the development of tubulointerstitial fibrosis (94). 
Although AGN reduces both albuminuria and mesangial expansion in 
diabetic animals (87), data from clinical studies in humans have been less convincing 
and have raised safety issues. Recently, a new class of compounds that cleaves 
AGEs-derived protein cross-link have been synthesised (95). Phenacylthiazolium 
bromide and other members of this family revert AGEs-mediated tissue damage and 
are effective in diabetic animals (96,97), however, their role in human disease is yet 
to be explored. 
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1.4.2.2. The Polyol Pathway 
In the polyol pathway, glucose is reduced to sorbitol by the enzyme aldose 
reductase. In many tissues, the physiologic significance of aldose reductase is 
difficult to define, but in the renal medullary cells, its primary role seems to be the 
formation of sorbitol, an organic osmolyte, in response to the high salinity in the 
medullary interstitium. 
It has been argued that, in tissues in which glucose entry into cells is insulin- 
independent, more glucose becomes available for reduction by aldose reductase, 
resulting in an increased concentration of sorbitol and/or a reduced intracellular 
concentration of myoinositol. These changes might contribute to diabetic 
complications, via an upset of cellular osmoregulation (98,99). 
Enhanced polyol pathway activity has been dernonstrated in diabetic 
glomeruli in humans (100). However, the initial hypothesis that sorbitol 
accumulation and myoinositol reduction cause tissue damage is unlikely to operate 
in the kidney, because compensatory mechanisms prevent inositol depletion in 
kidney cells (10 1). 
Enhanced AGEs production and oxidative stress have been more recently 
proposed as alternative mechanisms linking the polyol pathway to kidney injury in 
diabetes. In the polyol pathway, excess sorbitol is oxidated to fructose by the enzyme 
fructose dehydrogenase, a process that increases the ratio of nicotinarnide adenine 
dinucleotide/ nicotinamide adenine dinucleotide reduced (NADHNAD) and may 
result in cellular oxidative stress. In addition, fructose is a reactive sugar that can 
lead to AGEs produetion (102,103). 
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A series of studies of aldose reductase inhibitors (ARI) have, however, 
produced inconclusive results in both experimental and human diabetes (104). 
1.4.2.3 The Hexosamine Biosynthetic Pathway 
Approximately 5% of glucose entering the cell is metabolised via the 
hexosamine biosynthetic pathway (HBSP), which converts glucose 6 phosphate into 
hexosamine 6 phosphate. Glutamine: fructose-6-phosphate-amidotransferase 
(GFAT) is the first and the rate-limiting enzyme of this pathway. In both mesangial 
cells and fibroblasts GFAT overexpression, which increases the flux through the 
HBSP, leads to enhanced transforming growth factor-b (TGF-0), plasminogen 
activator inhibitor-I (PAI-1), and fibronectin expression (105,106). Furthermore, 
high glucose-induced TGF-01 and matrix production appear, at least in part, 
mediated by the HBSP because they are significantly reduced by the GFAT inhibitor 
azaserine (107). The mechanism by which increased flux through the HBSP 
mediates hyperglycaemia-induced increases in gene transcription is uncertain. The 
observation in mesangial cells that binding sites for the transcription factor SpI 
regulate hyperglycaemia-induced PAM promoter activation suggests that covalent 
modification of SpI by N-acetylglucosamine (GIcNAc) might provide a potential 
link between HBSP and hyperglycaernia-induced PAM overexpression. 
Accordingly, it is known that the glycosylated form of SpI is more transcriptionally 
active than the deglycosylated form. In addition to transcription factors, many other 
nuclear and cytoplasmic proteins, including protein kinase C (PKC) and endothelial 
nitric oxide synthase (eNOS), are dynamically modified by O-linked GlcNAc, and 
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may show reciprocal modification by phosphorylation in a manner analogous to Spl. 
Thus, activation of the HBSP by hyperglycaemia may result in many changes in both 
gene expression and protein function, which together contribute to the pathogenesis 
of diabetic complications (84). 
Very low level of expression of GFAT is usually found in glomerular cells, 
but this is significantly enhanced in glomerular cells from patients with diabetic 
nephropathy (108), suggesting a potential in vivo relevance of the in vitro findings. 
Both high glucose and angiotensin II activates the GFAT promoter in mesangial 
cells (109) and this provides a potential molecular mechanism of GFAT 
overexpression in the diabetic glomeruli. 
1.4.2 4 Glucotoxicity 
There is also evidence of a direct link between hyperglycaemia and 
functional/structural abnormalities seen in diabetic glomerulopathy. In vitro studies 
have shown the high glucose concentrations in the milieu can directly affect cell 
proliferation and protein synthesis (110). In mesangial cells, high glucose induces 
cell hypertrophy and increases both gene expression and protein secretion of 
extracellular matrix components, such as collagen, larninin and fibronectin (I 11). 
Similarly, type IV and I collagen mRNA levels are enhanced in tubular epithelial 
cells exposed to high glucose (59). A further mechanism whereby high glucose leads 
to exaggerated matrix deposition is by reducing the activity of metallo-Proteases, 
enzymes responsible for extracellular matrix degradation. In rat mesangial cells 
exposed to high glucose the production of the metallo-proteinase 2 (MMP-2) is 
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increased and that of its inhibitor, tissue inhibitor of metallo-proteinase-2 (TIMP-2), 
is reduced, resulting in reduced matrix demolition (112). 
Renal cells, similar to cells at other sites of diabetic complications, do not 
have an absolute requirement of insulin for glucose uptake, so that the intracellular 
glucose level more directly reflects its plasma concentration. The importance of 
excess glucose entry into mesangial cells is underscored by the observation that 
glucose-induced effects can be mimicked in normal glucose concentrations by over- 
expressing the cellular glucose transporter, GLUT-1, thus increasing basal glucose 
uptake (113). This finding also indicates that factors regulating glucose transporter 
expression and/or activity can influence glucose uptake and thus glucotoxicity. 
High glucose would be expected to reduce glucose transporter 
expression/activity in order to protect cell from excess glucose entry. However, in 
vitro studies on cultured mesangial cells show that exposure to elevated glucose 
concentration actually enhances mesangial cell GLUT-1 expression triggering a 
positive feed-back mechanism, that may result in progressive damage (114). 
Inhibition of GLUT-1 overexpression prevents extracellular matrix molecule 
overproduction in mesangial cells exposed to high glucose (115), providing evidence 
of a key role of GLUT-I in glucotoxicity. The cellular mediators and intracellular 
signalling molecules, whereby high glucose can lead to renal cell damage, have been 
extensively studied and reviewed (104) in the last ten years, and will be briefly 
described below (1.4.3 and 1.4.4). 
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1.4.2 5A Unifying Mechanism: The Oxidative Stress 
Increased production of reactive oxygen species (ROS), specifically 
superoxide, by the mitochondrial electron transport chain (METC) has been recently 
proposed as the unifying mechanism that integrates the pathways of hyperglycaemia- 
induced cell damage (84). 
Hypcrglycaemia-induced formation of the electron donors, such as NADH 
and flavin adenine dinucleotide reduced (FADH2), generates a high mitochondrial 
membrane potential by pumping protons across the mitochondrial inner membrane. 
When the mitochondrial membrane potential is high, the lifetime of superoxide- 
generating electrontransport intermediates is prolonged and the production of 
superoxide increased. Blockade of this sequence of events prevents hyperglycaernia- 
induced overproduction of ROS, demonstrating that the METC is the predominant 
mechanism of hyperglycaernia-induced oxidative stress (84). 
Superoxide overproduction induces poly(ADP-ribose) polymerase (PARP) 
activation, which in turn reduces the activity of the enzyme glyceraldehyde 3- 
phosphate dehydrogenase (GAPDI-D. Reduced GAPDH activity results in 
accumulation of glycolytic metabolites upstream of GAPDH with enhanced flux 
through alternative metabolic pathways. Specifically, increased glucose levels 
enhance the flux through the polyol pathway; enhanced triose phosphate levels lead 
to formation of AGEs; de novo synthesis of diacylglycerol (DAG) results in 
activation of intracellular signalling pathways (e. g. PKC); finally elevated fructose- 
6-phosphate levels augment the flux through the HBSP. Blockade of either 
superoxide overproduction or PARP prevents the activation of these four pathways 
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of hyperglycaemia-induced damage. This suggests that hyperglycaemia-induced 
overproduction of superoxide activates the major pathways of hyperglycaemic 
damage by inhibiting GAPDH activity and that superoxide overproduction is the 
common element linking these pathways (84,116). 
These findings are also highly relevant in diabetic kidney disease. 
Overexpression of superoxide dismutase (SOD), which blocks the production of 
superoxide, suppresses high glucose-induced collagen overexpression in vitro in 
mesangial cells. Furthermore, in vivo in diabetic mice it attenuates albuminuria, 
glomerular hypertrophy, mesangial matrix expansion, and expression of both TGF-P 
and collagen (84). 
1.4.3 The Role of Cytokines 
Increasing evidence suggests that cytokines play a pivotal role in translating 
the metabolic insult of hyperglycaemia in the specific structural and functional 
abnormalities seen in diabetic glomerulopathy. Numerous cytokines have biological 
functions potentially relevant in the pathogenesis of diabetic nephropathy and have 
been proposed as potential candidates. 
1.4.3.1 Transforming Growth Factor-fil 
Transforming Growth Factor-O (TGF-0) is a ubiquitous cytokine that 
regulates a variety of cellular processes. It exists in three isoforms, TGF-Pl, TGF-02 
and TGF-P3, of which TGF-PI is the best characterised and most highly expressed in 
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the kidney. Glomerular and proximal tubular cells produce TGF-01 and express both 
type I and type II TGF-P receptors, which bind to all TGF-P isoforms (117,118). The 
type I and 11 signalling receptors have a long cytoplasmatic transducing region with a 
serine/threonine kinase domain, while the type III receptor lacks an intrinsic signal 
transduction activity, but appears to function mostly to enhance the affinity of TGF- 
0 to the type 11 receptor (118). Smad proteins are critical intracellular mediators of 
TGF-P signalling. TGF-01 binding to the TGF-P receptors induces both Smad2 and 
Smad3 phosphorylation. Once activated, Smad2 and Smad3 are translocated by 
Smad4 into the nucleus, where they regulate target gene transcription. Conversely, 
Smad6 and Smad7 exert a negative feedback control over the action of TGF-P (119). 
TGF-01 has important prosclerotic properties and is a potent inducer of cell 
hypertrophy and apoptosis. In vitro both glomerular cells and tubular epithelial cells 
increase their synthesis of collagen, fibronectin and larninin in response to TGF-Pl. 
Furthermore, TGF-01 inhibits the synthesis of collagenases and stimulates 
production of metalloprotease inhibitors. This results in reduced extracellular matrix 
degradation and further contributes to matrix accumulation (118). In vivo TGF-P I 
induces glomerulosclerosis and proteinuria in healthy animals. Specifically, 
administration of high doses of recombinant human TGF-01 results in excessive 
fibrosis in the kidney of normal rats and rabbits (120). Transient transfection of 
TGF-01 complementary deoxyribose nucleic acid (cDNA) into the rat renal artery 
promotes extracellular matrix accumulation in the glomerulus (121), and transgenic 
mice having high levels of mature TGF-01 into the circulation develop mesangial 
expansion and proteinuria (122). 
38 
CHAPTER I INTRODUCTION 
Nurnerous studies have explored the role of TGF-01 in diabetic 
glomerulosclerosis and today there is overwhelming evidence implicating TGF-01 
overexpression in the pathogenesis of diabetic nephropathy. In both human and 
experimental diabetes TGF-P I gene expression and protein secretion are increased in 
the glomeruli and in the tubuli (123,124). This effect is sustained in time and closely 
correlates with the degree of mesangial matrix expansion and with the HbAlc levels. 
The TGF-P type 11 receptor is also overexpressed in diabetic animals (125), 
suggesting that the diabetic kidney is more responsive to TGF-P. Finally, 
intervention studies in diabetic mice have shown that TGF-p blockade significantly 
reduces overexpression of both type IV collagen and fibronectin. Further, it prevents 
glomerular hypertrophy, glomerulosclerosis and renal insufficiency (126,127). 
The imPOrtance of TGF-P I is ftuther highlighted by in vitro studies showing 
that diabetes-related insults promote the expression of this cytokine. High glucose 
induces TGF-01 expression in mesangial cells, podocytes, and tubular epithelial 
cells. In mesangial cells high glucose-induced TGF-PI production is paralleled by 
hypersecretion. of trombospondin that is important in TGF-P I activation (128). TGF- 
01 blockade prevents glucose-induced mesangial cell hypertrophy and extracellular 
matrix production, indicating that these effects are mediated by TGF-01 via an 
autocrine mechanism (129). Mesangial cell exposure to high glucose also induces 
TGF-P receptors overexpression, suggesting that high glucose may also enhance the 
response to TGF-01 (130). On the other hand, TGF-01 induces the GLUT-1 
transporter in mesangial. cells and can thereby enhance glucotoxicity (13 1). In vitro, 
AGEs induce TGF-P 1 gene expression and protein secretion by mesangial cells (9 1) 
and in vivo administration of AGEs upregulates TGF-01 in the kidney (132). Finally, 
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increased flux through the HBSP also enhances both TGF-01 expression and activity 
in mesangial cells in vitro (106). Recent studies in podocytes have shown that high 
glucose induces the TGF-P type 11 receptor without affecting TGF-PI production. 
TGF-p mediates high glucose-induced fibronectin and collagen type IV (a3 chain) 
production in podocytes, suggesting a role of TGF-01 in the thickening of the GBM 
(133,134). In rats with protein-overload nephropathy, inflammatory cells are 
recruited into the interstitium via a complement-mediated mechanism. These cells 
are then activated to secrete TGF-01, which in turn binds to specific receptors on 
interstitial fibroblasts and induces them to proliferate and secrete matrix components. 
Thus, TGF-01 is also crucial in proteinuria-induced interstitial remodelling and 
scarring (56). The link between hyperglycaemia, TGF-PI and kidney sclerosis is 
thus well established. 
1.4.3.2 Connective Tissue Growth Factor 
Connective Tissue Growth Factor (CTGF) is a cytokine overexpressed in 
various sclerotic conditions (13 5). The importance of CTGF in diabetic nephropathy 
followed its identification by differential cloning as a gene overexpressed in 
mesangial cells cultured in high glucose (136). CTGF is scarcely expressed in 
normal kidney, but it is strongly induced in the mesangium. in both human and 
experimental diabetic nephropathy (137,138). In mesangial cells CTGF expression is 
induced by high glucose, AGEs, and TGF-01 (138). Recent data dernonstmtes that 
CTGF inhibits matrix degradation by increasing TIMP-1 expression (139). CTGF is 
a crucial downstrewn mediator of TGF-PI signalling, and it appears to mediate both 
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TGF-01 prosclerotic and hypertrophic effects (140,141). Accordingly, high glucose- 
TGF bl-induced extracellular matrix production in mesangial cells appears, at least 
in part, mediated by CTGF. CTGF also stimulates its own expression and this 
capacity of auto-induction has been implicated in the perpetuation of the fibrotic 
process (138). Moreover, CTGF appears to enhance insulin growth factor I (IGF-1) 
prosclerotic effects, increase the binding of TGF-01 to its receptors, and prevent 
vascular endothelial growth factor (VEGF) binding to the VEGF receptor (142). 
Thus CTGF may play a role in the pathogenesis of diabetic nephropathy not only by 
acting directly on mesangial. cells, but also by modulating the activity of other 
cytokines implicated in the pathogenesis of the glomerular damage. Finally, CTGF 
may contribute to tubulo-interstitial fibrosis by stimulating epithelial cell 
transdifferentiation to myofibroblasts (143,144). 
1.4.3.3 Nitric Oxide 
Tle enzyme nitric oxide synthase (NOS) catalyses the conversion of L-Arg 
into cytrullin with fonnation of nitric oxide (NO), a potent inducer of vasodilatation 
and endothelial permeability. Endothelial cells constitutively express NOS (eNOS), 
while mesangial cells express NOS exclusively in response to stimuli (iNOS). 
There are no changes in NOS expression in the glomeruli of diabetic animals 
(145) and WOS knock-out animals do not develop glomerular haernodynamic 
abnormalities. By contrast, both expression and activity of eNOS are enhanced at the 
arteriolar level in hiunan and experimental diabetic nephropathy and NOS inhibitors 
prevent glomerular hyperfiltration in diabetic animals (146,147). This suggests a 
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potential role of NO in diabetic arteriolar vasodilation leading to glomerular 
hyperfiltration. Of interest eNOS expression increases in both afferent and efferent 
glomerular arteriolars of diabetic animals, but it is more marked in the afferent one, 
providing a potential pathophysiological mechanism for the predominant afferent 
arteriolar vasodilation in diabetes. 
1.4.3.4. Insulin Growth Factor-I 
Insulin growth factor-I (IGF-1) is a potent mitogenic polypeptide, under 
growth hormone (GH) regulation, which binds to a specific receptor (IGF-RI) and to 
six binding proteins (IGFBPs) that modulate its bioavailability (148). Although 
circulating IGF-I levels are normal or reduced in patients with diabetes (149), the 
local IGF-I system appears to be upregulated. There is increased kidney IGF-I 
content in experimental diabetes. Furthermore, increases in IGF-RI and changes in 
IGFBPs expression, leading to enhanced IGF-I trapping and possibly bioactivity, 
have been reported in kidneys from diabetic animals (148). Transgenic animals 
overexpressing IGF-I and GH develop glomerular hypertrophy (150). Furthermore, 
IGF-I infused in pharmacological concentrations in humans increases renal plasma 
flow and glomerular filtration rate (151). Finally, suppression of the GH/IGF-I axis 
prevents the onset of glomerular hyperfiltration and renal hypertrophy in diabetic 
animals (148,152). IGF is thus believed to play a role in the pathogenesis of early 
glomerular abnormalities in the diabetic kidney. 
IGF-I stimulates eNOS activity in vitro in endothelial cells and induces 
vasodilatation in vivo and this provides a potential link between IGF-I and 
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glomerular hyperfiltration and hypertrophy (153). In high glucose milieu, IGF-I 
induces mesangial cells proliferation, which may also contribute to the glomerular 
hypertrophy of early diabetes. In mesangial, cells IGF-1 increases both matrix 
production and GLUT-I activity (114,154) suggesting a role of IGF-l in 
glomerulosclerotic processes, however, the demonstration that mice transgenic for 
IGF-I do not develop glornerulosclerosis has weakened this hypothesis (150). 
1.4.3.5 Vascular Endothelial Growth Factor 
Vascular Endothelial Growth Factor A (VEGF), also known as Vascular 
Permeability Factor, is a homodimeric glycoprotein and alternative splicing of the 
mRNA generates over four isoforms ranging from 34 to 42Kd. Low molecular 
weight isoforms (VEGF121 and VEGF165) are secreted by the cells as freely 
soluble proteins, while VEGF206 and VEGF189 isoforms remains bound either to 
the cell surface or to the extracellular matrix. In physiological conditions all cell 
types but endothelial cells can produce VEGF, although in the adult animal this is 
restricted to specialised cells. VEGF receptors (VEGF-RI, VEGF-R2, neurophillin) 
are predominantly located on vascular endotheliurn (155). 
VEGF is a potent inducer of angiogenesis and vascular permeability and 
dilation. VEGF plays a key role in both tumour angiogenesis and retinal 
neovascularisation. and local hypoxia leading to activation of the tyrosine-kinase c- 
Src, appears to be the stimulus inducing VEGF overexpression in both ischernic 
tissues and tumours (156-158). VEGF is also a powerful promoter of vascular 
pen-neability to macromolecules with a molar potency 50,000 times greater than 
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histamine. VEGF affects endothelial permeability by inducing endothelial 
fenestration as well as formation of transendothelial channels with diaphragms on 
both luminal and abluminal sites (159,160). 
In the adult kidney VEGF is expressed by both glomerular and tubular 
epithelial. cells, while VEGF receptors are located on the vascular endothelium (16 1). 
However, other glomerular cell types can produce VEGF and express VEGF 
receptors in vitro and in pathological conditions (162,163). Exposure to high 
glucose, AGEs, and TGF-01 induces VEGF production in vitro in mesangial. cells 
(164-166). Moreover, in podocytes high glucose induces VEGF (167) in a TGF-P I- 
dependent manner (133). 
Both VEGF and VEGF receptors are overexpressed. in the glomeruli in vivo 
in experimental diabetes (168) and in type 2 diabetic patients with nephropathy 
(169), and plasma VEGF levels are increased in type I diabetic patients with 
nephropathy (170). Recent studies in experimental diabetes have shown that VEGF 
blockade prevents glornerular hypertrophy, glornerular hyperfiltration and ameliorate 
proteinuria (171,172), suggesting a role for VEGF in the early glomerular 
abnormalities of diabetes. VEGF potently stimulates eNOS expression and activity 
in cultured endothelial cells (173) and VEGF blockade normalises glornerular 
capillary eNOS expression (171), providing a potential link between VEGF and both 
glornerular hyperfiltration and hypertrophy in diabetes. 
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1.4.3.6 Angiolensin II 
INTRODUCTION 
Circulating angiotensin 11 is formed in the blood by the renin-angiotensin system 
(RAS). In addition, within the kidney, there is an intact, independent RAS (174), 
which is abnormally activated in diabetes. Indeed, in diabetic rats both renin and 
angiotensinogen gene expression are increased in the kidney, and the intensity of 
ACE immunostaining is enhanced in both glomendi and renal vessels (175). The 
angiotensin. II receptor AT-I is also overexpressed in early experimental diabetes 
suggesting increased local responsiveness to angiotensin. 11 (176). In vivo blockade 
of the RAS has antiproteinuric and renoprotective effects which appear to a large 
extent mediated via normalisation of the diabetes-induced increase in glomerular 
capillary pressure (177). Moreover, in the kidney angiotensin Il can bind to receptors 
expressed on various renal cell types (178) and exerts important effects, independent 
of its systemic haeniodynainic activity, that may contribute to the progression of 
renal disease (179,180). In both mesangial and tubular epithelial cells angiotensin 11 
directly induces matrix deposition via a TGF-P1 -dependent mechanism (181) and 
magnifies TGF-PI effects by enhancing the expression of the TGF-P receptors on 
mesangial cells. Angiotensin II also promotes mesangial matrix deposition by 
increasing the expression of PAI-1, an important factor in matrix degradation 
(179,18 1). Finally, high glucose induces angiotensin Il production in mesangial cells 
(182), suggesting a possible autocrine effect mediated by angiotensin Il. In 
podocytes angiotensin 11 induces apoptosis via a TGF-01 -dependent mechanism 
(183) and ACE-inhibitors prevent both proteinuria-induced podocyte damage and 
TGF-01 overexpression (184). This suggests that angiotensin 11 may be causally 
implicated in the podocyte, abnormalities seen in diabetic nephropathy (39). 
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In isolated glomeruli angiotensin 11 increases glomerular permeability to 
protein and impairs the size-selective function of the glomerular filter (185,186,187). 
The underlying mechanism is still unclear, however, recent studies in human 
podocytes have shown that angiotensin II induces a rapid reduction in the expression 
of nephrin, a protein of the slit diaphragm implicated in the pathogenesis of 
proteinuria (47). In addition, in vascular smooth muscle cells angiotensin II induces 
a dose-dependent increase in both the gene expression and the protein secretion of 
VEGF, a cytokine which is believed to be implicated in the pathogenesis of diabetic 
proteinuria (188). However, it is unknown whether angiotensin Il has a similar effect 
in glomerular cells. 
1.4.4 The Role ofIntracellular Mediators 
1.4.4.1 Activating Prolein-I (AP-1) Transcription Factor 
c-fos and c-jun are two highly conserved proto-oncogenes. c-fos and c-Jun 
proteins combine in homo/heterodimers, (c-fos/c-jun, c-jun/c-jun) to form the API 
transcription complex which binds to and induces genes with an activating protein- I 
(AP- 1) binding consensus sequences in their promoter regions (189). Gene encoding 
for TGF-01, fibronectin, and. laminin contain AP- I binding sites in their promoters, 
thus AP-1 may stimulate their transcription and induce expression of extracellular 
matrix protein genes via direct and indirect mechanisms (190,19 1). 
In vivo increased mRNA expression of c-fos and c-jun has been 
demonstrated in rat glomeruli 24-hours after the induction of diabetes (192). In vitro 
in rat mesangial cells high glucose induces c-fos and c-jun expression (193). There is 
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also in vitro evidence that high glucose-induced c-fos and c-jun expression in 
mesangial cells is associated with increased transcription of target extracellular 
matrix protein genes via formation of the AP- I transcription factor (194). 
1.4.4.2 Protein Kinase C 
Protein kinase C (PKC), a family of ubiquitous serine-threonine kinases, is 
important in the transduction of many extracellular signals. There are various PKC 
isoforms, which can be categorised into classical (a, 01,02, T), novel (8, c, 11,0) and 
atypical (ý, X, p) on the basis of their common structural features. Both classical and 
novel PKC isoforms are activated by DAG (195). 
PKC activation regulates a number of vascular fimctions such as vascular 
permeability, contractility, cellular proliferation, basement membrane synthesis, and 
signal transduction mechanisms for hormones and cytokines (196). Furthermore, 
PKC induces c-fos and c-jun expression (197,198). 
In diabetes DAG levels are increased and PKC is activated in a variety of 
tissues, including renal glomeruli (199). Activation of the DAG-PKC pathway in 
diabetic animals is maintained chronically and this supports the hypothesis of a role 
of this system in the pathogenesis of chronic diabetic complications. In vitro in 
human mesangial cells and in isolated glomeruli high glucose leads to de novo DAG 
synthesis, which is then responsible for PKC activation (200-202). Glycated 
products, the polyol pathway and the HBSP can also activate PKC, making this a 
common downstream mechanism by which multiple by-products of glucose may 
exert their adverse effects (203,204). Recent evidence from cultured bovine 
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endothelial cells indicates that, upstream DAG, hyperglycaernia induces superoxide 
production by the METC, and that this is the causal link between PKC activation, 
AGEs formation and sorbitol accumulation (84). 
In vitro in mesangial cells PKC agonists increase production of extracellular 
matrix components, while PKC inhibitors prevent glucose-induced collagen type IV 
and fibronectin expression (205). Moreover, PKC inhibitors prevent TGF-01 
overexpression in diabetic glomeruli (206). Thus, PKC activation may be 
responsible for the increased expression of matrix molecules both directly and 
through TGF-PI overexpression. The capacity of active PKC to induce c-fos and c- 
jun transcription (197,198) and thus to stimulate the formation of the AP-1 
transcription factor is believed to be the major underlying mechanism of this 
combined induction of TGF-P I and matrix protein genes (203). 
In the kidney activation of different PKC isoenzymes seem to affect diverse 
aspects of diabetic kidney damage. A specific inhibitor of the PKC-02 isoform, 
LY333531, has been found to prevent a number of in vivo abnormalities in diabetic 
rats, including glornerular overexpression of TGF-PI, type IV collagen, and 
fibronectin (203,207) and also to ameliorate proteinuria (208). On the contrary, 
blockade of the PKC a isoenzyme prevents proteinuria, but it does not affect 
glomerular hypertrophy and glomerular TGF-P I expression (209). 
1.4.4.3 Mitogen Activated Protein Kinases: p38 AMP kinase 
Extracellular signal related kinases (ERK), stress-activated protein kinases 
(jNK), and p38 are members of the mitogen-activated protein (MAP) kinase 
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superfamily. These kinases constitute functionally distinct, but structurally related 
transduction pathways by which extracellular signals are transmitted to the nucleus 
to regulate gene expression. Specifically, MAP kinases are activated by 
phosphorylation at specific threonine and tyrosine residues in response to various 
cytokines and extracellular stresses. Activated MAP kinases translocate to the 
nucleus where they phosphorylate and transactivate transcription factors (2 10). 
Several in vitro and in vivo evidence suggests a role of p38 MAP kinase in 
the pathogenesis of diabetic nephropathy. In experimental diabetes there is an 
increase in both total and phospho-p38 MAP kinase levels in the glomeruli (211,212) 
and in non-diabetic animals AGEs induce glomerulosclerosis via a p38 MAP kinase- 
dependent mechanism (213). In vitro in mesangial. cells high glucose, AGEs, flux 
through the HBSP, and angiotensin II induce p38 MAP kinase phosphorylation (106, 
214-216). Phospho-p38 MAP kinase, in turn, can activate transcription factor, such 
as AP-1, activating transcription factor-2 (ATF), and the cyclic AMP response 
element-binding protein (CREB), important in the regulation of both extracellular 
matrix production and inflammatory processes (210). Finally, in podocytes p38 
MAP kinase mediates both TGF-01-iqduced apoptosis and high-glucose-induced 
collagen overexpression (217). 
1.4.5 Role ofLIyj2ertension 
If diabetes-induced abnormalities were sufficient to cause renal disease, all 
diabetic patients, given time, would develop overt renal disease, and the study of 
hyperglycacmia-induced abnonnalities would be sufficient to explain the 
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pathogenesis of diabetic nephropathy. However, the risk of developing kidney 
disease is not directly related to the duration of diabetes and only a subgroup of 
diabetic patients ever develops the complication (1). This suggests that there may be 
other factors that influence the host response to diabetes-induced environmental 
disturbances, thus conferring susceptibility. Convincing evidence indicates that an 
increased haemodynarnic insult, secondary to elevations of both systemic and 
glomerular arterial pressure, in the setting of hyperglycaemia, is important in 
conferring susceptibility to kidney damage. 
1.4.5.1 Systemic Hypertension 
Arterial hypertension is present in up to 40% of patients with type I diabetes 
(1). The association between hypertension and diabetic nephropathy was first 
described by Kimmelsteil and Wilson in 1936 (218), though the adverse effect of 
hypertension in diabetic (and non-diabetic) renal disease was not appreciated until 
later. 
Regardless of its cause, hypertension in diabetes accelerates the progression 
of diabetic nephropathy. 
Blood pressure is increased in overt diabetic nephropathy and 
microalbuminuria (15,16). A gradual rise in systemic blood pressure parallels the 
development of proteinuria and coffelates with the rate of decline in GFR (16). 
Intervention studies in humans have demonstrated significant reno-protective 
and anti-proteinuric effects of anti-hypertensive therapy (219,220-224). Studies 
performed in experimental diabetes have also showed the importance of systemic 
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bypertension in accelerating the renal injury. In a model combining genetic 
hypertension with STZ-induced diabetes, different antihypertensive agents 
attenuated the rise in albuminuria and improved various glomerular morphological 
abnormalities (225,226). 
There is considerable clinical evidence that increased blood pressure levels 
are also important in the onset of diabetic nephropathy. 
A recent study over 3 years has shown that anti-hypertensive treatment 
retards the increase in albuminuria in normoalbuminuric Type I diabetic patients 
(227). Prospective studies in patients with both t)W I and type 2 diabetes and 
normal albumin excretion have demonstrated that mean arterial pressure levels are 
significantly higher in those patients who progress to microalbuminuria than those 
who do not progress, indicating that high blood pressure plays an important role in 
the pathogenesis of diabetic kidney disease (75,228). Finally, in Pima Indians higher 
mean blood pressure prior to the onset of diabetes actually predicts an abnormal 
albumin excretion rate after the diagnosis of diabetes (229). 
Family studies have also shown that a familial predisposition to raised 
arterial pressure is an important determinant of susceptibility to renal disease in 
diabetes. Blood pressure levels are significantly higher in the parents of diabetic 
subjects with proteinuria than in the parents of subjects without proteinuria (230). It 
has been calculated that the risk of nephropathy among type I diabetic patients is 3 
times higher in those having at least one parent with a history of hypertension (23 1). 
Among type 2 diabetic Pima Indians those with hypertensive parents have a higher 
prevalence of proteinuria than those with normotensive parents (229) and in fwnilies 
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with type 2 diabetes, AER is a heritable trait, with a heritability similar to that for 
blood pressure (232). 
Some insight into the predisposition to diabetic renal disease has come from 
studies of intermediate phenotypic markers of hypertension. The red blood cell 
sodium-lithium countertransport is a cell membrane cation transport system, whose 
activity is both genetically determined and increased in essential hypertension. 
Sodium-lithiurn countertransport activity is abnormally high in diabetic patients with 
proteinuria or microalburninuria (233,234). Similarly, the activity of sodium- 
hydrogen antiport that regulates cellular events possibly involved in the pathogenesis 
of hypertension, is increased in a number of cell types from type I diabetic patients 
with microalburninuria and proteinuria, as well as in subjects with hypertension 
(235,236). The activity of the sodium-hydrogen antiport is increased by high glucose 
concentration in cells from subjects with diabetic nephropathy, but not in cells from 
diabetic patients without nephropathy or healthy controls (236). Finally, red blood 
cells sodium-hydrogen activity predicts, in prospective studies, the development of 
proteinuria (237). Collectively all these studies of intermediate phenotype support 
the hypothesis that the increased susceptibility to diabetic nephropathy most likely 
resides in a genetically determined predisposition to hypertension (238). 
1.4.5. Z Glomerular Hypertension 
In the early stages the difference in arterial pressure levels between diabetic 
patients who develop renal complications and those who do not may be numerically 
small, and often occur in the "normotensive range". However, this difference 
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becomes biologically relevant in the presence of diabetes, which induces loss of 
glomerular capillary pressure autoregulation. 
Under normal conditions, intraglomerular capillary pressure is tightly 
regulated by precise adjustments in afferent and efferent arteriolar resistance. 
Hyperglycaemia induces vasodilatation and in diabetes there is a marked reduction 
in afferent and a lesser reduction in efferent arteriolar resistance. This leads to an 
increase in glomerular capillary pressure levels and allows ready transmission of any 
increase in systemic blood pressure to the glomerular capillary network (239). 
More than 20 years ago Brenner and colleagues proposed that elevated 
pressure within the glomerulus is a common pathophysiological derangement that 
follows renal injury and leads to a vicious cycle of barotraurna-induced 
glomerulosclerosis, proteinuria and progressive renal dysfunction (240). The central 
role of the glomerular hypertension in mediating glomerular injury was confirmed by 
micropuncture and intervention studies, initially in the 5/6 nephrectomy model, but 
soon extended to experimental diabetes. Micropuncture studies in diabetic rats 
showed a range of intrarenal haemodynamic abnormalities including increased 
intraglomerular pressure, increased single nephron GFR and preferential afferent 
compared with efferent arteriolar vasodilation (239,241). Furthermore, intervention 
studies in experimental diabetes have shown that conditions known to increase 
glomerular capillary Pressures, such as unilateral nephrectomy, Goldblatt 
hypertension, and high protein diet significantly worsen the extent of glomerular 
injury in STZ-induced diabetic rats. Conversely, measures that reduce glomerular 
pressure, such as systemic blood pressure reduction, a low protein diet or ACE 
53 
CHAPTER I INTRODUCTION 
inhibitors that block angiotensin 11-mediated efferent arteriolar constriction, all 
reduce the development of glomerular damage and proteinuria (242-244). 
Consistent with these animal studies, autopsy studies in diabetic patients with 
unilateral renal artery stenosis show nodular glomerulosclerosis lesions to be 
confined to the kidney with the patent renal artery (245). The presence of an 
impaired renal auto-regulation has been indirectly confmned in humans in type 2 
diabetic patients with nephropathy (246). Furthermore, skin capillary pressure has 
been shown to be elevated in type 2 diabetic patients with hypertension (247). 
Finally, the greater efficacy of ACE-inhibitors and angiotensin II ATI receptor 
blockers (ATIRB) as compared to other blood pressure lowering agents in their 
antiproteinuric and renoprotective action has been in part ascribed to their capacity 
to reduce glomerular capillary pressure by removing the tonic constrictor effect of 
angiotensin 11 on the efferent arteriole (248-250). Although increased glomerular 
capillary pressure has long been associated with the deposition of extracellular 
matrix, the mechanisms by which the mechanical insult of altered haernodynamics 
translates into kidney damage, have only recently been addressed. This has followed 
the demonstration of the unique elastic properties of the glomerular structure and the 
response of mesangial cells to mechanical stretch in culture. 
1.4.5.3 Glomerular Volume Expansion 
Glomeruli are highly compliant structures as demonstrated both in vivo and 
ex vivo in isolated microperfused systems. A rise in glomerular capillary pressure 
results in glomerular volume expansion. The relationship Apressure/Avolume, once 
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adjusted for glomerular volume, is linear and, on the basis of glomerular compliance, 
it is possible to predict the glomerular volume expansion induced by each pressure 
level. As the intraglomerular pressure rises to levels approximating those observed in 
the diabetic and remnant kidney model, glomerular volume increases by about 30% 
(251,252). Volume changes reach their maximum within 2-3 seconds following 
alteration in intraglomerular pressure, thus responding to the most transient 
variations of pressure. However, under normal conditions, because of tight control of 
intraglomerular pressure glomeruli are exposed to only small pulse pressure 
variations and their volume remains stable. The autoregulatory glomerular protection 
is impaired in diabetic nephropathy and continuous systemic blood pressure 
monitoring has shown that loss of autoregulation results in wid ngs in glomerular 
volume, an alteration that is ftirther magnified by arterial hypertension. Normal 
glomeruli with intact autoregulation vary their volume by a mere 0.4%, while 
glomeruli ftom. kidney with impaired autoregulation show variations 18-fold greater 
(251,252). 
In addition to glonierular capillary pressure, another factor affecting 
glomerular volume expansion is the basal glomerular volume. At any given 
intraglomerular pressure level, larger hypertrophied glonieruli are more distensible 
than smaller glomeruli. This is believed to result from enhanced capillary wall 
tension, resulting from the increase radius of hypertrophied capillaries. Therefore, 
glomerular hypertrophy secondary either to diabetes or to nephron loss magnifies the 
deleterious effects of altered glomerular haeniodynamics (252). Finally, glomerular 
volume expansion is also affected by the intrinsic rigidity of the glomerular scaffold, 
primarily determined by the composition and distribution of the collagen fibres in 
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both the GBM and the mesangium. However, this factor does not appear to play a 
major role in diabetes as it has been shown that rigidity is normal in the glorneruli 
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Figure FI-I: Mesanrial cell stretchinz durinz Womerular volume expansion 
Mesangial cells (yellow) are anchored to the glomerular basement membrane 
(green) via their cytoplasmatic projections. Therefore, increases and 
fluctuations in glomerular capillary pressure (red) result in glomerular 
volume expansion leading to mesangial cell stretching. 
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Glomerular expansion is associated with the stretching of its structural 
components, including the extracellular matrix and the cellular components. Due to 
the central location of the mesangial region within the glomerular lobule, mesangial 
cells experience substantial mechanical stretching. Detailed morphological studies 
have demonstrated how numerous cytoplasmatic projections emerging from the 
mesangial cell body extend between adjacent capillaries and firmly attach to the 
peri-mesangial regions of the glomerular basement membrane. Therefore, the 
centrifugal displacement of these regions during glomerular expansion results in 
marked three-dimensional mesangial cell stretching (254). It is therefore anticipated 
that cyclic changes in glomendar volume are associated with repeated episodes of 
mesangial cell stretch and relaxation (Figure FI-1). 
1.4.5.4. Haemodynamic Stretch 
Little is yet known of the mechanism by which systemic and glomerular 
haemodynarnic derangement leads to the development of the specific kidney lesions 
seen in diabetes, and the vast majority of the in vitro studies on mesangial cells have 
been performed under static conditions. It is, however, possible to mimic the 
haernodynamic insult in vitro by subjecting to cycles of stretch and relaxation cells 
seeded on silicone-deformable culture plates. This in vitro system has been used on 
several cultured cell types and constitutes a powerful tool for investigating the effect 
of the haemodynamic insult at cellular and molecular level (255-258). 
In cardiomyocytes this model has cast light on the molecular mechanisms 
underlying the development of cardiac hypertrophy in response to pressure overload. 
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Furthermore, the strict parallelism shown in these studies between in vitro stretch- 
induced effects and in vivo response to pressure overload in terms of activation of 
intracellular signalling cascade and gene expression provides an excellent validation 
of the model itself (259-262). 
Application of mechanical stretch to mesangial cells leads to changes in their 
morphology and synthetic activity. Mesangial cells exposed to mechanical stretch 
alter their shape from the normal stellate pattern to a straplike appearance. 
Furthermore, they align themselves with their long axis perpendicular to the 
direction of stretch and this is paralleled by a redistribution of cytoskeleton actin 
fibres at the intracellular levels (263). Of interest, increased expression and 
remodelling of contractile proteins, such as a-actin, caldesmon and myosin light 
chains, has also been reported in vivo in both rat and human diabetic glomeruli 
(264). 
In rat mesangial cells cyclical stretch induces the gene expression and protein 
secretion of matrix components, such as collagen (IJII and IV), fibronectin and 
laminin in a manner proportional to the intensity of cellular stretch (265,266). Of 
interest, while cyclical stretch stimulates collagen synthesis at all glucose 
concentration, it is only at high glucose levels that net collagen accumulation in the 
medium can be demonstrated. This is the result of catabolic rates insufficient to 
match the increased synthesis occurring in a high glucose environment (267). 
Therefore, the cellular response to a haemodynamic insult can be influenced and 
exaggerated by high glucose concentration in the milieu. There is also evidence in 
rat mesangial cells that stretch induces TGF-01 both gene expression and protein 
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secretion in an intensity-depcndent manner and it upregulates the expression of the 
TGF-P receptors (268,269). However, the role of TGF-PI in mediating stretch- 
induced matrix overexpression remains uncertain and results reported in the 
literature are still conflicting (265,266,270). Another prosclerotic cytokine, under 
TGF-P I regulation, CTGF is upregulated at the mRNA level by stretch, however no 
changes are seen after exposure to cyclic stretch in CTGF protein expression (252). 
The intracellular signalling pathway mediating stretch-induced effects 
remains, by and large, unknown. In mesangial cells stretch stimulates a rapid and 
transient uptake of calcium ions (271). Blockade of calcium entry significantly 
attenuates c-fos induction by stretch, suggesting calcium flux as a mechanism 
coupling stretch to activation of intracellular signalling molecules (272). Both PKC 
translocation from the cytosol to the plasmamembrane, an index of PKC activation, 
and phosphorylation of a PKC endogenous substrate occur within 5 minutes of 
mesangial cells exposure to stretch. Furthermore, after 30 minutes there is an 
increase in c-fos mRNA levels, an effect that is reduced by PKC both depletion and 
inhibition (272,273). These data suggest that both AM and PKC may be implicated 
in the intracellular signalling cascade activated by stretch and resulting in enhanced 
extracellular matrix production. Recent reports suggest that signalling molecule 
ERK, which belongs to the MAP kinase family, is also activated by stretch and 
involved in stretch-induced extracellular matrix overexpression (274). 
Recent studies have investigated the effect of stretch in podocytes. Podocytes 
are intrinsically sensitive to mechanical forces. Podocyte stretching induces 
important alterations in both cell morphology and F-actin organisation that are 
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highly different from that observed in other cell types. Opposite to mesangial cells, 
the cell body size of podocytes is reduced in response to mechanical stress, 
podocytes do not align in the force field, and their foot processes become thin and 
elongated. These morphological changes are paralleled by a unique reorganisation of 
the actin cytoskeleton: stretch induces formation of radial stress fibres that 
converged to an actin-rich centre (ARC), while transversal stress fibres disappear 
(275). Stretch also induces changes in the expression of molecules important in cell 
adhesion: a3pl, the predominant form of integrin expressed by podocytes, is reduced 
by stretch, while osteopontin is augmented (276,277). The relevance of this in terms 
of cell adhesion to the GMB and to neighbouring cells is under investigation. 
Mechanical stretch reduces podocyte proliferation rate; in addition recent 
data show that stretch induces podocyte aPOPtosis through an autocrine mechanism 
mediated by angiotensin II. Specifically, stretch induces the expression of 
angiotensin II that, in turn, stimulates podocyte apoptosis by binding to the AT-1 
receptor, upregulated in stretched podocytes. TGF-01 is also induced by stretch in 
this cell type and TGF-01 is known to have important proapoptotic effects in 
podocytes, however the direct role of TGF-01 in stretch-angiotensin II-induced 
apoptosis has not yet been defined (278). 
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Both systemic and glomerular hypertension play a key role in the 
pathogenesis of diabetic glornerulopathy. 
This haemodynamic insult can be mimicked in vitro by subjecting mesangial 
cells to mechanical stretch and this in vitro system can help improve our 
understanding of the cellular and molecular mechanisms whereby glomerular 
hypertension translates in glomerular dysfunction and damage. 
The aim of this work was to study in human mesangial cells the effect of 
mechanical stretch on matrix components, cytokines, and intracellular signalling 
molecules believed to be important in the pathogenesis of diabetic nephropathy. 
Furthermore, to clarify the cellular mechanism/s underlying the interplay between 
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3.1 Materials 
All materials were purchased from Sigma Chemical Co. (St. Louis, MO, USA) and 
BDH (Poole, UK) unless otherwise stated. 
3.1.1. Cell cuftu 
Foetal calf serum (FCS) was obtained from Gibco-BRL (Paisley, UK) and 
Dulbecco's phosphate buffered saline (PBS) tablets from Oxoid (Basingstoke, UK). 
Culture flasks, cell scraper and plastic tubes were from Falcon Trademarks (Cowley, 
UK) and the disposable filter unit from Nalgene (Nalgene, Rochester, USA). Flex (I 
and II) plates were purchased from Flexcell Corp (McKeensport PA). 
3. LZ Molecular biOlozv 
The Rneasy and QlAshredder columns were obtained from Qiagen (Crawley, UK) 
and Triazol from Gibco-BRL (Paisley, UK). Avian myeloblastoma virus (AMV) 
reverse transcriptase, reverse transcription buffer, molecular weight marker ((DX174 
DNA/Hae 111), and Blue/Orange 6x Loading Dye were from Promega, (Southampton 
UK). RnaGuard and poli-d(T)12-18 were from Amersham Life Science 
(Buckinghamshire, UK). AmpliTaq, M902 solution, and PCR buffer were 
purchased from Perkin Elmer (Warrington WA, USA) and oligonucleotide primers 
from Oswel (Southampton UK). 
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3.1.3 Immunoassa 
The rabbit polyclonal anti-VEGF antibody was obtained from Serotec (Oxford, UK). 
The mouse monoclonal anti-VEGF antibody and the human recombinant VEGF165 
were from R&D Systems (Minneapolis, MN, USA). The rabbit polyclonal anti- 
human fibronectin antibody was purchased from Calbiochem (Nottingham UK) and 
the TGF-01 E.., immunoassay system from Promega, (Southampton UK). 
3.1.4. Immunoblotting, immunohistochemistrv, and immunofluorescence 
Polyclonal rabbit anti-human ATI, goat anti-human P38 MAP kinase, and rabbit 
anti-TGF-01 and anti-TGF-P receptor antibodies were from Insight Biotechnology 
(Wembley, Middlesex, UK). The rabbit anti-fibronectin antibody was purchased 
from DAKO (Cambridge UK) and the anti-phospho-p38 MAP kinase antibody from 
Promega (Southampton UK). The rabbit anti-human GLUT-1 antibody and the 
GLUT-1 blocking peptide were from Alpha Diagnostic (San Antonio, USA). DC- 
Colorimetric Protein Assay, Bovine Serum Albumin standard solution, pre-stained 
molecular weight marker, acrylamide[bisacrylamide (30% solution Acrylamide/Bis 
Solution 37.5: 1), non-fat dry milk, and Coomassie Blue R-250 were from Bio-Rad 
(Hemel Hempstead, UK). Nitrocellulose membrane, HRP-conjugated secondary 
antibodies, enhanced chemiluminescence kit and HyperfilmTm ECL were from 
Amersham Life Science (Buckinghamshire, UK). The in vitro p38 MAP kinase 
activity assay was obtained from New England Biolabs (Hertfordshire, UK). The 
mouse anti-human cytokeratin, mouse anti-human factor VIII, mouse anti-human 
CD45 antibodies, the Envision System and the goat serum were from DAKO (High 
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Wycombe, UK). The mouse anti-human Thy- I antibody was purchased from Serotec 
(Oxford, UK). 
3.1.5. Inhibitors, receptor antagonist, blocking antibodies, cytokines 
The inhibitors H7 1-(5-Isoquinolinesulfonyl)-2-methylpiperazine, calphostin C 
(C44H38014)ý PMA (Phorbol-I 2-myristate-I 3 acetate), genistein (4', 5,7- 
Trihydroxyisoflavone), herbimycin A (C301142N209), peptide A (tyrosine kinase 
peptide inhibitor), PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4- 
d]pyrimidine, Wortmannin (C23H2408). SB203580 [4-(4-fluorophenyl)-2-(4- 
methylsulfinynphenyl)-5-(4-pyridyl)] imidazole were purchased from Calbiochern 
(Nottingham UK). The angiotensin II receptor antagonist Losartan-DuP753 (2-n- 
butyl- 4 -chloro- 5 -hydroxymethyl- I- [2 - (IH-tetrazole- 5 -yl) biphenyl- 4- 
hy]methyl) imidazole was kindly supplied by Dr Ronald D. Smith, Dupont 
Company Merck & Co. Inc (West Point, PA, USA). The monoclonal anti-IGF-I type 
I receptor antibody (aIR3) was purchased from Calbiochem (Nottingham UK). 
Neutralizing anti-TGF-P antibodies (pan-neutralising and anti-TGF-PI) and human 
recombinant TGF-PI were obtained from R&D Systems (Minneapolis, MN, USA). 
CII] 2-deoxyglucose was from Amersham Life Science (Buckinghamshire, UK). 




3.21 Cefl Culture 
MATERIALS AND METHODS 
Recipes for cell culture media and reagents are detailed in Appendix I (Table 1-2-3). 
3.2 1.1. Isolation ofhuman glomeruli 
Human mesangial cells were isolated as previously described (279). Normal renal 
cortex was taken either from the opposite tumour-free pole of nephrectomy 
specimens, removed for localised, capsulated grade I hypernephromas, or from 
donor nephrectomies found to be unsuitable for transplantation on the basis of an 
abnormal vascular supply. Tissue was analysed by light microscopy and by 
immunofluorescence to exclude the presence of tumour cells and glomerular 
abnormalities. Cells obtained from five separate kidneys were used in this work. 
Intact glomeruli were collected by serial sieving of cortical homogenates. 
Specifically, the renal capsule was removed; the cortex was separated from the 
medulla and gently cut into small fragments, which were ground through a 425- 
micron nylon mesh with the rubber plunger of a 50ml syringe. The mesh was washed 
with ice-cold PBS containing penicillin (100units/mi) and streptomycin (100pg/ml) 
and the resulting filtrate was then sequentially passed over 180 and 125-micron 
nylon meshes. Retained glomeruli were washed with ice-cold PBS, transferred into a 
50 ml falcon tube and allowed to sediment for approximately 10 minutes, the 
supernatant was then removed and the glomeruli re-suspended in excess ice-cold 
PBS. This step was repeated a further 3 times to minimise tubular contamination. 
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Absence of tubular contamination was confirmed by examination under light 
inicroscoPy. 
3.2 1.2 Primary cultures ofhuman mesangial cells 
Isolated glomeruli were incubated in a 1: 1 solution of collagenase (type IV, 750 
units/ml) in PBS at 37'C for 5 minutes to digest the glomerular capsules and allow 
attachment to the culture flasks. Following collagenase neutralisation by addition of 
a large volume of PBS, glomeruli were collected by centrifugation (100xg for 5 
minutes), re-suspended in RPMI 1640 culture medium (see Appendix 1), seeded in 
25cmý culture flasks, and placed in a 5% C02 incubator at 370C. 
Following the outgrowth of mesangial cells (- 4-5 days), the glomcruli were 
removed by washing with ice-cold PBS on ice and the cells were cultured in Roswell 
Park Memorial Institute (RPMI) 1640 medium, supplemented with insulin- 
transferrin-selenium (ITS) and L-glutamine, and containing 20% FCS, 7 mM 
glucose, 100 U/ml penicillin, and 100 pg/ml streptomycin in a humidified 5% C02 
incubator at 370C. The media was changed on average every other day. Once 
confluent, cells were subcultured into 75cm 
3 culture flasks by trypsinisation (see 
3.2.1.4). 
3.21.3 Characterisation ofhuman mesangial cells 
Mesangial cells were characterised by morphological criteria: under light 
microscoPy, cells were stellate or fusiform. in appearance, grew in multilayers and 
formed hillocks in long-term culture. Identification was confirmed by direct and 
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indirect immunofluorescence. Cells at the 4h passage were seeded on sterile 
immunofluorescence slides at a very low density (-10-20/well) and left to attach 
overnight in a 5% C02 incubator at 37T. After washing twice with PBS, cells were 
fixed by immersion in excess ice-cold methanol at -200C for 5 minutes, then washed 
with excess PBS twice for 5 minutes each, and blocked in the serum from the host 
species of the second antibody at a 1: 20 dilution in 0.25% bovine serum albumin at 
37'C for I hour in a humidified chamber. 
After blocking, cells were incubated for I hour with the primary antibodies 
diluted in 0.25% BSA in PBS [fluorescein isothiocyanate (FITC)-conjugated mouse 
anti-a smooth muscle actin 1: 20, mouse anti-cytokeratin 1: 50, mouse anti-CD45 
1: 50, mouse anti-Tby 1 1: 20, mouse anti-Factor VIII 1: 25 antibodies). After washing 
three times with PBS, cells were incubated with a tetramethy1rhodamine 
isothiocyanate (TRITC)-conjugated rabbit anti-mouse secondary antibody (1: 30) for 
one hour at 37*C (for indirect immunofluorescence only). Following washing with 
excess PBS, slides were mounted in PBS-glycerol (1: 1), sealed with nail varnish, and 
observed under fluorescent microscopy (Olympus BX60 reflected light fluorescence 
microscope). 
Mesangial cells stain for a-smooth muscle actin, while positive staining for 
cytokeratin, factor VIII, CD45, and Thy-I indicates contamination with other 
glornerular cell types (epithelial and endothelial cells, lymphomonocytes, and human 
fibroblasts, respectively) (280). 
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Figure F3-1: Poskive stainin_e for a smooth muscle actin in mesan--ial cells 
Human mesangial cells stained for a-smooth muscle actin by direct 
immunofluorescence (fluorescent microscopy magnification 40x). 
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3.2.1.4. Trypsinisation of human mesangial cells 
MATERIALS AND METHODS 
Once confluent, cells were washed twice with PBS, incubated with trypsin (0.25%) 
and ethylenediaminetetra-acetic acid (EDTA) (0.5%) for about 5 minutes at 37'C to 
induce cell detachment. Trypsin activity was neutralised by adding culture media 
containing FCS. Cells were then harvested by centrifugation (200xg for 5-10 
minutes), the supernatant was removed and the pellet re-suspended in culture 
medium and split evenly among 2 or 3 75cm3 flasks. 
3.2.1.5 Seeding ofhuman mesangial cells 
Experiments were performed between the 4th and 70' passages, while the cells retain 
all the morphologic and immunofluorescent features described above. The cells were 
trypsinised (as detailed in 3.2.1.4) and the cell number determined by a Coulter Cell 
Counter (Coulter Electronics Ltd, Luton Beds UK). Equal numbers of cells were 
seeded into six-well type I collagen-coated culture plates with flexible silicone 
elastomer-bases (Flex 1). Control cells were seeded into 6-well plates with non- 
deformable rigid bases (Flex 11). The cells were serum and insulin deprived (see 
Appendix I) for 24-48 hours prior to the experiment to synchronisc them in the same 
phase of the cell cycle. 
3.2-1.6 Cell number determination 
Cells were washed twice with PBS, incubated with trypsin (0.25%) and 
ethylenediaminetetra-acetic acid (EDTA) (0.5%) for about 5 minutes at 37T to 
induce cell detachment. Trypsin activity was neutralised, by adding culture media 
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containing FCS. The cell suspension was diluted (1: 10) in Isoton (Beckman/Coulter 
Electronics) and the cell number determined in duplicate by a Coulter Cell Counter 
(Coulter Electronics Ltd, Luton Beds UK). 
3.2.1.7 Cryopreservation oftells 
Cells in the exponential phase of growth were trypsinised and harvested by 
centriftigation as described above. The cells were counted and 106 cells per vial were 
cryopreserved. The cell pellet was resuspended in a solution containing 95% FCS 
and 5% dimethyl sulphoxide (DMSO) and I ml placed into each pre-cooled cryovial. 
The DMSO was added slowly to reduce both the osmotic shock and the increase in 
temperature. T'he cryovials were frozen at -801C overnight before placing into the 
liquid nitrogen container at -I 96'C. 
3.2 1.8 Thawing ofcryopreserved cells 
A vial of frozen cells was removed from the liquid nitrogen tank and placed in a 
beaker of water pre-warmed to 37'C. Once the cell suspension had completely 
thawed it was placed into a sterile 50ml falcon tube with 10ml of sterile media and 
centrifuged at 200x g for 5 minutes. The cell pellet was resuspended in 5 ml media 
and placed in a 25cm3 flask and left to attach overnight at 37"C in the 5% C02 
incubator. The medium was changed the following day. 
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3.2.1.9 Cell viability 
MATERIALS AND METHODS 
Cell viability was assessed using the trypan blue dye exclusion test. Briefly, the cell 
suspension was incubated with a 0.4 % trypan blue in PBS for 5 minutes at room 
temperature. The number of stained cells was counted in a counting chamber 
(Neubauer) under light microscopy and expressed as percentage of total cells. 
Positive staining indicates loss of the integrity of the plasmamembrane, thus the 
percentage of cells that exclude the trypan blue dye is an index of cell viability. 
3.2. LI 0 Skinfibroblasts 
A subset of experiments was performed on human skin fibroblasts to evaluate the 
cell-specificity of the stretch-induced effects and to control for potential non-specific 
protein release from plasma membrane stretch-induced damage. Skin fibroblasts 
were obtained from a forearm skin biopsy performed on normal subjects (kindly 
provided by Dr A Morocutti). The cells were used after 5"' passage and the 
experimental protocol paralleled that described for mesangial cells (281). 
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3. Z2 Application of mechanical stretch 
MATERIALS AND METIIODS 
Cells were seeded in equal number (I 2,000/cm2) into six well silicon elastomer-base 
culture plates (Flex I plates) and control plates (Flex 11 plates). Experiments were 
performed on subconfluent cells as confluency interferes with stretching and there is 
a negative correlation between cell density and stretch-induced effects (265). 
In both plates (Flex I and Flex 11), collagen type I is covalently bonded to the upper 
surface of the silicon elastomer base to form a uniform matrix monolayer. 
Experimental and control cells are, thus, cultured on an identical substrate. A plastic 
base preventing mechanical deformation is present beneath to the silicon layer in the 
Flex 11 plates, but absent in the Flex I plates. 
Cells were subjected to repeated stretch/relaxation cycles by mechanical deformation 
using firstly an in-house Stress Unit, then a Flexercell Strain Unit (FX3000 Flexcell 
International Corporation McKeensport, PA). T'he Stress Unit is a modification of 
the unit initially described by Banes and co-workers (282) and consists of a vacuum 
unit and a baseplate. A valving mechanism automatically regulates and maintains the 
negative pressure to provide the required strain regimen. The negative pressure, 
created by the vacuum pump, is cyclically applied beneath to the flexible membrane 
plates via the baseplate, which is placed in a humidified incubator with 5% C02 at 
370C. This results in a downward deflection of the flexible bases of the Flex I plates 
with stretching of the cells. Release of the pressure allows the deformable bases to 
return to their resting position, thereby relaxing the cells. Control cells, grown in 
non-deformable, but otherwise identical plates (Flex II plates) are unaffected by the 
vacuum. 
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Figure F3-2: Schematic representation of the Stress Unit. The Stress Unit consists 
of a vacuum pump and a baseplate. The negative pressure, created by the vacuum 
pump and regulated by the manometer, is applied beneath to the plates via the 
baseplate. This results in a downward deflection of the flexible bases of the Flex I 















Figure F3-3: The Stress Unit induces mesangial cell elongation. (A) Cells (yellow) 
seeded in flexible plates. When the vacuum is applied there is a downward deflection 
of the flexible base with stretching of the cells. (B) Cells seeded in rigid control 
plates. The plastic base beneath to the base prevents deflection and stretching. 
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The mechano-physics of the set-up dictates that stretch is maximal at the periphery 
of the well base with a gradual decline towards the centre of each well. The 
mathernatic relationship between the negative pressure applied and the average 
elongation of the deformable base allows to calculate the vacuum pressure required 
to obtain the desired average degree of elongation. In this study, vacuum pressures 
were applied to induce an average of either 4% or 10% uniaxial elongation in the 
culture surface, which mimics that present in vivo in glomeruli exposed to either 
normal or supernormal pressure levels (239,251). The vacuum was applied at 60 
cycles per minute, a frequency that resembles the in vivo pulsatility of the 
glomerular capillary pressure (283). 
3.2.2.1 Validation ofthe Stretch System 
To confirm that the flexible base and hence cells were exposed to the predicted 
degree of elongation, the flexible membranes were tattooed, then acrylic resin casts 
were made while the flexible membranes were held in stretched position at 
increasing negative pressure levels. 'Me distances between the concentric circles of 
the tattoos on the casts were, then, measured by micrometric methods and the 
elongation calculated. Using this empirical method it was possible to confirm that 
the pressure applied induced, as expected, a mean 10% uniaxial elongation of the 
culture surface. 
Stretched cells were stained with Giemsa and actin cytoskeleton distribution studied 
by immunofluorescence for a-actin. Stretched mesangial cells had a straplike 
appearance rather than the normal stellate shape. Furthermore, they aligned 
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themselves with the long axis perpendicular to the direction of stretch. This was 
paralleled by a redistribution of the intracellular actin fibres. These alterations, which 
had been previously described in stretched rat mesangial cells (263), confirm that the 
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Figure F3-4: ffect ofmechanical stretch on cell moMholM. 
Human mesangial cells exposed to stretch for 30 minutes (A), control non-stretched 
mesangial cells (B). (Giemsa staining magnification 20x) 
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MATERIALS AND METHODS 
To test whether stretch induces cell darnage the Trypan Blue exclusion test was 
performed on mesangial cells exposed to stretch for various time periods. Cell 
viability was normal in stretched cells, indicating that the integrity of the 
plasmamembrane was Preserved. 
Stretch has been reported to enhance cell proliferation rate in mesangial cells of 
murine origin (263). In preliminary setting up experiments, no changes were seen in 
mesangial cell number up to 33 hours of stretch (non stretch: 26390±1343 vs stretch: 
25657±380), indicating that stretch did not stimulate cell proliferation over this time 
period. However, to account for this possible confounding factor, all protein 
measurements were corrected for cell number. Cells were stretched up to 33 hours, 




3. Z3 mRAIA Analvsis 
Recipes and reagents are detailed in Appendix II. 
3. Z3.1 Extraction of total RIVA 
MATERIALS AND METHODS 
Both guanidinium-phenol extraction and silica-membrane columns were used for 
total RNA extraction. 
Guanidinium and phenol extraction Total RNA was isolated using a commercial 
preparation based on a guanidinium. and phenol extraction (Triazol Gibco-BRL, 
Paisley, UK). The medium was aspirated, the cells washed twice with ice-cold PBS 
on ice, and incubated for 5 minutes with Triazol (1801d per well). Following 
scraping, lysates were homogenised with 20 strokes in a Dounce homogeniser, 
centriftiged at 12,000xg for 10 minutes at 4*C to remove matrix components, and 
then incubated for 15 minutes with chloroform (0.2 ml for each 0.75 ml of Triazol). 
Following incubation, lysates were separated by centrifugation (12,000xg for 20 
minutes at 4"C) in three phases: upper phase containing RNA, intermediate phase 
containing DNA, and lower phase containing Triazol and proteins. The upper phase 
was incubated with an equal volume of isopropanol at -20'C overnight. After 
centrifugation (I 2,000xg for 10 minutes at 40C), the RNA pellet was incubated for 4 
hours in 2.5 ml of ethanol (100%) at -20'C, washed extensively in ethanol (75%), 
then dissolved in 20 ýd of DNAse-RNAse-free water and stored at -800C. 
RNeasy silica-membrane columns. Total RNA was extracted according to the 
manufacturer's protocol. The medium was aspirated, the cells washed twice with 
PBS, and incubated for 10 minutes in RTL lysis buffer containing 10ýtl/ml B- 
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mercaptoethanol (I OORI per well) at room temperature. Following scraping, lysates 
were homogenised by microcentrMgation. in a QIAshredder spin column for 2 
minutes at maximum speed. An equal volume of 70% ethanol was added to the 
homogenised lysate and mixed by pipetting to provide the correct binding 
conditions. The solution was applied to the RNeasy column and centrifuged for 15 
seconds at I 0,000xg to allow RNA binding to the silica-membrane. Bound RNA was 
washed with 700pl RWI buffer and twice with 5OOpI RPE buffer. Finally, RNA was 
eluted in 15pl of Dnase-free and Rnase-free water and frozen at -70*C. (Composition 
ofRTL, R W1, and RPE is patent and not disclosed by Qiagen) 
3.2.3.2 Quantification oftotal RNA 
The concentration of RNA recovered was determined by UV spectrophotometry. 
Total RNA (5 pl) was added to 495 pl of ultrapure water (dilution factor DF= 100) and 
the absorbance measured, after zeroing with water, at 260run, 280nm. and 320nm 
(background) in a clean quartz cuvette. As the RNA extinction coefficient is 40, the 
RNA concentration in the sample can be calculated using the following formula: 
RNA concentration (pg/gl) = Absorbance (260nm-3 20nm) x 40 x DF/ 1000 
3.2.3.3 Determination ofRNA quality 
RNA absorbance at 260nm and 280nm was measured by LTV spectrophotometry and 
the ratio (A26o/A280) calculated to assess the relative degree of protein contamination. 
A260/A280 measurements are expected to be 1.7-2.0 to indicate pure RNA. In this 
work RNA samples were used only if the A2601A280 ratio was greater than 1.8. 
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Total RNA (0.8pg) was separated by electrophoresis in a 1% Tris, Acetic acid, 
EDTA buffer (TAE) agarose gel containing ethidiurn bromide and analysed under 
UV light to exclude RNA degradation and DNA contamination. Two bands 
corresponding to 28S and 18S of eukaryotic ribosomal RNA (rRNA) should be 
visualised with the intensity of the 28S band approximately double that of the 18S 
band. If 18S rRNA is more intense than 28S rRNA, or if both bands are smeared, 
RNA degradation is likely. Extra bands at high molecular weight indicate genomic 
DNA carry-over. Samples with RNA degradation/contamination were not analysed. 
3.2.3.4 Competitive Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
The polymerase chain reaction (PCR) involves DNA polymerase driven 
amplification of a specific DNA sequence flanked by two oligonucleotide primers. 
In Reverse-Transcription PCR (RT-PCR), mRNA is converted to cDNA using a 
reverse transcriptase before being amplified. VEGF mRNA levels were quantified by 
competitive RT-PCR using deletion-mutated cDNA to control for PCR amplification 
efficiency and for use in quantitative analysis (17). Expression of the housekeeping 
gene GAPDH was determined in parallel by competitive RT-PCR to control for 
amount of RNA input and reverse transcription efficiency. 
3.2.3.4.1 Reverse Transcription 
The recipe for reverse transcription is detailed in Appendix II-Table 4. 
Total RNA (I gg) was reverse transcribed in cDNA according to standard protocols 
using the enzyme AMV reverse transcriptase and the POli-d(T)12-18 in a 20gl mix 
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containing reverse transcriptase buffer (lOmM Tris-HCI pH 8.8 at 25oC, 50MM KCI 
and 0.1% Triton X-100), a ribonuclease inhibitor (RnaGuard), M902, 
dexossinucleotides (dNTDs), and molecular water. Samples were left at room 
temperature for 10 minutes, then placed in a DNA Thermal Cycler 480 (Perkin 
Elmer, Warrington WA, USA) for 45 minutes at 420C. Finally, they were heated at 
990C for 5 minutes followed by a 5-minute incubation at 0-50C to inactivate the 
reverse transcriptase and prevent it from binding to the cDNA. cDNA was stored at - 
700C. 
3.2.3.4.2. Polymerase Chain Reaction (PCR) 
cDNA (5pl) was amplified by PCR in a 40pl mix containing PCR buffer, dNTDs, 
primers, M902, the enhancer Perfect Match, and AmpliTaq DNA polimerase. A 
negative control without cDNA was included in each PCR reaction to exclude 
contamination. Composition of the PCR mix for each amplicon studied is reported in 
Appendix II-Table 8. The mix, prepared on ice, was overlaid with mineral oil to 
prevent evaporation, vortex, briefly microcentrifuged, and placed in a DNA Thermal 
Cycler 480 (Perkin Elmer, Warrington WA, USA) for amplification. Thermalcycler 
parameters (number of cycles, temperature and duration of denaturation, annealing, 
elongation) are reported in Appendix II-Table 7. 
The magnesium ions concentration and the annealing temperature were optimised for 
each amplicon. A titration was performed with varying Mg++ concentration (0.5,1,2,3, 
and 4 mM), following which further optimisation was carried out by fine-tuning the 
Mg++ concentration. Ile starting annealing temperature was three degree lower than 
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the calculated melting temperature [Tm = 4(G +Q+ 2(A + T)]. If unwanted bands 
were observed, the annealing temperature was raised in 2*-5*C increments in 
subsequent optimisation runs. 
To ensure that the correct product was being amplified, the molecular weight of the 
PCR products were calculated from their migration relative to that of the molecular 
weight marker. Ibe expected product sizes were 317 bp for VEGF and 600 bp for 
GAPDH. Additionally, the PCR products were digested with restriction endonucleases 
known to have a unique site in the PCR product to give digestion products of an 
expected size. Specificity was confinued by the absence of extra-bands. 
Primcrs 
Oligonucleotide primer sequences for VEGF and GAPDH are reported in Appendix 
11-Table 5. VEGF primers were complementary with sequences located in exons 2-3 
and 5-7 of human VEGF (284,285). Ile primer for exon 2 was based on that 
described by Iijima. et al (166), while the primer for exon 5-7 was designed to amplify 
specifically the 165 isoform of human VEGF, which lacks exon 6 (284,285). GAPDH 
primer sequences were that reported in previous studies (286,287). To ensure that 
there was not amplification of any contaminating genomic DNA sequences, primers 
were designed so that they were spanning different exons. 
Competitive PCR 
PCR amplification was performed in the presence of a cDNA fragment (competitor), 
which has the same primer sequences, but it is 50 bp shorter than the target cDNA. 
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Native and competitor cDNAs, which have a high degree of homology, compete for 
primer binding and amplification, but their PCR products can be distinguished, after 
resolution on an agarose gel, because that derived from the competitor is smaller. 
Competitive RT-PCR for VEGF and GAPDH was performed by preparing serial 
dilutions of a known concentration of deletion-mutated competitor cDNAs that were 
co-amplified with constant volume of native cDNA (50) in separate reaction tubes 
(288). When the molar ratio of the competitor to target is equivalent (competitor 
signal/target signal = 1), the amount of target is equal to the competitive product and, 
after taking into consideration the different sizes of competitor and target, the molar 
concentration of the target cDNA can be calculated. 
Generation of Competitor cDNA. 
Competitors for VEGF and GAPDH with a 50 bp deletion were generated by RT- 
PCR according to the method described by Celi et al. (289). cDNA was amplified by 
PCR using a conventional downstream primer and a mutated (50 bp deletion) 
upstream primer (40 nucleotides in length) yielding to a mutated PCR product (see 
Appendix 11-Table 6). The mutated amplicon was separated by agarose gel 
electrophoresis, cut out of the gel using a sterile scalpel, purified by passage through 
a Geneclean column, and quantified by densitometry. 
Competitive RT-PCR validation 
Kinetic analysis was performed to compare amplification efficiency of native and 
competitive cDNA. Equal molar of native and competitor cDNA were co-amplified 
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for increasing numbers of cycles. PCR products were separated by agarose gel 
electrophoresis and quantified by densitometry. Band intensities, corrected for the 
difference in molecular weight, were expressed as logarithm, plotted against the 
cycle number and the slope of the curves for native and competitor cDNA compared. 
The curves of the target and the competitor overlapped, indicating similar 
amplification efficiencies. 
To assess whether the competitive RT-PCR could accurately detect small changes in 
mRNA concentration, cDNA, obtained by reverse transcribing I and 2 fig of the 
same total RNA, were amplified with dilution series of competitor. The observed 
fold-differences were 1.98 for VEGF, 2.19 for GAPDH. 
3.2.3.5 Preparation ofagarose gel 
Buffers and recipes for agarose gel electrophoresis are listed in Appendix IL 
PCR products were separated, according to their molecular weight, by agarose gel 
electrophoresis. Percentage of agarose in the gel was chosen based on the molecular 
weight of the amplicons. High-resolution and wide range agarose were used to 
increase band definition and separation, if required. The agarose powder in Tris 
Borate EDTA (TBE) buffer was solubilised by boiling in a microwave for 2-3 
minutes, then the ethidiurn bromide, a fluorescent dye that binds to nucleic acids, 
was added and the solution poured into a minigel tray, where a well-forming comb 
was inserted. After polymerisation, the comb was removed and the gel was placed in 
the minitank and covered with IxTBE running buffer. Samples and molecular 
weight marker ((DX174 DNA/Haelll 150ng per line) were mixed with Blue/Orange 
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Loading Dye (1: 6) to allow monitoring of migration, loaded into the gel wells, and 
run at 20 volts (V) for 10 minutes and then at 80V for 30-60 minutes. PCR-products 
and marker were visualised by fluorescence of the incorporated ethidium bromide, 
using a UV transilluminator, analysed by an image system (Eagle Eye System, 





MATERIALS AND NI ETHODS 
Culture supernatants from all experimental conditions were collected, centrifuged to 
remove cell debris and stored at -70'C for analysis. For each experiment protein 
levels were detennined within a single assay run. All protein results were adjusted 
for cell number. 
3.2 4.1 Human Vascular Endothelial Growth Factor measurement 
Reagents, solutions and recipes are detailed in Appendix Ill. 
VEGF protein concentration was measured by an in-house two-site 
immunoenzymometric assay using a mouse monoclonal and a rabbit polyclonal anti- 
human VEGF165- 96-well microtiter plates were coated overnight at 40C with 
200ýd/well of mouse monoclonal anti-VEGF antibody (capture antibody) diluted in 
carbonate/bicarbonate buffer at the final concentration of 2pg/ml. The coating 
solution was removed and the plates blocked with 300ýd per well of 3% bovine 
serum albumin in carbonate/bicarbonate buffer for 2 hours at 37"C in a dry 
incubator. After blocking, 200pI of standards and samples were added to each well 
and incubated for five hours at room temperature. The plates were then washed three 
times with PBS-Triton X buffer in an automatic plate washer and the detection 
antibody (mbbit polyclonal anti-human VEGF165, diluted in matrix solution at the 
final concentration of 0.5gg/ml) was added to the plates and incubated overnight at 
4'C. Immuno-complexes were detected by alkaline phosphatase-conjugated goat- 
anti-rabbit IgG and revealed by 3,3', 5,5' tetramethylbenzidine (TMB) 
dihydrochloride substrate. Specifically, the plates were washed three times with 
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PBS-Triton X buffer in an automatic plate washer and the goat anti-rabbit alkaline 
phosphatase-conjugated antibody, diluted 1: 2000 in the protein matrix solution, was 
added to the plates and incubated for 2 hours at room temperature. After washing, 
200 [LI of the substrate solution were added to each well and incubated for 10-15 
minutes at room temperature. The reaction was stopped with H2SO4 (2M) and the 
absorbance measured at 450/690mn. The assay also detects the VEGF121 iSOfOnn, 
but no cross-reactivity was detected with human platelet derived growth factor 
(PDGF), human TGF-PI-5 and bovine VEGF. The assay range was 1-40 pM and the 
intra-assay coefficient of variance (CV): 5.3%. 
3.2.4.2 Human TGF-, 81 measurement 
Activation of latent TGF-01 was obtained by acidification. Samples, diluted 1: 5 in 
PBS, were incubated with HCI (IN, 2 jil in 50 til of diluted sample) at room 
temperature for 15 minutes to lower the pH to approximately 2.6 and activate latent 
TGF-01, then neutralised to approximately pH 7.6 by addition of NaOH (IN, 2 111 in 
50 ýtl of diluted sample). 
Total TGF-01 protein concentration was measured by Enzyme-linked Immunoassay 
ELISA using a mouse monoclonal and a polyclonal anti-human TGF-01 accordingly 
to manufacturer's instructions. 96 well plates were coated overnight at 40C with a 
monoclonal anti-TGF-01 as capture antibody. Plates were blocked for 35 minutes at 
37'C and then incubated with standards (human recombinant TGF-PI 1000,500, 
250,125,62,31,15.5,0 pg/ml) and samples for 90 minutes at room temperature with 
shaking. After washing, a polyclonal anti-TGF-p I antibody was added and incubated 
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for 2 hours at room temperature with shaking. Immuno-complexes were detected by 
horseradish peroxidase-conjugated IgG and revealed using a chromogenic substrate. 
Briefly, the horseradish peroxidase-conjugated antibody was added to the plates and 
incubated for 2 hours at room temperature with shaking. After washing, the TMB 
substrate solution was added to each well and incubate for 10-15 minutes at room 
temperature without shaking. The reaction was stopped by addition of HCI (IN) and 
the absorbance measured at 450nm. The assay has no cross-reactivity with TGF-P2 
and 3. The assay range is 16-1000 pg/mI and the intra-assay CV 1.6. 
3.2.4.3 Human Fibronectin measurement 
Fibronectin protein levels were measured using a modification of the competitive 
inhibition ELISA described by Rennard (290). 96-well cluster plates were coated 
overnight at 40C with 100 [d of a solution Ing/IgI of human fibronectin in coating 
buffer. Standards (0.5,0.25,0.125,0.06251,0.03125 Pg/ml) (see Appendix 111-Table 
10) and samples were diluted in medium containing 0.5% BSA, then incubated 
overnight at 4"C with equal volumes of rabbit-anti-human fibronectin antibody. The 
following day the plates were washed four times with PBS, 0.1% Tween-20, then the 
solutions of samples/standards-antibody were added to the plate and incubated for I 
hour at 370C. After washing four times with PBS 0.1% Tween-20, anti-rabbit IgG 
(whole molecule) horseradish peroxidase conjugated antibody was added and 
incubated for I hour at 37'C. After washing, the substrate solution was added to 
reveal immunocomplexes. The reaction was stopped by addition of 100 [tl of H2SO4 
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(2M) and the absorbance measured at 450nm. The assay range was 0.05-0.5 [Lg/mi 
and the intra-assay CV 5%. 
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MATERIALS AND METHODS 
All reagents, buffers, solutions, and recipes are detailed in Appendix IV. 
3.2.5.1 Protein Extraction 
Protein extraction was performed on ice to prevent enzymatic digestion of extracted 
proteins. The medium was aspirated, the cells washed twice with ice-cold PBS, and 
60gl of lysis buffer added to each well. The lysis buffer comprised Tris-IICI (50mM) 
and Triton (1%) and a variety of protease [EDTA, ethylene- 
bis(oxyethylenenitrilo)tetraacetic acid (EGTA), phenylmethylsulfonyl fluoride 
(PMSF), leupeptin, aprotinin] and phosphatase (sodium orthovanadate, NaF, sodium 
pyrophosphate) inhibitors to prevent protein digestion/degradation (see Appendix 
IV). Following incubation with the lysis buffer, cells were scraped and lysates 
transferred to pre-chilled microcentrifuge tubes and sonicated four times for 5 
seconds on ice. The lysates were then microcentrifuged for 20 minutes at 12,000xg 
at 40C to remove cell debris. Supernatants were aliquoted for protein measurement 
and western blotting analysis and stored at -70'C. 
Protein extraction for AT-1, GLUT-1, and TGF-BI assessment was performed with a 
lysis buffer containing 50 mmol/L Tris-HCI, pH 7.6, with 1% Triton, 2 mmol/L 
ethylenediaminetetraacetic acid (EDTA), I mmol/L dithiothreitol (DTI), I mmol/L 
PMSF, and 100 mmol/L sodium chloride. Lysates were then sonicated for 45 
seconds at 41C. A lysis buffer containing deoxycolate and NP40 was used in TGF-P 
receptors protein extraction (see Appendix IV). 
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Levels of pericellular polymeric fibronectin were determined in deoxycolate- 
insoluble and SDS-soluble protein extracts as previously described (291) (see 
Appendix IV-Table 14). Protein extraction was performed with a lysis buffer 
containing Tris-HCl (PH 8.8 20mM), deoxycolate 2%, and protease inhibitors 
(PMSF, EDTA, iodoacetic acid, and N-ethyl-maleimide). The cell lysates were 
centrifuged at 10,000xg for 20 minutes to spin out deoxycolate-insoluble material, 
which was then dissolved in Tris-HCI (pH 8.8 20mM), containing sodium dodecyl 
sulphate (SDS) 1% and protease inhibitors (PMSF, EDTA, iodoacetic acid, and N- 
ethyl-maleimide). 
3.2.5.2 Total Protein Measurement 
Total protein concentrations in the samples were quantified using a detergent- 
compatible (DQ, colorimetric protein assay (Bio-Rad, USA) based on the reaction 
of protein with an alkaline copper tartrate solution and Folin reagent. A standard 
solution of 13.6 mg/ml of Iyophilised bovine serum albumin (BSA) was obtained by 
dissolving 27.2mg of the powder in 2ml of ultra-purified water. A stock of 3.0 
mg/mi was then prepared by the addition of 221 ttl of this to 779 ttl of the lysis 
buffer used for the protein extraction. A serial dilution of the 3. Omg/ml stock 
produced five different albumin concentrations that were used to generate a standard 
curve. Dilutions were performed using the same lysis buffer used to obtain the 
samples (see Appendix IV-Table 11). 
In accordance to the manufacturer's protocol, 5ýd of samples and standards were 
added to a microplate in duplicate. 25pl of alkaline copper tartrate solution (Reagent 
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A) and 200pl of dilute Folin solution (Reagent B) were then added and the plate left 
to stand for 15 minutes at room temperature. The copper treated proteins react with 
and reduce the Folin reagent, thereby producing one or more reduced species which 
have a characteristic blue colour with maximum absorbance at 750nm that was 
measured using a spectrophotometer microplate reader (Labsystems Multiskan 
Biochromatic, Lab Systems, UK). The amount of albumin in the standards was 
plotted against this average absorbance to produce a standard curve, which was then 
used to determine the amount of protein in the samples. 
3.2 5.3 SM-Polyacrylamide Gel Electrophoresis (SDS-PA GE) 
Extracted proteins were separated, according to their molecular weight, using SDS 
polyacrylamide gel electrophoresis (SDS-PAGE). A discontinuous polyacrylamide 
gel, consisting of a 4% stacking gel where proteins were concentrated, and a 5-12% 
separating gel where they were resolved. The acrylamide solution was prepared (as 
detailed in Appendix IV-Table 15) and de-gassed under vacuum for 20 minutes in 
order to limit inhibition of acrylamide polymerisation by oxygen dissolved in the gel. 
The polymerisation enhancers, ammonium persulphate (APS) and N, N, N', N'- 
tetramethylethlyenediamide (TEMED), were added and the solution poured into a 
gel mould consisting of two glass plates separated by 1.5mm spacers. A thin layer of 
de-ionised water was placed on top of the separating gel solution, to exclude 02, 
from the surface during polymerisation. After I hour the water overlay was poured 
off and a 4% acrylarnide solution, prepared as detailed in Appendix IV-Table 16, 
was poured on top of the separating gel. A well-forming comb was inserted carefully 
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so as not to trap air bubbles under the teeth. The gel was left to polymerise for 45 
minutes, after which the comb was gently removed and the wells washed three times 
with distilled water and dried using filter paper. The results of the DC Protein assay 
were used to calculate the volumes of samples required to ensure an equal amount of 
protein was loaded across all wells and to allow for direct comparison between lanes 
during analysis. Equal amounts of sample protein (-40gg) were solubilised and 
denatured at 95'C for 4 minutes in the loading buffer (see Appendix IV-Table 17) 
containing P-mercaptoethanol and SDS. SDS is an anionic detergent that gives the 
proteins a net negative charge that is proportional to the size of the protein, thus 
separation is based solely on the molecular weight of the proteins. Samples were 
subsequently mixed by vortexing, and left in ice for 5 minutes. ne electrophoresis 
tank was set up according to the manufacturer's instructions (Bio-Rad, Hemel 
Hempstead, UK) and running buffer (see Appendix IV-Table 18)) poured into both 
the inner and outer chambers. Electrophoresis was performed by the application of a 
JOOV voltage across the gel for the first 10 minutes and 140V for the subsequent 50 
minutes. A pre-stained molecular weight marker was run in parallel (Bio-Rad, 
Hemel Hempstead, UK) and used to visualise protein migration, confirm subsequent 
transfer to a nitrocellulose membrane and calculate protein molecular weight. 
3.25.4 Western blotting 
Following electrophoresis, proteins were blotted from the polyacrylamide gel onto a 
nitrocellulose membrane (NCM; pore size 0.451im, Amersham Life Science, 
Buckinghamshire, UK) using a Mini Trans-Blot cell (Bio-Rad, USA). Tle NCM was 
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activated by soaking in distilled water for 10 minutes. Both the NCM and gel were 
then placed in the blotting buffer (see Appendix IV Table 19) to equilibrate for 15 
minutes. A transfer stack was then compiled of layers of sponge, filter paper, gel and 
membrane and enclosed in a cassette which was fully submerged in cold blotting 
buffer, great care being taken to exclude any bubbles between layers. The transfer 
stack was placed in a blotting tank according to the manufacturer's instructions, fully 
submerged in blotting buffer. Electrophoretic transfer was achieved by the 
application of aI OOV potential difference across the gel and adjacent membrane. 
After the transfer, gel staining with the protein dye Coomassie-Brilliant Blue was 
performed to assess whether proteins had been efficientlY removed for the gel. The 
gel was stained by soaking in excess 0.1% Coomassie-Brilliant Blue staining 
solution (see Appendix IV-Table 21) for 30 minutes, then de-stained with a large 
excess of acetic acid (10%) and-methanol (40%) de-staining solution (see appendix 
IV-Table 22) until the background had been satisfactorily removed. The gel was 
dried and kept as a record. Furthermore, equal protein loading and transfer efficiency 
to the NCM was verified using the protein dye Ponceau S. The NCM was stained in 
excess 0.1% Ponceau S staining solution (see Appendix IV-Table 23) for 10 minutes 
on a rocker platform. Excess stain was washed off with distilled water until bands 
contrasted with an increasingly white background and records of the results were 
taken. 
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The membrane was air-dried for approximately 10 minutes to enhance protein 
binding. Prior to immunodetection the NCM was blocked in a solution of tris- 
buffered saline (TBS) (pH 7.6), 0.5% Tween-20 and 5% non-fat dry milk for one 
hour at room temperature while placed on a rocker platform, in order to decrease 
unwanted background. The membrane was then incubated with the first antibody 
diluted in 20ml of TBS containing 5% non-fat dry milk, overnight at 4'C (see 
Appendix IV Table 20 for details on the dilution used for each antibody). Following 
extensive washing using TBS (pH 7.6) with 0.5% Tween 20 (20 minutes, three 
times) to remove unbound antibody, the membrane was incubated at room 
temperature for I hour on a rocker platform with the secondary species-specific 
antibody conjugated to horseradish peroxidase (HRP) and diluted in 20ml of TBS 
containing 5% non-fat dry milk and 0.5% Tween 20. The membrane was then 
cleared of unbound secondary antibody by a series of washings identical to the first, 
before undergoing detection. 
3.2.5.6 Enhanced Chemiluminescent (ECL) detection 
Detection was performed by enhanced chemiluminescence (ECL; Amersharn Life 
Science, Buckinghamshire, UK). 'Ibe membrane was incubated with an ECL reagent 
mix (0.125ml per crný of membrane) containing luminol, hydrogen peroxide and 
phenol for precisely I minute at room temperature. The luminol is oxidiscd by the 
horseradish peroxidase enzyme on the secondary antibody in the presence of 
hydrogen peroxide and phenol. As the luminol returns from its oxidised, excited 
state to its former (lower energy) ground state, it emits a blue light that can be 
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captured on autoradiography film. The intensity of the blue light emitted is 
proportional to the amount of HRP enzyme and hence antigen present. The 
membrane was drained of excess ECL reagent, enclosed in Saran Wrap and exposed 
to light-sensitive autoradiography film (Hyperfilm ECL) for various time periods. 
The autoradiographs were scanned with Eagle Eye 11 Still Video System 
(Cambridge, UK) and the band intensity was quantified using a computer software 
package (QGEL- I D, Strategene). 
3.2.5.7 In vitro kinase assay 
p38 NW kinase activity was determined using a non-radioactive 
immunoprecipitation-kinase assay. The medium was aspirated; the cells washed 
twice with ice-cold PBS, and the lysis buffer added to each well. The lysis buffer 
comprised Tris (20mM), NaCI (150 mM) and Triton X-100 (1%) and a variety of 
protease (EDTA, EGTA, PMSF, leupeptin) and phosphatase (sodium orthovanadate, 
sodium pyrophosphate) inhibitors to prevent protein digestion/degradation. 
Following incubation with the lysis buffer for 5 minutes, cells were scraped and 
lysates transferred to pre-chilled microcentrifuge tubes and sonicated four times for 5 
seconds on ice. The p38 MAP kinase antibody (dilution 1: 50) was added to the cell 
lysate and incubate with gentle rocking overnight at 4'C. Protein A sepharose beads 
were then added and the mixture left to incubate for 3 hours at 41C. After 
microcentrifugation for 30 seconds at 4"C the pellet was washed twice with lysis 
buffer, then twice with kinase buffer. The pellet was suspended in kinase buffer (50 
pl), adcnosine tri-phosphate (ATP) 200 pM, and 2 gg of ATF-2 fusion protein for 30 
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minutes at 301C. The kinase buffer comprised Tris (25mM, pH7.5), 0- 
glycerolphosphate (5niM), DTT (2mM), 
Na3V04 (0-1 mM) and MgC12 (10 MM)- 
After the addition of sample loading buffer, the samples were boiled for 5 minutes, 
vortex, then microcentrifuged for 2 minutes. Analysis of ATF-2 phosphorylation at 
Thr-71 was performed by immunoblotting using a specific phospho-ATF-2 (Thr7l) 
rabbit polyclonal antibody. 
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MATERIALS AND METHODS 
Kidney tissue was frozen in isopenthane, cooled in liquid nitrogen, and stored at - 
80'C. GLUT-1 immunoperoxidase staining was carried out on 4-pm frozen tissue 
sections fixed in acetone at 4'C for 10 minutes. Tissue sections were washed in 0.2% 
Tween-TBS (TTBS), pH 7.4, followed by peroxidase blocking step with 0.03% 
hydrogen peroxide for 10 minutes. The sections were blocked for 30 minutes with 10 
% goat serum in TTBS, and this was followed by 1-hour incubation at room 
temperature with primary rabbit polyclonal anti GLUT-1 antibody (1: 600 dilution). 
After washing with TTBS, sections were incubated with a peroxidase-labelled 
polymer conjugated to a goat anti-rabbit IgG for 30 minutes, and then washed again 
in TTBS. GLUT-I was revealed by addition of the substrate 3,3'-diaminobenzidine 
giving a brown staining. The sections were counterstained with haematoxylin to 
visualize nuclei, and finally were mounted in mounting medium. Negative controls 
were performed by either omitting the anti-GLUT-1 antibody or by pre-incubation 
of the antibody in excess GLUT-1 blocking peptide. 
Fifteen randomly selected glomeruli were analysed for each animal by a masked 
observer; the calculated average GLUT-I staining was then used for statistical 
analysis. Areas positive for GLUT-1 were calculated by using a computer-assisted 
image analysis system KS-300 (Zeiss) connected to a BX60 microscope (Olympus) 
and a KY-F5513 (JVC) colour videocarnera. Glomeruli boundaries were defined by 
external perimeter of the capillary loops. Determinations were made using the same 
light microscope intensity. 
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3. Z7 Glucose Transport Assav 
MATERIALS AND METHODS 
Glucose transport assay in mesangial cells in vitro was performed according to the 
method described by McClain and Heilig with minor changes (292). Cell culture 
medium was removed and wells washed twice with PBS, then cells were incubated 
for 2 hours in glucose-deprived RPMl quiescent medium made iso-osmolar with 
mannitol. After washing twice with PBS, basal transport was started by the addition 
to cells of 100 pM 2-deoxyglucose (2-DOG) and 0.4 [LCi/ well of [3 H] 2-DOG in 
glucose-free minimal essential media. Transport was performed at 37'C for 5 
minutes as in preliminary experiments we observed a linear 2-DOG uptake up to 15 
minutes. Transport was stopped by addition of I ml phloretin solution in PBS (82 
mg/L), rapid removal of the radioactive solution, and washing with ice-cold PBS. 
Plates were left to dry for 30 minutes at 37'C and NaOll (IM) was incubated in for 
I hour at 37*C. The lysates were harvested in counter vials and neutralised with an 
equal volume of HCI (IM). After addition of scintillation fluid, [31 1] 2-DOG 
incorporation into cells was measured in a B-counter. 2-DOG uptake was calculated 
after subtraction of 2-DOG-non-specific uptake determined in parallel samples 
incubated in the presence of 10 pmoVL cytochalasin B. Results were normalised for 
cell number determined in parallel wells. 
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MATERIALS AND METHODS 
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The number of experiments is reported in the figure legends. Experiments were 
carried out in duplicate-triplicate. All data are presented as mean ± SEM. t test was 
used for comparison between two groups. When more than two groups were studied, 
data were analysed by ANOVA and, if significant, the Neuman-Keuls procedure was 





STRETCH INDUCES VEGF GENE EXPRESSION AND PROTEIN 
SECRETION IN HUNL4, N MESANGIAL CELLS VIA A PKC AND Sre- 
DEPENDENT MECHANISM 
4.1 Background 
Haemodynamic factors have been pathogenically implicated in the increased 
glomerular permeability to macromolecules, which characterises diabetic and other 
glomerulopathies (239,293), and treatment strategies that reduce glomerular 
capillary pressure have an antiproteinuric and renoprotective effect in both human 
and animal studies (219,220,241). Mesangial cells are in apposition to and in 
continuum with the glomerular capillaries and thus constitute a primary target for the 
mechanical insult induced by increased glomerular capillary pressure. The 
mcsangium plays a crucial role in the glomerular trafficking of plasma protein, and 
their deposition and accumulation within the mesangium may eventually lead to the 
development of glomerular sclerotic lesions (25). 
The vast majority of the in vitro studies on mesangial. cells have been 
performed under static conditions and little is known about the response of 
mesangial cells to a mechanical insult. Application of mechanical stretch to mimic a 
haemodynamic insult has been reported to induce mesangial cell matrix production 
in rat mesangial cells (265,266), suggesting a potential mechanism whereby a 
haemodynamic insult may be translated into a glomerular sclerotic process. Whether 
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mechanical stretch could also induce the expression of factor(s) that may influence 
glomerular permeability is unknown. 
The VEGF family consists of more than five different isoforms of highly 
conserved homodimeric glycoproteins, with heparin-binding properties (155). 
VEGF165 is the predominant VEGF isoform. VEGF binds to three receptors 
predominantly located on vascular endothelium and induces endothelial cell 
proliferation and increased vascular permeability to macromolecules (155,156,159- 
160). In the kidney VEGF is predominantly secreted by podocytes and tubular cells, 
while VEGF receptors are expressed on the endotheliurn (161). However, both in 
vitro and in pathological conditions VEGF is also produced by several other 
glomerular cell types (166,294), including mesangial cells. Further, VEGF receptors 
have been shown in vitro in both mesangial cells and podocytes (162,163). In both 
human and experimental diabetic nephropathy VEGF and its receptors are 
overexpressed in the glomeruli (168,169). VEGF plasma levels are increased in type 
I diabetic patients with nephropathy (170). Moreover, VEGF blockade ameliorate 
proteinuria in animal models of both type I and type 2 diabetes (171,172), 
suggesting a role of VEGF in the increased glomerular permeability to protein seen 
in diabetic glornerulopathy. 
Little is known as yet about the modulation of kidney VEGF production in 
response to haemodynamic perturbations. The present study was designed to test 
whether the application of mechanical stretch induces VEGF gene expression and 
protein secretion in human mesangial cells and to investigate the signal transduction 
pathways involved in this process. 
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4.2 Experimental Design 
Materials and Methods are detailed in Chapter 3 and Appendix I, II, III, V 
Human mesangial cells were seeded in equal number (12,000/cm2) into six 
well collagen-coated silicone elastomer-base culture plates (Flex I plates) and 
control plates (Flex Il plates). After 3-5 days, they were both serum and insulin- 
deprived for 48 hours. Cells were then subjected to repeated stretch/relaxation cycles 
by mechanical deformation using a Stress Unit for 6,12, and 24 hours. Vacuum was 
cyclically applied (60cycles/min) to induce an average of either a 4% or 10% 
uniaxial elongation in the culture surface. Control cells were grown in non- 
d6ormable, but otherwise identical plates (Flex It plates) in parallel. A subset of 
experiments was performed on human skin fibroblasts to evaluate the cell-specificity 
of the stretch-induced effects. Total RNA was extracted and VEGF mRNA levels 
measured by competitive RT-PCR. Supernatants were collected and VEGF protein 
levels measured by ELISA, then corrected for cell numbers. 
To investigate the intracellular mechanism/s of stretch-induced VEGF, we 
either inhibited or blocked PKC, protein tyrosine kinases (PTK), and TGF-B. Cells 
were exposed to either PKC inhibition by pre-incubation for I bour with H7 (50gM) 
or PKC downregulation by pre-incubation for 24 hours with PMA (10-7 M). PTK 
inhibition was obtained by pre-incubation for an hour with genistein (20[Lg/ml), 
herbimycin A (3-4 tiM), or the pp60src tyrosine kinase peptide inhibitor (peptide A, 
21gM), a 21-residue peptide corresponding to a part (residues 137-157) of the 
noncatalytic domain of pp60src (295). TGF-P was blocked by addition of a specific 
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pan-neutralising anti-TGF-P antibody (20 Itg/ml). Inhibition experiments on basal 
VEGF protein secretion were also carried out simultaneously and appropriate control 
experiments were conducted in parallel. 
43 Results 
4.3.1. ffect ofstretch on mesangial cell VEGF mRNA levels 
Both stretched and control cells expressed the VEGF165 iSOfOrm. At 10% elongation 
stimulus VEGF mRNA level rose to a peak by 6 hours (2.4 fold increase over 
control, p<0.05) and diminished towards the basal level by 12 hours (1.3 fold 
increase over control) as assessed by competitive RT-PCR (Figures F4-1 and F4-2). 
4.3.2. ffLect ofcell stretch on VEGF protein levels 
To determine whether altered VEGF MRNA levels were accompanied by an 
increased protein secretion, the VEGF concentration was measured in the culture 
supernatant by ELISA. VEGF protein was detected in control conditions and the 
application of a low level of mechanical stretch (4% elongation) did not alter VEGF 
protein secretion (1.03 ± 0.08 fold increase over control). In contrast higher degrees 
of mechanical stretch (10% elongation) resulted in a marked increase in VEGF 
protein levels by 12 hours (3.1 ± 0.3 fold increase over control, p<0.001) with a 
return to the baseline by 24 hours (Figure 174-3), in keeping with the changes in 
mRNA. The application of mechanical stretch (elongation 10%) for 12 hours did not 
alter VEGF protein level in cultured human fibroblasts (1.05 ± 0.37 fold increase 
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over control), confirming the cell-specificity of the stimulus and the absence of non- 
specific protein release due to stretch-induced cell membrane damage. 
4.3.3 Stretch-induced VEGF secretion is independent of TGF- 
TGF-P is a known VEGF inducer in mesangial. cells (166) and stretch stimulates 
TGF-P production in rat mesangial cells (269). To assess whether TGF-P was the 
mediator of stretch-induced VEGF, serum- and insulin-deprived mesangial cells 
were exposed to cyclical stretch for 12 hours in the presence or in the absence of a 
specific pan-neutralising anti-TGF-P antibody (20 ýLg/ml). Stretch induced a 
significant 2.85 fold increase in VEGF secretion, which was unaltered by the 
inhibition of TGF-B activity (stretch: 2.85 + 0.82 vs stretch + anti-TGF-B: 2.84 ± 
0.01 fold increase over control) (Figure F44), indicating that VEGF protein 
production in response to stretch is independent of TGF-B. 
4.3.4 Intracellular mechanismls ofstretch-induced VEGF secrellon 
To investigate the intracellular mechanisms by which stretch induces VEGF 
production, we examined the effect of PKC and PTK inhibition. Basal secretion of 
VEGF was unaffected by pre-treatment with H7, PMA, genistein, herbimycin A, and 
peptide A (Figure F4-51)). Pre-treatment with H7 significantly inhibited the VEGF 
secretion to stretch (72% inhibition; p<0.05). PKC depletion by pre-treatment with 
pMA also significantly reduced the VEGF response to stretch by 74% (P<0.05), 
confirming the involvement of PKC (Figure F4-5A). The addition of genistein 
reduced significantly the VEGF response to stretch by 63% (p<0.05) (Figure F4-5B). 
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Because genistein, a PTK inhibitor which competes with ATP, is also reported to 
have a PKC inhibitory activity at high concentration, we tested the effect of 
herbimycin A, which blocks PTK activity through benzoquinone interactions with 
protein sulphydral. groups, and of peptide A, which has a direct and specific effect on 
the PTK pp60src (295). Neither of these compounds has an inhibitory activity on 
PKC (295,296). Herbimycin A reduced stretch-induced VEGF secretion by 80% and 
peptide A induced a 75% inhibition (p<0.05 for both) (Figure F4-5B). Pre-treatment 
with a combination of H7 and genistein totally abolished stretch-induced VEGF 
protein secretion (100% inhibition, p<0.05) (Figure F4-5Q. Cell viability, confirmed 
by trypan blue exclusion, was similar in all experimental conditions. 
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Figure F4-1: Quantitative analysis of VEGF mRNA by competitive RT-PCR in 
mesangial cells exposed to stretch for 6 hours. cDNAs obtained from both stretched 
and control cells were amplified in the presence of serial dilution of mutated cDNA. 
Line a: c-DNA native. Line b: serial dilution (1: 2) of mutated cDNA, maximal 
concentration: 0.4 xI 0-6attomoles in lines 11-12. MW: molecularweight 0174, Hae 
111. Line 2: negative control. Lines 3-5-7-9-11: amplicons from stretched cells. Lines 
4-6-8-10-12: amplicons from control cells. 3% Nu-Sieve/1% agarose gel stained 
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Figure F4-2: Human mesangial cells were serum and insulin-deprived for 48 hours, 
then exposed to mechanical stretch for the indicated time periods. VEGF mRNA 
level was quantitated and expressed as fold increase vs control non-stretched cells (n 
= 4). * P<0.05 stretched vs control non-stretched cells at 6 hours. 
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Figure F4-3. Human mesangial cells were serum and insulin-deprived for 48 hours, 
then exposed to mechanical stretch for the indicated time periods. VEGF protein 
level was measured by ELISA, corrected for cell numbers, and expressed as fold 
increase vs control non-stretched cells (n = 15). * P<0.001 stretched vs control non- 
stretched cells at 12 hours. 
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RESULTS 
Figure F44 Serum and insulin-deprived human mesangial cells were exposed to 
mechanical stretch for 12 hours in the presence or in the absence of an anti-TGF-B 
(20ptg/ml) neutralizing antibody. VEGF protein levels were measured by ELISA, 
corrected for cell numbers, and expressed as fold increase vs control (n=3). *P<0.05 
stretch and stretch + anti-TGF-B vs others. 
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4 St Figure F4-5 Mesangial cells were exposed for 12 hours to stretch in the presence or 
in the absence of (A) PKC inhibition by I hour pre-incubation with 117 (50AM) or 
PKC depletion by 24 hours PMA pre-incubation (10-7 M), (B) PTK inhibition by I 
hour pre-incubation with genistein (20ILg/ml), or herbimycin A (3.4 gM), or peptide 
A (2lgM), (C) PKC and PTK inhibition by I hour pre-incubation with genistein 
(20gg/ml) plus H7 (501N). Results are expressed as fold increase vs control non- 
stretched cells (n = 4). Stretched cells vs stretched cells plus inhibitors * P<0.05 for 
all. Panel (D) shows the effect of PKC and PTK inhibition on basal VEGF secretion 
in control non-stretched cells (absolute values in nanogram, adjusted for cell number) 
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These results demonstrate that mechanical stretch of cultured human 
mesangial cells induces VEGF gene expression and protein secretion. 
Mesangial cells subjected to cyclic stretching, to simulate an in vivo 
haemodynamic insult producing an approximately 10% elongation, showed a 
significant increase in VEGF mRNA level, which was maximal after 6 hours and 
diminished by 12 hours. These changes in VEGF mRNA level were temporally 
related to a significant three-fold increase in the secretion of VEGF peptide, which 
peaked after 12 hours returning to the baseline values by 24 hours. Using precise 
quantitative determinations by immunoenzymometric; assay, we confirmed here that 
secretion of VEGF protein occurs in human mesangial cells under static basal 
conditions as previously suggested by other studies in experimental animal 
mesangial cells (166). Moreover, in rat mesangial cells stretch induces the gene- 
expression of other molecules, such as matrix components - laminin and fibronectin, 
with a similar pattern (266). Ile progressive reduction in response with time is a 
common feature of response to in vitro stimuli. The explanation for this is unclear, 
however, downregulation or depletion of cellular components necessary for the 
signal transduction may be important. Furthermore, in vitro exposure to a constant 
insult may induce desensitisation, an effect that in vivo is prevented by momcnt-to- 
moment variations in intraglomerular prcssurc levels. 
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Cell viability was preserved in stretched cells indicating the rise in VEGF 
was not due to a cytotoxic effect. Furthermore, the observation that stretch does not 
induce VEGF in fibroblasts suggests a cell specificity of stretch-induced effects. 
TGF-B is a known inducer of VEGF expression in mesangial cells and stretch 
stimulates TGF-B production in rat mesangial cells (166,269), suggesting TGF-B as 
potential mediator of stretch-induced VEGF. However, the VEGF response to stretch 
was very rapid making unlikely an indirect effect. Accordingly, the addition of a 
TGF-13 neutralizing antibody did not alter stretch-induced VEGF secretion. It is, 
however, possible that, once released in response to stretch, TGF-B induces further 
VEGF secretion. 
Our experiments, designed to determine the intracellular mechanisms 
mediating VEGF induction by stretch, provided evidence that PKC and PTK are 
components of the signalling mechanisms involved. The significant blunting of the 
increase in VEGF protein secretion in response to stretch by either the addition of 
the PKC inhibitor, H7, or PMA-induced PKC depletion, strongly supports a role of 
PKC as an intracellular mediator of stretch. PKC-responsive loci have been 
described on the VEGF gene promoter and other stimuli have been shown to induce 
VEGF via a PKC-dependent mechanism (284,297,298). PKC translocation to the 
cell membrane with phosphorylation of an 80kDa endogenous substrate of PKC 
occurs within minutes of mechanical stretch (272,299) and several other 
observations in both cultured myocardial cells and rat mesangial cells underscore the 
role of PKC activation in response to mechanical overload (260,300,301). 
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We further have demonstrated that mechanical stretch-induced VEGF protein 
secretion also was significantly impaired by genistein and herbimycin A, two 
mechanistically unrelated protein tyrosine kinase inhibitors. These results prove that 
protein tyrosine kinases are directly implicated in the VEGF response to mechanical 
stretch in human mesangial cells. Hypoxia was so far the only other stimulus known 
to induce VEGF through a protein tyrosine kinase-dependent mechanism (15 8). Of 
interest, tyrosine kinases have been implicated also in stretch-induced TGF-P 
expression in rat mesangial cells (270). Which protein tyrosine kinases are 
responsible for VEGF induction remains to be elucidated, but the protein tyrosine 
kinase pp60src is a likely candidate because it is activated by stretch in foetal lung 
cells (302) and has been implicated in VEGF induction by hypoxia (15 8). In keeping 
with this hypothesis, we observed an inhibition of stretch-induced VEGF protein 
secretion in the presence of a tyrosine-kinase peptide inhibitor, which is highly 
specific for pp60src. 
The response to stretch was partially prevented by either PKC or PTK 
inhibition and the combined inhibition of both PKC and PTK totally abolished 
VEGF induction by mechanical stretch. These results suggest that separate signalling 
cascades are likely to be implicated and raise the possibility that they may act 
independently. 
These in vitro findings may have important implications for in vivo 
pathophysiological conditions in renal disease. Rises in intraglomerular pressure as 
measured in experimental diabetes and remnant kidney models can be calculated to 
result in an expansion in glomerular volume, which entails approximately a 10% 
114 
CHAPTER 4 RESULTS 
radial elongation (251,252). Of interest, the increase in VEGF protein seen in 
response to stretch was only evident at these higher degrees of elongation, whereas 
the application of more "physiological" levels of mechanical stretch (4% elongation) 
did not alter VEGF protein secretion. These data suggest that stretch-induced VEGF 
expression may be a specific feature of glomeruli with high intraglomerular pressure. 
We applied a cyclical mechanical stretch on the evidence that in the normal 
glornerulus capillary pressure is pulsatile (283) and that in situations such as diabetes 
this pulsatility may be enhanced because of defective autoregulation (239,303). 
Glomerular expression of VEGF and its receptors is enhanced in both human 
and experimental diabetic nephropathy (168,169) to suggest a role of this cytokine 
in diabetic glomerular damage/dysftmction. VEGF is a potent vasopermealising 
agent and blockade of VEGF ameliorate proteinuria in experimental models of both 
type I and type 2 diabetes (171,172). VEGF receptors are predominantly expressed 
on endothelial cells and VEGF action on vascular permeability is mainly due to its 
effect on endothelial fenestration (159,160). However, in vitro VEGF receptors have 
been demonstrated in mesangial cells and podocytes (162,163), suggesting that 
VEGF may affect glornerular permeability also by acting on these cell types via 
auto/paracrine mechanisms. These in vitro results may provide a potential molecular 
mechanism by which a haernodynamic insult translated into a greater transcapillary 
transit of macromolecules resulting in proteinuria, a key factor in the progression of 
renal disease. 
The observation that stretch-induced VEGF is mediated via PKC activation 
has particular relevance for diabetes because PKC is also activated by high glucose 
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concentration (196). Moreover an oral inhibitor of the B isoform of PKC prevents 
significantly the development of proteinuria in the experimental diabetic rat (208). 
Finally, after the publication of the present study, it has been reported that PKC also 
mediated high glucose- and AGEs-induced VEGF expression in mesangial cells 
(164,165), supporting the hypothesis that in diabetes metabolic and haemodynamic 
perturbations converge in a common deleterious intracellular signalling pathway. 
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CHAPTER 5 
INTERACTION BETWEEN STRETCH AND ANGIOTENSIN 11 ON 
VEGF EXPRESSION IN HUMAN MESANGIAL CELLS 
5.1 Background 
Diabetic nephropathy is characterised by both excess extracellular matrix 
deposition in the mesangium and increased glomerular permeability to proteins (1). 
The underlying mechanisms remain unclear, even though the anti-proteinuric and 
reno-protective effect, in both human and animal studies, of blood pressure lowering 
drugs and particularly angiotensin converting enzyme inhibitors (ACE inhibitors) 
(219,220,241) strongly suggests the importance of the haemodynamic insult and 
implicates, in particular, the renin angiotensin system (RAS). 
Angiotensin II (AngII) affects the level of glornerular hypertension and 
thereby the degree of mesangial cell stretching through its action on both systemic 
and renal haemodynamics. Within the kidney, there is an intact, independent RAS 
(180), and locally produced Ang Il exerts important effects independent of its 
haernodynamic activity that may contribute to the progression of renal disease 
(179,180). In particular, Ang II can directly induce mesangial cell TGF-BI 
production, extracellular matrix deposition (181), and increased glomerular 
permeability to protein (186,187). In cardiac myocytes, stretch-induced cffects are 
partially mediated via Ang Il release (304). Furthermore stretch and Ang II act 
synergistically in inducing cardiac myocyte proliferation (305) and additively in 
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inducing mesangial cell TGF-PI expression (270). The haemodynarnic and non- 
haemodynamic actions of Ang II may thus combine at the cellular level promoting 
glomerular injury. To date, there is no information in human mesangial cells on the 
role of Ang 11 as a potential mediator of stretch-induced effects or on its interaction 
with stretch. 
Having established that mechanical stretching of cultured human mesangial 
cells stimulates VEGF expression (see Chapter 4), we tested whether Ang II also 
alters VEGF expression in mesangial cells, and investigated the interactions between 
Ang Il and mechanical stretch on VEGF production. 
5.2 Experimental Design 
Materials and Methods are detailed in Chapter 3 and Appendix I, 11,111, IV, 
and V 
Cells were seeded in equal number (12,000/cm2) and senim- and insulin- 
deprived for 48 hours prior to the experiment, because VEGF mRNA expression is 
stimulated by low concentrations of foetal. calf serum (166) and by insulin (306). 
Cells were then exposed to increasing Ang II concentrations (10" 0,10-9 1 o-6,10-4 M) 
for various time periods (6,12,24, and 48 hours) to establish the time-course and 
dose response of Ang II-induced VEGF in mesangial cells. Subsets of experiments 
were performed in the presence of Losartan (I OgM), an angiotensin 11 AT-1 receptor 
antagonist. Total RNA was extracted and VEGF mRNA levels measured by 
competitive RT-PCR. Supernatants were collected and VEGF protein levels 
measured by ELISA and corrected for cell number. 
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To investigate the role of Ang II in stretch-induced VEGF expression, cells 
were subjected to repeated stretch/relaxation cycles as described in Chapter 34 for 
12 hours in the presence and the absence of Losartan (I OgM). The 12 hours time 
point was chosen on the basis of our previous results (see Chapter 4) showing that 
stretch for 12 hours maximally induces VEGF secretion in mesangial cells. 
To assess if stretch affects Ang II-induced VEGF, cells were simultaneously 
exposed to Ang 11 (1 ýLM) and stretch (10% elongation) for 12 hours. In addition, the 
effect of pretreating cells with stretch prior to the application of Ang II was also 
explored. In details, cells were exposed to stretch (10% elongation) for 12 hours, 
then the conditioned medium was removed and after repeated washes in PBS, both 
prestretched and control unstretched cells were exposed for a further 12 hours to Ang 
II (IgW or vehicle in fresh culture media. VEGF levels were measured in the 
supernatants by ELISA and the expression of AT-I studied in total protein extracts 
from stretched and control cells by immunoblotting. 
5.3 Results 
5.3.1 Angff induces VEGFgene wression inhuman mesangial cells. 
After preliminary experiments to establish the optimum concentration of Ang 11, 
VEGFI 65 RNA levels were measured after 4-, 6-, and 12-hour exposure to either Ang 
11 (ljtý or vehicle. VEGF, 65 mRNA was expressed in basal conditions and was 
induced by Ang 11 after 6 hours (1.5 =E: 0.09 fold increase p<0.05) (Figure F5-1) with 
a return to baseline levels by 12 hours. 
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5.3.2. A ngg II induces VEGF protein secretion 
To investigate the effect of Ang II on VEGF protein production, serum and insulin- 
deprived mesangial cells were exposed to increasing Ang 11 concentrations (10- 10,10- 
8,10-63110-4 M) for various time periods (6,12,24, and 48 hours). Maximal VEGF 
protein production was seen at a dose of IgM. Ang II-induced VEGF protein 
production increased by 12 hours (1.74 ± 0.25 fold increase p<0.05) and 
progressively diminished towards baseline by 48 hours (Figure F5-2A-B). 
5.3.3 Ang II-induced VEGF protein secretion occurs via the AT] recentor 
ATI is the Ang II receptor expressed by adult human mesangial cells and is 
responsible for all of the known actions of Ang li (179,307,308). Supplementation 
with Losartan (IOILM), a selective and specific ATI receptor antagonist (309), had 
no effect on basal VEGF secretion, but completely abolished Ang Il (I gM, 12 hours) 
induced VEGF protein production (Figure F5-3A). 
5.3.4 Stretch-induced VEGF secretion is independent ofA TI-receptor 
Seruin- and insulin-deprived mesangial cells were exposed to cyclical stretch for 12 
hours in the presence or in the absence of Losartan (10gm). Stretch induced a 
significant 2.4 fold increase in VEGF secretion, which was unaffected by the 
addition of Losartan (stretch: 2.40 ± 0.40 vs stretch + Losartan: 2.62 4- 0.53 fold 
increase over control) (Figure F5-3B), indicating that stretch-induced VEGF protein 
production is indepcndent of the ATI reccptor. 
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5.3.5 Simultaneous uposure to Ang II and stretch additively enhances VEGF 
production 
To study the effect of combined exposure to Ang II and stretch on human mesangial 
cell VEGF production, mesangial cells were exposed to stretch and/or Ang Il (I [LM) 
for 12 hours. Ang II and stretch had a numerically additive effect on VEGF 
production (Ang 11: 1.60 ± 0.13, stretch: 2.59 ± 0.27, Ang 11 + stretch: 3.07 ± 0.35 
fold increase over control) (Figure F54), but this was not statistically significant 
compared with stretch alone. 
5.3.6 Pre-Mosure to stretch augments the cellular VEGE msponse to A nig 
Cells preexposed to stretch, and then exposed to vehicle for an additional 12 hours, 
showed a slight but non-significant rise in VEGF compared with unstretched cells 
exposed to vehicle (1.09 J= 0.06 fold increase, pre-stretch + vehicle vs unstretched + 
vehicle p= ns). Ang 11 induced a 1.33 fold increase in unstretched cells (unstretched 
+ Ang II vs unstretched + vehicle p<0.05) and a twofold increase in cells preexposed 
to stretch (prestretch + Ang 11 vs unstretched + vehicle p<0.001, prestretch + Ang 11 
vs unstretched + Ang 11 p<0.01) (Figure F5-5A). 
5.3.7 Stretch qMliflcs the 4n. QII--eff-ectbv induction of the ATI recgplor 
To investigate the mechanism of the magnified Ang II effect in prestretched cells, 
the AT1 receptor was studied in total protein extracts from mesangial cells. An 
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upregulation in the ATI receptor (1.5 ± 0.05 fold increase over control, p<0.05) was 
seen in cells prestretched for 12 hours and then exposed to either Ang Il or vehicle 
for another 12 hours (Figure F5-5B). In time-course experiments it was found that 
the application of mechanical stretch for 24 hours increased the ATI receptor level 











Figure F5-1: Serum- and insulin-deprived human mesangial cells were exposed to 
Ang II (I ILM) for 4,6 and 12 hours. VEGF mRNA levels were quantified as 
described in the Methods and expressed as fold increase vs control (n = 3). * P<0.05 
Ang 11 vs control at 6 hours. 
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Time Course and Dose-Response of VEGF Protein Production by Ang 11 
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Figure F5-2: Serum. - and insulin-deprived human mesangial cells were exposed to: 
Ang II (I pW for 6,12,24 and 48 hours (A) and Ang 11 (10-10,10-8,10-6,101 M) for 
12 hours (B). VEGF protein levels were measured as described in the Methods and 
expressed as fold increase vs control (n--3). 
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Effect of Losartan on Both Ang 11- And Stretch-Induced VEGF 
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Figure F5-3. Mesangial cells were exposed to Ang II (I pM) for 12 hours in 
the presence or in the absence of Losartan (I OýLM) (n=7) (A) and stretch for 
12 hours in the presence or in the absence of Losartan (I OpM) (n=3) (B). 
VEGF protein levels were measured as described in the Methods and 
expressed as fold increase vs control *P<0.05 Ang II vs others IP<0.05 
stretch, stretch + Losartan vs others. 
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Effect of Combined Ang 11 and Stretch on VEGF Protein Secretion 
0. -0 
Control Ang n Stretch Stretch + 
Ang ii 
Figure F54 Serum- and insulin-deprived mesangial cells were exposed for 12 hours 
to mechanical stretch and/or Ang 11 (110.4). VEGF protein levels were measured as 
described in the Methods and expressed as fold increase vs control (n =6). *P<0.05 
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Figure F5-5 (A) Mesangial cells were exposed for 12 hours to stretch. The 
conditioned medium was removed and after repeated washes in PBS, both pre- 
stretched cells and control unstretched cells were exposed for an additional 12 hours 
to either Ang 11 (1 gM) or vehicle in fresh culture media. VEGF protein levels were 
expressed as fold increase vs control (n =3). *P<0.05 Ang 11 vs control : P<0.01 
prestretch + Ang 11 vs unstretched + Ang 11, ** P<0-001 prestretch + Ang Il vs 
others (B) AT-I levels in total proteins lysates from 12 hour prestretched and 
control cells was analysed by immunoblotting. T'he arrow indicates the ATI band 
(n--3 p<0.05), MWM the molecular weight marker. 
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The present study demonstrates that Ang 11 and stretch independently induce 
the production of VEGF in human mesangial cells. 
Exposure to Ang 11 induced a significant increase in VEGF secretion, 
peaking after 12 hours and returning to baseline by 48 hours, with a temporally 
related increase in VEGF mRNA. There was a peak effect on VEGF secretion at an 
Ang 11 dose of IýM, consistent with previous reports on Ang 11-induced TGF-Pl 
expression in rat mesangial cells (181). At doses higher than this, there was a 
diminution in Ang 11 induced VEGF production, a phenomenon also reported for 
other in vitro Ang 11 effects, such as mesangial cell proliferation, which may relate to 
toxicity at these high concentrations (3 10). Although aI PM Angil concentration is 
high compared with Ang 11 plasma levels, local Ang II levels in the kidney are 
reported to be significantly higher than those found in the circulation (311,312). 
Ang II induced VEGF protein secretion maximally by 12 hours, a similar 
time course to that described for serum, PDGF, 12-0-tetradecanoylphorbol-13- 
acetate (TPA), and stretch-induced VEGF (166,298,313) (Chapter 4). After this there 
was a progressive reduction in Ang II-induced VEGF production possibly due to 
desensitisation or down-regulation of the Ang Il receptor (ATI) (314,315). This 
progressive reduction in response with time is a common feature of response to in 
vitro stimuli. 
Seveml known Ang II-induced effects, such as TGF-81 expression and cell 
growth, are critically modulated by the presence of insulin and serum (316-318). 
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Both serum and insulin are, however, potent inducers of mesangial cell VEGF 
production in their own right (166,306). The present study therefore was performed 
on serum- and insulin-deprived cells. This may in part explain the more modest 
effect of Ang Il on mesangial cell VEGF production compared with that reported in 
vascular smooth muscle cells (188) or observed for other Ang II-induced cytokines 
(181,319,320). 
The complete inMbition of Ang II-induced VEGF production by Losartan 
indicates a specific Ang Il effect occurring via the ATI receptor. Although two Ang 
II receptors have been described in human tissues (ATI and AT2), only the ATI 
subtype is expressed on human mesangial cells, and its activation is responsible for 
all of the known biologic effects of Ang II in human mesangial cells (179). 
Furthermore, ATI blockade completely prevents the increase in glomerular 
permeability to proteins seen in rat kidneys perfused with Ang 11 (187). 
We have shown in Chapter 4 that both tyrosine kinase and protein kinase C 
activation are important in stretch-induccd VEGF production in human mesangial 
cells. In cardiac myocytes, stretch also activates these intracellular signalling 
pathways as well as inducing the local release of Ang 11, which then acts in an 
autocrine manner (304,305,321). Although human mesangial cells share similarities 
with cardiac myocytes, stretch-induced VEGF production is unlikely to be mediated 
via Ang 11, because it is independent of the ATI receptor. Whether Ang 11 has a role 
in other stretch-induced effects in this cell type remains uncertain. 
The simultaneous exposure to Ang 11 and stretch had an additive cffcct on 
VEGF production, similar to that reported in stretch and Ang 11-induced TGF-BI 
129 
CHAPTER 5 RESULTS 
-z:; z , 
expression in rat mesangial cells (270). In addition, our results suggest that stretch 
may augment the effect of Ang Il on human mesangial cell VEGF production by 
upregulating the ATI receptor. Preexposure to stretch for 12 hours resulted in a 
threefold increase in Ang 11-induced VEGF production. This is unlikely to be due to 
a direct effect of stretch, because stretch-induced VEGF protein secretion peaks at 12 
hours, returning to baseline by 24 hours with maximal VEGF mRNA levels at 6 
hours, disappearing by 12 hours (see Chapter 4). Because VEGF protein 
concentrations in the prestretching experiments were determined after 24 hours, 12 
hours after the withdrawal of stretch, we would expect very little direct stretch- 
induced VEGF protein production. Indeed, there was a comparatively small and non- 
significant increase in VEGF protein after 24 hours in prestretched cells compared 
with control unstretched cells. 
The stretch-induced magnification of the VEGF response to Ang II was 
likely to be mediated by the observed 1.5-fold upregulation of the ATI receptor. 
This effect on the ATI receptor was not seen after 12 hours of stretch but only at 24 
hours, explaining perhaps why the simultaneous application of Angil and stretch 
only had an additive effect at 12 hours on VEGF production. 
These findings could have important pathophysiologic implications in 
clinical renal disease. Ang II infusion increases protein excretion rate in animal 
studies (186), and both ACE inhibitors and ATI receptor antagonists have powerful 
anti-proteinuric and renoprotective actions in animal and human studies 
(180,219,220,241). 
130 
CHAPTER 5 RESULTS 
Ang 11 exerts a powerful effect on renal haemodynamics and intraglomerular 
pressure, which may in turn affect VEGF production via mechanical stretch. We 
have shown that the degree of stretch required to induce VEGF would only occur in 
glomeruli exposed to high intracapillary pressure (see Chapter 4). Furthermore, Ang 
II may induce VEGF via a nonhaemodynamic mechanism by thus further 
exacerbating the local VEGF production. 
in conclusion, the complex interaction between AngIl and mechanical insult 
on VEGF reported here raises the interesting possibility that the preexistent 
intraglomerular pressure level modulates Ang 11 effects on mesangial cells. 
Furthermore, it also suggests that the deleterious cffect of high intraglornerular 
pressure results not only from a direct mechanical insult, but also from an enhanced 
response to Ang 11. The renoprotective cffect of ACE inhibitors and Ang 11 receptor 
antagonists may thus result from reductions of both the direct action of Ang 11 and 





EFFECT OF IGF-I ON VEGF EXPRESSION BY HUMAN 
MESANGIAL CELLS: INTERACTION WITH MECHANICAL STRETCH 
6.1 Background 
IGF-I has been implicated in early renal dysfunction in diabetes (148). 
Transgenic animals overexpressing IGF-l develop glomerular hypcrtrophy (150) and 
IGF-I infused in pharmacological concentrations in humans increases renal plasma 
flow and glomerular filtration rate (151). Furthermore, suppression of the GIVIGF-l 
axis prevents the onset of these early glomerular abnormalities in diabetic animals 
(148,152). Circulating IGF-I levels are either normal or reduced in diabetic patients 
(149), but the kidney content and the urinary excretion of IGF-I are elevated both in 
human and experimental diabetes (148,322,323). Furthermore, increases in IGF-RI 
and changes in lGFBPs expression, leading to enhanced IGF-I trapping and possibly 
bioactivity, have been reported in kidneys from diabetic animals (148,322,324,325). 
The local IGF system appears, thus, to be the major determinant of IGF-I. induced 
glomerular abnormalities in diabetes. However, the mechanisms linking IGF-I to 
early renal dysfunction in diabetes remain largely unknown. 
In experimental diabetes inhibition of VEGF prevents both glomerular 
hyperfiltration and glomerular hypertrophy and ameliorates albuminuria (171,172). 
VEGF exists in 5 isoforms, VEGF165 being the most abundant (155). Tle main 
VEGF binding sites are on endothelial. cells and VEGF stimulates and promotes 
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vascular permeability and endothelium-dependent vasodilatation (155). VEGF is 
expressed constitutively in the kidney in glornerular epithelial cells (161) and in 
pathological conditions by other glornerular cell types, including mesangial cells 
(166,294). 
Given the similarities between the glomerular effects of IGF-l and VEGF we 
tested in human mesangial cells whether IGF-I stimulates VEGF gene expression 
and protein secretion and examined the signal transduction mechanisms involved. 
Furthermore, having established that mechanical stretch is a potent VEGF inducer in 
mesangial cells (see Chapter 4), we also studied the interaction between IGF-I and 
mechanical stretch on VEGF production. 
6.2 Experimental Design 
Materials and Methods are detailed in Chapter 3 and Appendix 1,11,111, V 
Mesangial cells were serum- and insulin-deprived for 24 hours prior to the 
experiment because VEGF and IGF-I receptor expression are respectively enhanced 
and diminished by small concentrations of foetal calf serum (166,326). Cells were 
exposed to increasing IGF-I concentrations (10'11,10-10,10,10-8 10'7 M) for 12 
hours to determine the effective IGF-I dose. Twelve hours was chosen as being a 
known time period in which various stimuli uprcgulate VEGF protein production 
(see Chapter 4 and 5). The dose-response of insulin-induccd VEGF was also studied 
in parallel. Once established the optimum dose of IGN, time-course experiments 
were performed by exposing mesangial cells to IGF-I for 6-12-24 hours. 
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Total RNA was extracted and VEGF mRNA levels measured by competitive 
RT-PCF. Supernatants were collected, VEGF protein levels measured by ELISA, 
and results corrected for cell nwnber. 
To study the interaction of IGF-I and stretch on VEGF production, insulin 
and serum deprived mesangial cells were exposed simultaneously to IGF-I and/or 
mechanical stretch (10% elongation, 60 cycles/minutes) for 12 hours. Control cells 
were grown in non-deformable, but otherwise identical plates (Flex 11 plates) in 
parallel. 
The monoclonal neutralising antibody aIR3 0 ttg/ml) was used to block the 
fi IGF-RI and assess the specificity of potential positive indings. Pre-incubation for I 
hour with either wortmannin (600 nM) and PP2 (10ýLM) was performed in subset of 
experiments to explore the role of phosphatidylinositol 3-kinase (Pl3K) and Src in 
IGF-1-induced VEGF. Inhibition experiments on basal VEGF protein secretion were 
also carried out simultaneously. 
63 Results 
6 3.1 IGF-I and insulin induces VEGF protein secretion 
IGF-I induced VEGF secretion in a concentration-dependent manncr (10" 1 M: 5%, 
10-10 M: 14%, 10-9 M: 46%, 10-8 M: 66%, 1 0'7M: 68%) with a minimum effective 
concentration of InM and a plateau effect at 100 nM (Figure F6-IA). In subsequent 
experiments a l0nM IGF-I concentration was used as this concentration maximally 
induced VEGF. In time course experiments, we observed IGF-I-induccd VEGF 
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secretion by 6 hours, with a peak at 12 hours and a decline thereafter (52%, 72% and 
34% respectively; p<0.01 IGF-I over control at 12 hours) (Figure F64B). 
A significant increase in VEGF production was also observed in mesangial. cells 
exposed to insulin, however, this occurred only at pharmacological insulin 
concentration of I gM (1.78 ± 0.05 fold increase over control p<0.05, n=3). 
63.2 IGF- induces VEGFgene gMression 
To assess whether this rise in VEGF protein secretion was preceded by an increase 
in mRNA levels, we measured by competitive RT-PCR VEGF mRNA in cells 
exposed to IGF-I (10 nM) for 6 hours. This time point was chosen based on results 
obtained in Chapter 4 and 5 showing that VEGF mRNA levels rise approximately 6 
hours earlier than VEGF protein levels. VEGF was expressed in the basal condition 
and significantly rose by 50% in cells exposed to IGF-I (Figure F6-2). 
6 3.3 Mesangial cell VEGF induction by IGF-I occurs via the IGF-RI recepto 
IGF-I binds to the IGF-RI receptor as well as to the insulin receptor, although with a 
50-100-fold reduction in affinity (327). A murinc monoclonal antibody against the 
IGF-RI, aIR3 (Iltglml), specifically recogniscs the cxtraccllular a-subunit of the 
IGF-RI and inhibits receptor-mediated effects (328) Pre-incubation with aIR3 
(I pg/ml) for 30 minutes before IGF-I (I OnM) addition led to complete inhibition of 
IGF-I-induced VEGF protein production (Figure F6-3), indicating that this effect 
was mediated exclusively by the IGF-Rl receptor. The aIR3 neutralising antibody 
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induced a modest and not-significant rise in basal VEGF levels due its weak agonist 
activity (329). 
6 3.4 IGF-I-induced VEGF secretion is independent of PI3K. 
To test the role of P13K, an intracellular mediator of IGF-I signalling (330,331), in 
IGF-I-induced VEGF production, serum and insulin-deprived mesangial cells were 
exposed to IGF-I (10 nM) for 12 hours either in the presence or in the absence of the 
P13K inhibitor, wortmannin (600 nM). IGF-I-induced VEGF secretion was not 
affected by the addition of wortmannin indicating that VEGF induction was P13K- 
independent (Figure F64A). By contrast, in parallel experiments wortmannin 
completely abolished insulin-induced VEGF production [insulin (IPM) + vehicle: 
1.78 ± 0.03; insulin (IpM) + wortmannin (600nM): 1.12 ± 0.04 fold increase over 
control; P<0.05 insulin vs others, n--3]. This indicates that insulin induces VEGF 
through a P13K-dependent pathway, and it confirms that, in our experiments, 
wortmannin was both active in the preparation and used at a concentration adequate 
to block P13K-dependent effects. 
6.3.5 Inhibition ofSrc by PP2 prevents IGF-1-induced VEGF secretion 
Src mediates stretch-induced VEGF in human mesangial cells (see Chapter 4), we 
thus tested whether this intracellular signalling molecule could also be involved in 
IGF-1-induced VEGF. Serum and insulin deprived human mcsangial cells were 
exposed to IGF-I (I OnM) for 12 hours either in the presence or in the absence of PP2 
(I. OtM), a selective Src inhibitor (332). PP2 induced a modest non-significant 
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reduction in basal VEGF production, but significantly reduced by 72% IGF-1- 
induced VEGF secretion (p<0.01), providing evidence of a Src role in IGF-I 
induction by VEGF (Figure F64B). 
63.6 Simultaneous gaosure to IGLI and stretch does not enhance VEGF 
production 
To study the effect of combined exposure to IGF-I and stretch on human mesangial 
cell VEGF production, serurn- and insulin-deprived mesangial cells were stretched 
(elongation 10%) either in the presence or in the absence of IGF-I (10 nM) for 12 
hours. Both IGF-I and stretch induced a significant increase in VEGF production, 
however, simultaneous exposure to both stimuli failed to further increase VEGF 
production (Figure F6-5). 
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. 1. * 
Figure F6-1. Serum and insulin-deprived human mesangial Cells were exposed to 
increasing IGF-I concentrations (10- 11,1 0-10,10-9 1 0-8 , 10 M) for 12 hours (panel A); 
and to IGM at lOnM for various time periods of 6,12, and 24 hours (panel B). 
VEGF protein levels were measured as described in the Methods and expressed as 
fold increase vs control *p<0.001 vs control (n=3). **p<0.01 vs control (n=4). 
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Figure F6-2. Serum and insulin-deprived human mesangial cells were exposed to 
IGF-I (IOnM) for 6 hours. VEGF mRNA levels were quantified as described in the 















Figure F6-3. Serum and insulin-deprived human mesangial cells were cxposcd to 
IGF-I (10 nM) for 12 hours in the presence or in the absence of cdR3 (IFU I Ag/ml). 
VEGF protein levels were measured as described in the Methods and cxprcsscd as 
fold increase vs control *p<0.001 IGF-I vs others (n--3). 
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Figure F64. Serum and insulin-deprived human mesangial cells were exposed to 
IGF-I (10 nM) for 12 hours in the presence or in the absence of. - wortmannin (W 
600nM) (panel A), and PP2 (10ýtM) (panel B). VEGF protein levels were measured 
as described in the Methods and expressed as fold increase vs control * P<0.001 
IGF-I and IGF-I + Wortmannin vs, others (n =3); ** P<0-0 I IGF-I vs others (n =3). 
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Figure F6-5. Serum- and insulin-deprived mesangial Cells were exposed for 12 
hours to: vehicle, IGF-I (IOnM), stretch (10% elongation), IGF-I + stretch. VEGF 
protein levels were measured as described in Materials and Methods and cxprcssed 
as fold increase versus control (n = 3). *P < 0.05 IGF-I, stretch, and IGF-l + stretch 
over control. p=NS IGF-I vs stretch vs stretch + IGF-I 
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This work demonstrates that IGF-I induces VEGF production in human 
mesangial cells. There was a peak 72% increase after 12 hours. This increase in 
VEGF is commensurate with that we observed in response to angiotensin 11 (see 
Chapter 5). The doses of IGF-I eliciting VEGF production were in the physiological 
range and comparable to those used in previous reports on IGF-I-induced fibronectin 
and collagen production in murine mesangial cells (333). Addition of exogenous 
JGF-I, however, is superimposed to the IGF-I endogenously produced by mesangial 
cells (334) and thus mimics a state of IGF-I excess, suggesting that 
superphysiological IGF-I levels are required for VEGF induction. IGF-1-induced 
VEGF protein level rose after 6 hours peaked at 12 hours and declined thereafter. A 
temporally related increase in VEGF mRNA level was seen at 6 hours. This time 
course of VEGF production was similar to that we observed for angiotensin 11 and 
stretch-induced VEGF in human mesangial cells (see Chapters 4 and 5). 
IGF-1-induced VEGF expression has been previously reportcd in non-renal 
cell lines, such as simian virus 40 (SV40)-transformed retinal pigment cpithelial 
cells (335), endometrial adenocarcinoma cells (336), and COL0205 colon carcinoma 
cells (329). The magnitude and duration of the IGF-induccd VEGF production we 
observed in human mesangial cells was lower than that reported in these transformed 
non-renal cell lines. The reasons for this are unclear, however, increased expression 
of IGF-I receptor and altered regulatory mechanisms in transformed cells may 
explain the enhanced response to IGF-I. Our findings, although smaller in 
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magnitude, are likely to be more physiologically relevant as they were shown in 
primary cultures of normal human cells. 
IGF-I-induced VEGF production was completely inhibited by alR3, a 
neutralising antibody blocking the IGF-I type I receptor (328). Imis indicates a 
specific IGF-I effect occurring via the IGF-Rl receptor. IGF-l can also bind to the 
insulin receptor, but insulin receptors are expressed at a low level in mesangial cells 
and are not activated in response to the IGF-I concentrations used in this study (337). 
Consistently, we found that pharmacological insulin concentrations were required to 
induce VEGF production in this cell type. 
VEGF induction occurs via different mechanisms, including a Src/Raf/MAP 
kinase pathway (158) and a P13K/protein kinase B (PKB) pathway (338,339). P13K 
plays a key role in IGF-I intracellular signalling in most ccil types and mediates IGF- 
I-induced VEGF expression in human osteoblast-like cells (340). 1 lowevcr, in our 
experiments the addition of wortmannin, a P13K inhibitor, did not affect IGF.. I- 
induced VEGF secretion, indicating that in human mesangial cells this IGF-I cffect 
was P13K-independent. 
A previous report in fibroblasts had shown that VEGF induction by IGN 
and insulin occurs via different signalling pathways, which are, respectively, 
independent and dependent of P13K (341). In line with this, we found that in human 
mesangial cells insulin induces VEGF via a P13K-dcpcndcnt mechanism. 
Members of the Src family of non-receptor tyrosine kinascs arc important 
intracellular signalling molecules for the expression of VEGF (158,342). Cell lines 
transfected with v-Src overexpress VEGF (158) and we have seen that mechanical 
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stretch induces VEGF via a Src-dependent mechanism in human mesangial cells (see 
Chapter 4). In this study the significant inhibition of IGF-I-induced VEGF 
expression by the highly specific Src inhibitor PP2 (332) indicates that Src plays a 
key role in mediating VEGF production in response to IGF-I. This observation is in 
agreement with previous studies showing that the IGF-1 receptor activates the 
Src/Raf pathway in other cell types (341,343). In addition, the small reduction of 
baseline VEGF by PP2 suggests that Src may also be important for the maintenance 
of basal VEGF levels. 
Both IGF-I and stretch induce in mesangial cells the production of VEGF via 
a Src-dependent mechanism, they may thus converge on a common Src-dcpcndcnt 
signalling pathway leading to VEGF production. In keeping with this hypothesis we 
found that the simultaneous exposure to IGF-I and stretch failed to further increase 
VEGF production. 
These in vitro findings may have important in vivo implications. IGF-I 
transgenic animals develop glomerular hypertrophy (150) and IGF-I infusion induces 
glomerular hyperfiltration in both human and experimental diabetes (151,344). 
Selective GHIIGF system antagonists, which normalise IGF-I kidney content, 
prevent the onset of glomendar abnormalities in diabetic animals (148,152) 
Mesangial cells overexpress IGF-I receptors in vivo in diabetic animals 
(148,345) and are thus a likely target for local IGF-I action. IGF-1-induccd 
mesangial cell VEGF production is of particular relevance for diabetic ncphropathy 
as VEGF is overexpressed in diabetic glomeruli (168) and VEGF blockade prevents 
early renal dysfunction in diabetic rats (171,172). 
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There is evidence that glomerular hyperfiltration in diabetes results from 
enhanced glomerular vessel NO formation due to increased eNOS expression and 
activity (145-147,346). VEGF potently stimulates eNOS expression and activity in 
cultured endothelial cells (173,347) and VEGF blockade, which prevents glomerular 
hyperfiltration in vivo, also normalises glomerular capillary eNOS expression (17 1). 
IGF-I also has vasoactive properties in vivo and induces renal vasodilatation via a 
NO-dependent mechanism, but this effect is transient and does not involve eNOS 
overexpression (153,348). It is, thus, conceivable that in a chronic condition such as 
diabetic nephropathy IGF-I mediates hyperfiltration through an increase in VEGF 
production. Both IGF-I and VEGF are implicated in the pathogenesis of diabetic 
retinopathy (349,350). Multiple interactions between IGF-I and VEGF pathways 
have been described at the cellular level in the retina (351,352), including an 
enhanced VEGF production in response to IGF-I by retinal epitbelial cells (335). 
These results suggest a similarity between pathogenic mechanisms of vascular 
dysfunction in two separate bcds of the microvascular circulation. 
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CHAPTER 7 
EFFECT OF STRETCH ON FIBRONECTIN PRODUCTION AND ON 
THE TGF-p SYSTEM IN HUMAN MESANGIAL CELLS. 
7.1 Background 
Diabetic nephropathy is characterised by an excess deposition of extracellular 
matrix in the mesangium. This leads to glomerular volume expansion and results 
eventually in glomerulosclerosis and progressive renal impairment (25). The TGF- 
pl/TGF-P receptor system is considered the mediator of a final common pathway 
leading to glomerulosclerosis in diabetic nephropathy (118). In both human and 
experimental diabetes TGF-Pl gene expression and protein secretion are increased in 
the glomeruli (123,124). This effect is sustained in time and closely correlates with 
the degree of mesangial matrix expansion and with the HbAlc levels (118,124). The 
TGF-P type Il receptor is also overexpressed in diabetic animals (125), suggesting 
that the diabetic kidney is more responsive to TGF-P. Finally, in diabetic mice TGF- 
P blockade significantly reduces both type IV collagen and ribronectin 
overexpression and prevents glomerular hypertrophy, glomerulosclerosis and renal 
insufficiency (126,127). 
The importance of TGF-PI is further highlighted by in vitro studies in 
mesangial cells showing that high glucose-induccd extraccliular matrix component 
overexpression is mediated by TGF-PI via an autocrinc: mechanism (129). 
Mesangial cell exposure to high glucose also induces TGF-P receptors 
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overexpression, suggesting that high glucose may enhance the response to TGF-01 
(130). The link between hyperglycaemia, TGF-01 and diabetic glomerulosclerosis is 
thus well established. 
Haemodynamic factors have been pathogenically implicated in the 
exaggerated extracellular matrix deposition in the mesangium that characterises 
diabetic and other glomerulopathies (239,293), and treatment strategies that reduce 
glomerular capillary pressure have a potent renoprotective effect in both human and 
animal studies (219,220,241). In vivo in the remnant kidney, an animal model of 
progressive renal injury with many haemodynamic and structural similarities to 
diabetes, treatment with ACE-inhibitors, which normalises glomerular capillary 
pressure, is associated with reduced TGF-P1 expression (353). This provides indirect 
evidence that the haemodynamic insult may also affect the TGF-P system. 
Mesangial cells, the principal glomerular cells involved in cxtraccllular 
matrix synthesis, are directly connected with the glomerular capillary basement 
membrane via their cellular projections and are thus affected by the mechanical 
insult of an increased glomerular capillary pressure (251). Application of mechanical 
stretch to mimic a haemodynamic insult has been reported to induce TGF-01 and 
mesangial cell matrix production in rat mesangial cells (263,265,266,268), 
suggesting a potential mechanism whereby a hacmodynamic insult may be translated 
into a glomerular sclerotic process. However, this effect has not been confirmed yet 
in mesangial cells of human origin and it is unclear whether the TGF-O system is the 
mediator of the enhanced extracellular matrix production in response to stretch. 
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RESULTS 
Materials and Methods are detailed in Chapter 3 and Appendix 1,111, IV, V. 
Human mesangial cells were cultured as described above. Cells were seeded 
in equal number (12,000/cm2) into six well type I collagen-coated silicon elastomer- 
base culture plates (Flex I plates) and control plates (Flex II plates). After 3-5 days, 
they were serum-deprived and incubated in insulin-free medium for 48 hours, and 
then subjected to repeated stretch/relaxation cycles by mechanical deformation using 
a Stress Unit for 12,24, and 33 hours. Cells were stretched up to 33 hours, as 
preliminary experiments showed that longer periods of serum-deprivation affected 
cell viability. At the end of the experimental period supernatants were collected, 
TGF-01 and fibronectin protein levels measured by ELISA, and results corrected for 
cell number. Measurements of pericellular polymeric fibronectin were performed by 
immunoblotting on deoxycolate-insoluble and SDS-soluble protein extracts as 
previously described (291). Expression of the TGF-P receptors both type I and type 
II (TGF-P RI and TGF-P RII) was assessed by immunoblotting on total protein 
extracts. In a subset of experiments a specific neutralising anti-TGF-P antibody (20 
Itg/mi) was added to the culture media to investigate the role of TGF-P in the 
expression of both fibronectin and TGF-P receptors. A non-immune IgG was used as 
control. 
Serum-starved (0.5% FCS) mesangial cells were exposed to th-TGF-D I (I. I 
ng1ml) for 6,12,24,48, and 72 hours and fibronectin protein levels measured in the 
supematants. 
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7.3 Results 
.Z3.1 
Stretch induces fl bronectin production in human mesanizial cells 
The application of stretch to rat mesangial cells induces fibronectin and other matrix 
components (263,265). To test the effect of mechanical stretch in mesangial cells of 
human origin, serum and insulin-deprived human mesangial cells were exposed to 
cyclical stretch (elongation 10%) for 12,24, and 33 hours. Cyclical stretch induced a 
significant 67% increase in fibronectin levels in the medium at 33 hours, with no 
increase at 12 or 24 hours (Figure F7-1). At the 33 hour time point there was also a 
significant increase in pericellular polymeric fibronectin (1.3 ± 0.03 fold increase 
over control p<0.05), indicating that the increase in fibronectin in the supernatant 
was paralleled by enhanced fibronectin incorporation in the matrix. 
7 3.2 Stretch induces overgMression of both TG U-- I and TGE-A RII 
Both TGF-01 and TGF-P RII are over-expressed in the glomeruji from diabetic 
animals and this parallels the degree of mesangial matrix accumulation. We, 
therefore, studied in human mesangial. cells the effect of mechanical stretch on both 
TGF-PI and TGF-P receptors. A rise in TGF-PI protein levels was seen after 24 
hours of stretch (1.2 fold:: i: 0.03, increase over control, p=ns) and reached a peak 
1.5-fold increase by 33 hours (Figure F7-2A). At 33 hours there was also a 
significant twofold increase in the TGF-P RIT, while no changes were seen in the 
expression of TGF-P RI at any time point (Figure F7-213). Die significant stretch- 
induced increase in TGF-P RII was not altered by the addition of an anti-TGF-0 
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neutralising antibody, indicating that TGF-P RII up-regulation was independent of 
TGF-P (Figure F7-3). 
7.3.3 Stretch-induced fibronectin production is TGL-fl- inde: penden 
To test the role of TGF-P in stretch-induced fibronectin, human mesangial cells were 
exposed to cyclical stretch for 33 hours in the presence of a pan-neutralising anti- 
TGF-P antibody (201tg/ml) antibody or control non-immune IgG. A pan-neutralising 
anti-TGF-P antibody previously used by other workers (267,270) was chosen to 
allow comparison with previous studies. Stretch produced a significant increase in 
fibronectin, which was not prevented by TGF-P blockade (Figure F74), confirming 
that at this 33 hour time-point stretch-induced fibronectin was TGF-p-independent. 
To further investigate this relationship, we performed time course experiments to 
examine the effect of TGF-PI on fibronectin production. Iffie addition of exogenous 
TGF-PI (1.1 ng/ml) to mesangial cells induced a significant 1.3 fold increase in 
fibronectin protein levels after 72 hours with no increase at earlier time points (6,12, 
24,48 hours) (Figure F7-5). 
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Figure F7-1: Time course of fibronectin accumulation in human mesangial cells 
exposed to stretch (10% elongation) for 12,24 and 33 hours. Results are expressed 
as fold increase over control values represcnted by the dotted I ine. n =5 *P<0.00 I 
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Figure F7-2: Mesangial cells were exposed to stretch for 33 hours. A) TGF-jjl 
protein levels in control and stretched cells. Results are expressed as l'old increased 
over control. # p<0.05 stretch vs control. B) TGI--p RI and TGI, '-ji R11 expression in 
total proteins extracts from stretched (grey columns) and control (black columns) 
cells. The inserts show representative immunoblots fbrTGl-'-ji RI and TGI`-13 Ifll. 
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Figure F7-3. Serum and insulin-deprived human mesangial cells were exposed to 
stretch for 33 hours in the presence and in the absence of a blocking anti-TGF-0 
antibody (20 pg/ml). TGF-O RII expression was assessed by immunoblotting on total 
protein extracts *p<0.01 Stretch, stretch + anti-TGF-0 antibody vs control (n=3). 
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Figure F74. Serum and insulin-deprived human mesangial cells were exposed to 
stretch for 33 hours in the presence of either a neutmlising anti-TGF-P antibody (20 
pg/ml Ab) or an irrelevant isotype specific antibody. Fibroncctin protein levels were 
measured in the superriatants and expressed as fold increase over control non- 
stretched cells. * P<0.01 Stretch, stretch + anti-TGF-P antibody vs others (n =4). 
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Figure F7-5. Mesangial cells were exposed to rh-TGF-01 (1.1 ng/ml) for 12,24,48 
and 72 hours. Fibronectin protein levels were measured in the supernatants and 
expressed as fold increase over control (n = 3). *P < 0.05 rh-TGF-01 at 72 hours vs 
others 
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This work demonstrates that stretch has important effects on key elements of 
the prosclerotic machinery of human mesangial cells. Specifically, stretch induces 
fibronectin production and both TGF-01 and TGF-P RII overexpression. 
There was a significant 67% increase in fibronectin protein levels after 33 
hours exposure to stretch. This was paralleled by enhanced fibronectin incorporation 
in the matrix as assessed by measuring pericellular polymeric fibronectin levels. 
Recombinant human TGF-PI also induced fibronectin production in human 
mesangial cells, but this occurred only after 72 hours exposure. 
Under our experimental conditions the effect of stretch and TGF-Pl on 
fibronectin was more modest compared to that of other studies (268). Previous 
studies have used rat mesangial cells, which May have a difTerent quantitative 
response. In addition, we specifically used serum and insulin free experimental 
conditions to test purely the effect of a mechanical insult. Serum induces a 50-60% 
augmentation in stretch-induced matrix production in mesangial cells (266) and 
insulin enhances TGF-PI and fibronectin production (316), thus confounding and 
amplifying the effect of stretch. Our findings, although smaller in magnitude, arc 
likely to be more physiologically relevant as they were shown in primary cultures of 
human mesangial cells. 
A significant rise in TGF-01 protein levels was seen afler 33 hours of stretch 
and it was paralleled by a significant up-regulation of the TGF-P R11. Similarly, high 
glucose induces TGF-p receptor overexpression in mcsangial cells (130). I'llis 
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indicates that both high glucose and stretch can not only increase TGF-PI 
expression, but also enhance the mesangial cell response to TGF-P. 
Stretch did not alter the expression of TGF-P RI in human mesangial cells. 
On the contrary a stretch-induced TGF-P RI upregulation has been reported in rat 
mesangial cells by immunohistochernistry. However, this was detectable exclusively 
in the outermost zone of the culture well, where cells experience the greatest degree 
of elongation (269). The TGF-P RIII was not investigated as it lacks an intrinsic 
signal transduction activity (118). 
TGF-01 induces the expression of its own receptors in various cell types 
(354), we thus tested whether stretch-induced TGF-P RII was mediated by TGF-01 
itself. We did not observed any significant change in stretch-induced TGF-P R11 
expression in the presence of an anti-TGF-01 neutralising antibody. Therefore, 
stretch-induced TGF-P RII appears to be independent of TGF-P I in this system. 
Tle addition of TGF-01 to mesangial cells resulted in fibronectin 
accumulation after 72 hours. At 33 hours, however, TGF-P blockade did not affect 
stretch-induced fibronectin indicating that this enhanced production of fibronectin in 
response to stretch was TGF-0-independent. Accordingly, it has been previously 
reported that stretch-induced ct(I) collagen expression precedes that of TGF-01 (266) 
and that in the rat remnant kidney model the early alterations in matrix accumulation 
precede any increase in local TGF-PI expression (355). Furthermore, in 
immunohistochemistry studies using different degrees of ccli-stretching in a single 
culture well, the magnitude of matrix production correlated directly with the degree 
of cell elongation (265,266), a finding against a role of a secreted cytokine, such as 
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TGF-P I, and in favour of a direct effect of stretch. Previous studies investigating the 
role of TGF-01 in stretch-induced matrix component production in mesangial cells 
have produced conflicting results. Hirakata M et al reported that stretch-induced 
fibronectin gene expression in rat mesangial cells was abolished by an anti-TGF-PI 
antibody (270), whereas Riser and Yasuda found no effect of TGF-PI inhibition on 
stretch-induced collagen production (266,267). Our data raises the possibility that 
stretch-induced fibronectin occurs via a biphasic mechanism. Firstly, stretch induces 
fibronectin production in a TGF-PI -independent manner. TGF-pl, once secreted in 
response to stretch, perpetuates the fibronectin production. 
These in vitro findings may have important in vivo implications. There is 
overwhelming evidence of the key role of the TGF-P-extracellular matrix axis in the 
pathogenesis of diabetic glomerulosclerosis (118). Furthermore, the haemodynamic 
insult of glomerular capillary hypertension is important in both onset and 
progression of the glomerular damage in diabetes (239,293). 
Our data provide a potential molecular mechanism by which a 
haemodynamic, insult translates into extracellular matrix accumulation in the 
mesangium, a key factor in the progression of renal disease. 
The observation that both stretch and high glucose induce fibronectin 
overexpression as well as activate the TGF-P system suggests that in diabetes the 
metabolic and the haemodynamic insult may converge in a common deleterious 
cellular pathway. 
Finally, the demonstration that stretch enhances the expression of TGF-P RII 
is also of relevance as TGF-P RII is the most important receptor in TGF-01 
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MECHANICAL STRETCH-INDUCED FIBRONECTIN AND TGF-PI 
PRODUCTION IN HUMAN MESANGIAL CELLS IS P38 MITOGEN 
ACTIVATED PROTEIN KINASE-DEPENDENT 
8.1 Background 
P38 Mitogen-Activated Protein (MAP) kinase is a member of the MAP 
kinase family, which also includes ERK and JNK. T'hese kinascs constitute 
functionally distinct, but structurally related transduction pathways by which 
extracellular signals are transmitted to the nucleus to regulate gene expression (210). 
Specifically, they are activated by phosphorylation at specific threonine and tyrosine 
residues in response to various cytokines and extraccilular stresses and, once 
activated, translocate to the nucleus where they phosphorylate and transactivate 
transcription factors (210). P38 MAP kinase is activated by cxtracellular stresscs, 
such as hyperosmolar and oxidative stress, and by several cytokines (212,356,357), 
including TGF-PI (358). Furthermore, p38 MAP kinase is activated in the glomeruli 
of diabetic rats (212,359) and induces in various cells types transcription factors 
(360-362), which can enhance extracellular matrix gene expression (190,363-366). 
MAP kinases are induced by stretch in rat mcsangial CcIls (367) and ERKI-2 
have been implicated in matrix production (274), but to date there is no information 
on the role of p38 MAP kinasc. Having established (see Chapter 7) that the 
application of mechanical stretch to human mesangial cells results in an increased 
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production of fibronectin and TGF-01, we have investigated whether p38 MAP 
kinase is implicated in these stretch-induced effects and examined the interaction 
between p38 MAP kinase and TGF-01 in relation to extracellular matrix production. 
8.2 Experimental Design 
Materials and Methods are detailed in Chapter 3 and in Appendix 1,114 IV, V 
Human mesangial cells were cultured as described above. Cells were seeded 
ype I collagen-coated silicon elastomer- in equal number (12,000/cm2) into six well V 
base culture plates (Flex I plates) and control plates (Flex II plates). After 3-5 days, 
they were serum-deprived and incubated in insulin-free medium for 48 hours, and 
then subjected to repeated stretch/relaxation cycles by mechanical deformation using 
a Stress Unit for short (0,5,10,30,60 minutes) and prolonged (6,12, and 33 hours) 
time periods. Mesangial cells were also exposed to hyperosmolar (440 mosml/l) 
media, a known activator of p38 MAP kinase (357), and to rh-TGF-01 (1.1 ng/ml), 
an established inducer of fibronectin production in mesangial cells. 
At the end of the experimental period total protein were extracted and p38- 
MAP kinase activity/activation was assessed immunoblotting using a spccific anti- 
phospho-p38 MAP kinase antibody and by in vitro kinase assay. Supernatants were 
collected and both TGF-P I and fibronectin protein levels measured by ELISA. 
inhibition experiments were perfortned at relevant time points to assess the 
role of 1) PKC in stretch-induced p38 MAP kinase activation 2) p38 MAP kinase in 
both TGF-PI and fibronectin production 3) TGF-PI in p38 MAP kinase activation. 
In the experiments to inhibit PKC activity calphostin C, a specific PKC inhibitor, 
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was added to the culture media at aI jiM concentration 4 hours prior to stretch. P3 8 
MAP kinase was inhibited by the addition of the imidazole derivative SB203580 
Ihour prior to stretch. This compound inhibits p38 MAP kinase activity by binding 
to the p38 MAP kinase ATP pocket (368), and does not inhibit other relevant kinases 
such as ERK and PKC (369-372). Because SB203580 has an inhibitory effect on the 
JNK-2 isoforms at high concentrations (>IOpM) (372), we used lower 
concentrations of 1,5, and 10 ýM TGF-PI blockade was obtained by the addition of 
a specific neutralising anti-TGF-PI antibody (Ipg/ml). Inhibition experiments on 
basal protein production were carried out simultaneously. 
83 Results 
8.3.1 P38 MAP kinase is gMressed by human mesangial cells and is activated in 
reMonse to hyj2erosmolar stress. 
To determine whether p38 MAP kinase can be activated in human mesangial cells, 
we exposed human mesangial cells for 20 minutes to either iso-osmolar (290 
mosm/1) or hyperosmolar media (440mosm/1) and analysed total protein extracts by 
immunoblotting. Using a specific anti-p38 MAP kinasc antibody a single band (- 40 
Kd), consistent with the reported molecular weight of p38 MAP kinasc (357), was 
detected, indicating that p38 MAP kinase is expressed as a single isoform in human 
mesangial cells. Activated phospho-p38 MAP kinase levels were very low in cells 
exposed to iso-osmolar media, but were induced by exposure to hypcrosmolar 
media, which, however, had no effect on total p38 MAP kinase (Figure F8-1). 
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8.3.2 Stretch induces p38 AMP kinase activation in human mesangial cells. 
To test the effect of mechanical stretch on p38 MAP kinase, serum and insulin- 
deprived human mesangial cells were exposed to cyclical stretch (elongation 10%) 
for short (1,5,10,30,60 minutes) and long (6,12,33 hours) time periods. 
We found that stretch induced p38 MAP kinase activation by 5 minutes, with a 
maximum eleven-fold increase at 30 min. High levels were sustained for up to 33 
hours. Total p38 MAP kinase protein levels were unaltered by stretch. A stretch- 
induced increase in p38 MAP kinase activity peaking at 30 minutes was also 
observed by in vitro kinase assay. This increased activity was virtually totally 
abolished by SB203580 (IgM), indicating the inhibitory efficacy of this compound 
in our experimental setting (Figure F8-2). 
8.3.3 Stretch-induced P38 MAP kinase activation is PKC-dependent. 
PKC is rapidly activated in stretched mesangial cells (299) and mediates glucose- 
induced p38 MAP kinase activation in vascular smooth muscle cells (373). To 
investigate the role of PKC in stretch-induced p38 MAP activation in human 
mesangial cells, mesangial cells were exposed to stretch for 30 minutes either in the 
presence or in the absence of calphostin C0 pM). We found that stretch-induced p3 8 
MAP kinase activation was PKC-dependent, as it was completely abolished by 
calphostin C (Figure F8-3). 
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8.3.4 Stretch-induced fibronectin in human mesanggial cells is p38 MAP kinase 
dependent., 
To investigate the role of p38 MAP kinase in stretch-induced fibronectin, serum and 
insulin deprived human mesangial cells were exposed for 33 hours to stretch in the 
presence and in the absence of SB203580 (1,5,10 pM), the p38 MAP kinase 
inhibitor. This time point was chosen on the basis of previous results (see Chapter 7) 
showing that stretch-induced fibronectin peaks at 33 hours. SB203580 completely 
abolished at all concentrations the increase in fibronectin levels in the supernatant 
seen in response to stretch, with no effect on basal fibronectin levels (Figure F84). 
8.3.5 Stretch Induces TGF- fl I via p38 AMP kinase. 
A significant rise in TGF-PI protein levels was seen afler 33 hours exposure to 
stretch. The addition of SB203580 abolished stretch-induced TGF-P I protein levels, 
but did not alter basal TGF-01 levels (Figure F8-5), indicating that strctch-induced 
TGF-p I is p3 8 MAP kinase-dependent. 
8.3.6 Late P38 AMP kinase activation by stretch is TGU- 1-dependent. 
TGF-PI is a known activator of p38 MAP kinase in other cell types (358). 1 laving 
established that stretch activates p38 MAP kinasc, which induces TGF-PI, we 
investigated the effect of TGF-PI on p38 MAP kinasc in human mesangial cells. 
Following preliminary dose response experiments, mcsangial cells wcrc exposed to 
human recombinant TGF-01 (rh-TGF-01 1.1 ng/mI) for 1,10,15 and 30 minutes. 
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TGF-PI induced a two-fold increase in activated phospho-p38 MAP kinase levels by 
I min, which rose to a four-fold increase at IS and 30 min. 
To test the role of TGF-01 in stretch-induced p38 MAP kinase activation, mesangial 
cells were exposed to cyclical stretch for 6,12 and 33 hours in the presence or 
absence of a specific neutralising anti-TGF-01 antibody (Iýtg/ml). Stretch-induced 
p38 MAP kinase activation was not affected at the early time points of 6 and 12 
hours, but was significantly reduced, though not abolished, at 33 hours by TGF-01 
neutralisation (Figure F8-5). This suggests that late stretch-induced p38 MAP kinasc 
activation is, at least in part, TGF- 01 -dependent. 
8.3.7 TGF- fl] requires p38 MAP kinase for the induction oýfibronecfln. 
To test the role of p38 MAP kinasc in TGF-PI-induce fibroncctin production, human 
mesangial cells were exposed to rh-TGF-P I (I. I ng/mI) for 72 hours (see Chapter 7) 
in the presence and in the absence of the p38 MAP kinase inhibitor SB203580 
(IILM). In the presence of the p38 MAP kinase inhibitor SB203580 (111M), TGF-Pl- 
induced fibronectin production was completely abolished (Figure F8-6), indicating 
that TGF-PI-induced fibronectin production was also p38 MAP kinase-dcpcndcnt. 
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Figure F8-1: Serum and insulin-deprived human mesangial cells were exposed flor 
20 minutes to iso-osmolar (290 mosml/l) and hyperosmolar (440 mosmi/1) media. 
Total protein extracts were analysed by immunoblotting using rabbit anti-phospho- 
p38 MAP kinase and goat anti-p38 MAP kinase antibodies 
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Stretch Induces a Rapid and Sustained P38 MAP Kinase Activation 
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Figure 8-2: Human mesangial cells were exposed to cyclical stretch (10%, 
elongation) for short (1,5,10,30 and 60 minutes) and long (6,12 and 33 hours) time 
periods. Active and total p38 MAP kinase levels were determined by 
immunoblotting using anti-phospho-p38 MAP kinase and anti-p38 MAP kinasc 
antibodies (A and B). P38 MAP kinase activity was determined in the presence and 
the absence of SB203580 (SB IýLM) by in vitro kinase assay using ATF-2 fusion 
protein (35 kDa) as substrate. Inhibition experiments with SB203580 were carried 
out after 30 minutes exposure to stretch (C). Results were quantitated by 
densitometric analysis and expressed as fold increase over control values represented 
by the dotted line (D and E). n=3-5 *P<0.001 stretched vs non-stretched cells. 
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Figure F8-3. Serum and insulin-deprived mesangial cells were exposed to stretch for 
30 minutes in the presence or absence of the specific PKC inhibitor, calphostin C. 
Total protein extracts were analysed by immunoblotting using rabbit anti-phospho- 
p38 MAP kinase 
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Figure F84 Mesangial cells were exposed to stretch for 33 hours in the presence 
and in the absence of SB203580 (SB). Effcct of Si3 on strctch-induccd fibronectin 
(A) and TGF-01 (B) Results are expressed as fold increase over control values 
represented by the dotted line. n =5 *P<0.001, # P<0.01 Stretch vs others. 
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Figure F8-5 Mesangial cells were exposed to stretch for 6,12 and 33 hours in the 
presence (hatched columns) or absence (black columns) of a specific neutralizing 
anti-TGF-PI antibody (Igg/ml). Active p38 MAI) kinase levels were determined by 
immunoblotting using an anti -phospho-p3 8 MAI' kinase antibody and quantified by 
densitometric analysis. Results are expressed as fold increase over control and 
representative immunoblots are shown in the Inserts. n=4 *P, -0.05 stretch and strctch 
+ anti-TGF- PI vs non-stretch at 6 and 12 hours, # 111<0.05 stretch vs stretch -4 anti- 
TGF-01 and 0 P<0.05 stretch vs non-stretch at 33 hours. 
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Figure F8-6. Serurn and insulin-deprived human mesangial cells were exposed to 
rh-TGF-01 (1.1 ng/ml) for 72 hours in the presence or in the absence of SB203580 
(SB IýLM). Fibronectin protein levels were measured as described in the Methods 
and expressed as fold increase vs control (dotted line). n=5. *P<0.01 th-TGF-01 vs 
rh-TGF-PI+SB. 
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Proposed Sequence of Molecular Events from Mechanical Stretch to 




*P38 Fibronectin MAPK 
T( : -Pl 
Figure F8-7. Stretch via PKC activates p38 MAP kinase (indicated by: * ), which 
induces TGF-PI and fibronectin (indicated by :f). TGF-Rl in turn maintains 
activation of p38 MAP kinase perpctuating fibroncctin production. 
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8.4 Discussion 
This study demonstrates that stretch activates p38 MAP kinase in human 
mesangial cells and suggests that p38 MAP kinase activation has a central role in the 
process of extracellular matrix accumulation initiated by a mechanical insult. 
The application of cyclical stretch to human mesangial cells induced a 
significant eleven-fold increase in activated p38 MAP kinase levels. 'Mis provides 
the first evidence of stretch-induced MAP kinase activation in any human cell. 
The complete abrogation of p38 MAP kinase activation in the presence of the 
PKC inhibitor calphostin C strongly supports a role of PKC as an intracellular 
mediator of stretch-induced p38 MAP kinase activation. PKC is rapidly activated 
within minutes, in stretched rat mesangial cells (299), and mediates glucose-induced 
p38 MAP kinase activation in vascular smooth muscle cells (373). 
P38 MAP kinase activation occurred by 5 min, reached a peak at 30 min and 
was sustained for up to 33 hours. This sustained p38 MAP kinase activation is of 
interest as in rat mesangial cells stretch induced activation of other MAP kinases, 
such as ERKI and 2, occurs within 10 minutes, returning to basal levels by 60 
minutes (274). This late p38 MAP kinase activation is temporally related to an 
increase in TGF-01 protein levels and is reduccd by TGF-01 inhibition, indicating 
that while the rapid stretch-induccd p38 MAP kinase activation is TGF-01- 
independent, TGF-01 becomes important in the sustained activation of p38 MAP 
kinase. Accordingly, the addition of TGF-01 to human mcsangial cells resulted in 
p38 MAP kinase activation confirming findings previously reported in non-renal cell 
174 
CHAPTER 8 RESULTS 
types (358). Ile intracellular mediator(s) responsible for TGF-01-induced p38 MAP 
kinase activation remain(s) to be elucidated, but the TGF-p activated-kinase-I 
(TAKI), known to stimulate p38 MAP kinase activity, is a likely candidate (374). 
The magnitude of stretch-induced p38 MAP kinase activation was 
comparable to that observed in human mesangial cells exposed to hyperosmolar 
media. Furthermore, it was greater than that reported in cardiac and vascular smooth 
muscle cells exposed to angiotensin II, endothelin 1, and high glucose 
(373,375,376). 
Our data indicate that the stretch-induccd increase in mesangial cell TGF-PI 
and fibronectin protein production is p38 MAP kinase-dependent as it was abolished 
by S13203580, a specific p38 MAP kinase inhibitor. 1"bis inhibitor was highly 
cffective in blocking P38 MAP kinase activity in response to stretch in our 
experimental setting. Although the highest dose of SB203580 used (10gM) may not 
be entirely selective for p38 MAP kinase because of its inhibitory effect on JNK-2 
(372) an equal effect was seen at lower doses with no loss of cfficacy. Moreover, the 
effect of SB203580 on stretch-induccd TGF-PI and fibronectin is unlikely to be due 
to JNK inhibition, because stretch at 10% elongation does not activatc JNK in 
mesangial cells (274,367,377) 
P38 MAP kinase phosphorylates transcription factors inducing c-fos and c- 
jun transcription (360-362). c-fos and c-jun combine to form the API transcription 
complex, which binds to and activates genes with a TPA-response element (TRE) in 
their promoter region. TGF-PI and fibronectin both contain TRE rcgions 
(190,191,363,364) and p38 MAP kinase is thus likely to induce fibronectin and 
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TGF-01 production via this mechanism. c-fos expression has been shown to be 
induced by stretch in rat mesangial cells (299). 
The addition of TGF-01 to mesangial cells resulted in fibronectin 
accumulation after 72 hours via a p38 MAP kinase dependent mechanism, 
suggesting that p38 MAP kinase may be an important pathway for a number of 
matrix promoting stimuli. 
These results together with those reported in Chapter 7 suggest the following 
sequence of events: stretch, via PKC, causes early activation of p38 MAP kinasc, 
which induces TGF-PI and fibronectin production. In turn, TGF-01 maintains late 
p38 MAP kinase activation, which perpetuates fibronectin production (Figure F8-7). 
These findings could have important clinical pathophysiological implications 
for renal disease. P38 MAP kinase is known to be important in mediating 
inflarnmatory responses in neutrophils and cell hypertrophy in the heart (356,378), 
and this report is the first evidence that p38 MAP kinase participates in the 
intracellular signalling cascade leading to mesangial cell cxtmcellular matrix 
production and presumably glomerulosclerosis. The interplay between p38 MAP 
kinase and TGF-01, here described, provides a potential mechanism for a 
progressive and sustained sclerotic process, initially triggered by a hacmodynamic 
insult. Our observations may have particular relevance for diabetes because p38 
MAP kinase is also activated by high glucose via a PKC-dependcnt mechanism 
(373), and active p38 MAP kinase levels are augmented in vivo in glomeruli from 
diabetic rats (212,359). 
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Following the publication of these results other groups have reported data 
supporting the hypothesis that p38 MAP kinase is of relevance in the pathogenesis of 
diabetic nephropathy. In vivo it has been shown that AGEs induce 
glornerulosclerosis via a p38 MAP kinase-dependent mechanism in non-diabetic 
animals (213). In vitro several insults important in diabetes, such as high glucose, 
AGEs, hexosamine, and angiotensin II, have been shown to induce p38 MAP kinase 
activation in mesangial cells (106,214-216). Finally, in podocytes p38 MAP kinase 
activation mediates both TGF-PI-induced apoptosis and high-glucose-induced 
collagen overexpression (217). 
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CHAPTER 9 
HAEMODYNAMIC STRESS INDUCES UPREGULATION OF THE 
GLUT-1 GLUCOSE TRANSPORTER ]BOTH IN VITRO IN MESANGIAL 
CELLS AND IN VIVO IN THE GLOMERULI 
9.1 Background 
In hypertensive glomerular injury, mesangial expansion vAth extracellular 
matrix accumulation is one of the harbingers of glomerulosclerosis (379,380). 
Similarly, mesangial expansion is a central feature of diabetic glomerulopathy, in 
which both haemodynamic and metabolic perturbations play a crucial role in the 
pathogenesis of this disease (381). 
Animal models and humans with combined hypertension and diabctcs show 
the most severe glomerular lesions (381). Furthermore, reduction of glomcrular 
pressure, with agents that interrupt the RAS, downregulatcs TGF-BI and delays the 
progression toward renal failure (382,383). 
Mesangial cells express primarily two tYPCS of glucose transporters: the 
facilitative brain type glucose transporter GLUT-1, the predominant isoforin, and the 
sodium-coupled glucose transporter (384). GLUT-I is ubiquitously expressed, and 
its cellular distribution resides mainly in the cellular plasma membrane, where it 
plays a major role in the basal rate of glucose transport into the ccIl (385). Ilis is 
particularly relevant for glucose metabolism of cells such as mesangial cells in 
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which glucose uptake is relatively insulin-independent (384). As with all the other 
members of the facilitative glucose transport family, GLUT-I is a high-affinity, low- 
capacity glucose transporter and is at or near saturation at physiological glucose 
levels. Therefore, changes in GLUT-I expression, translocation, or intrinsic activity 
are necessary for cells to significantly increase their basal glucose uptake (386). 
The importance of excess glucose entry into mesangial cells is underscored 
by the observation that glucose-induced effects can be mimicked in normal glucose 
concentrations by GLUT-I overexpression, thus increasing basal glucose uptake 
(113). Furthermore, overexpression. of an antisense GLUT-I mRNA in mesangial. 
cells leads to reduction of glucose uptake and prevention of glucose-induced 
fibronectin (115), providing evidence of a key role of GLUT-I in glucotoxicity. 
In hypertensive as well as in diabetic glomerulopathy, similar signalling 
pathways and cytokines are up-regulated, notably TGF-BI (127,387). Exposure of 
mesangial cells in vitro to high glucose induces expression of TGF-PI, VEGF, and 
mesangial matrix components as well activation of both PKC and p38 MAP kinase 
(111,128,164,201,214). These effects are virtually superimposable to those we have 
described in response to stretch in the previous Chapters (Chapters 5,7,8), suggesting 
that interplay between the metabolic and the haemodynamic insult may take place at 
the cellular level. 
In this part of the study we have tested the hypothesis that the injurious effect 
of the haernodynamic stress of glomerular hypertension could be mediated, at least 
in part, by upregulation of GLUT-1 expression resulting in a pathologically 
increased glucose uptake. Specifically, we have investigated whether in mcsangial 
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cells mechanical stretch upregulates GLUT-1, leading to an increased transport of 
glucose. In addition, we have compared GLUT-1 expression in the glomeruli of 
hypertensive Dahl salt-sensitive rats and spontaneously hypertensive rats (SIIR). In 
Dahl salt-sensitive rats but not in SHR, systemic hypertension is accompanied by 
glomerular hypertension and injury (388). 
9.2 Experimental Design 
Materials and Methods are detailed in Chapter 3 and Appendix I, III, IV, V 
In vitro 
Subconfluent human mesangial cells were cultured as described above. Cells 
were seeded in equal number (12,000/cm) into six well type I collagen-coatcd 
silicon elastomer-base culture plates and control plates, serum deprived for 12 hours 
then subjected to repeated stretch/relaxation cycles by mechanical deformation using 
a Stress Unit for 12,24, and 33 hours. 
At the end of the experimental period basal glucose transport and GLUT-1 
expression were assessed by 2-dexossiglucose (2-DOG) basal glucose transport 
assay and immunoblotting, respectively. In subset of experiments either a specific 
neutralising anti-TGF-PI antibody (200 ng/ml) or an irrelevant isotype spccific 
antibody were added to the culture media to investigate the role of TGF-P1 in both 





Animals were provided by Harlan SD. The in vivo work was performed in 
the Nephrology and Hypertension Division, Department of Veterans Affairs Medical 
Centre and University of Miami School of Medicine, Miami (ProE Leopoldo Raij). 
Male Dahl salt-sensitive (DS) rats, SHR, and Wistar-Kyoto (WKY) rats were 
studied between II and 12 weeks of age. DS rats were fed from the age of 4 weeks 
either a low (0.5%) or a high (4%) salt diet (DSN nonnotensive control and DSIl 
hypertensive animals, respectively) (389). DSH were used as a model of systemic 
and intraglomerular hypertension (390.391); SIM served as a model of systemic 
hypertension without intraglomerular hypertension (392). The WKY was used as the 
normotensivc control for the SHR. All rats were maintained in a 24"C environment, 
with a 12 hours light/dark cycle, and fed ad libitum with water and standard chow 
diet. 
Before killing, animals were weighted and both systolic blood pressure and 
24 hour urinary protein excretion were measured by tail non-invasive blood pressure 
determination system and by the BioRad protein assay, respectively (388). Body 
weight was similar in all groups of rats studied (DSII, 349.3 ± 63 g; DSN, 332 +- 53 
g; SHR, 285 ± 33 g; WKY, 293 153 g, n=4). Systolic blood pressure was similar 
between DSH (236 ±9 mm Hg, n=4) and SIM (230 -+ 10 min 11g, n=4) but 
significantly elevated as compared to that of the normotensive controls DSN (145 -+ 
5 turn Hg, n=4) and WKY (137 ±3 mm. 11g, n=4) rats. Twcnty-four-hour urine 
protein excretion in the DSII (147 ± 23 mg/24 h, n=4) was 5-fold highcr than in the 
normotensive DSN rats (36.6 ± 11 mg/24 h, n=4). Protcinuria in the SIM (8.5 ±3 
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mg/24 h, n--6) was lower than the DSH; normotensive WKY did not show 
significant proteinuria. 
immediately after death, the kidneys were harvested. A portion of kidney 
cortex was used for glorneruli isolation by serial sieving. The remaining tissue was 
snap frozen in isopentane cooled in liquid nitrogen for immunohistochemistry. 
Immunohistochemistry on frozen kidney sections and immunoblotting for both 
GLUT-1 and TGF-PI on total protein extracts from isolated glomeruli were 
performed as detailed in Materials and Methods. 
93 Results 
In Vitro Stud 
9.3.1 Mechanical stretch yRreeulates GLUT- I protein level 
We studied the effect of mechanical stretch on GLUT- I protein expression in human 
mesangial cells exposed to stretched for 12,24, and 33 hours. Exposure to 
mechanical stretch for 33 hours significantly increased GLUT-I protein level by 
40% over control non-stretched cells (P=0.01) (Figure F9-1), whereas no significant 
changes were observed at earlier time points (arbitrary units percentage change over 
control= 100%, at 12 hours, 11 9±14%; at 24 hours, 127±14%; P= NS). 
9.3.2 Mechanical stretch ypregulafes glucose tramport 
To investigate whether GLUT-I upregulation was paralleled by an increase in 
cellular glucose uptake, 2-DOG basal glucose transport assay was performed after 33 
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hours of stretch when GLUT-1 upregulation was observed. There was a significant 
60% increase (P=0.002) in 2-DOG uptake in human mesangial cells exposed to 
stretch as compared with control non-stretched cells (Figure F9-2). 
9.3.3 LQF- -induced GLUT-] and basal galucose irans . 
§I mediates stretch _: por 
unreizulation 
To elucidate the mechanism of stretch-induced GLUT-I and basal glucose transport 
upregulation in human mesangial cells, we studied GLUT- I expression and basal 2- 
DOG glucose uptake in mesangial cells stretched either in the presence or absence of 
a specific anti-TGF-BI -neutralizing antibody. TGF-BI blockade significantly blunted 
by 80% both the stretch-induced GLUT-1 protein expression (P=0.04) and basal 
glucose transport (P=0.006), observed at 33 hours. No change was detected when the 
control IgG was added (Figures F94 and F9-2). Thus, stretch-induced GLUT-1 
overexpression and basal glucose transport appear largely mediated by TGF-Bl. 
In vivo Studies 
Wylated in Glomeruli ofDSH Rat 9.3.4 GLUT-] Is Upre 
By inununohistochemistry renal cortex analysis, the percent change in staining for 
GLUT-I per glomerular area was significantly higher in DSII than DSN rats (182 ± 
19.7% versus 100 ± 22.1%, respectively, P=0.03), whereas no difference was found 
between SHR and WKY rats (109.6 ± 5.8% versus 100 ± 6.4%, respectively). The 
staining pattern in the glomeruli of DSH mts suggested GLUT-1 uprcgulation in 
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different glornerular cell types, including the mesangium. GLUT-1 immunostaining 
was present in the tubules of all animals. No staining was observed when the first 
antibody was omitted or blocking peptide added. Figure F9-3 shows representative 
glomeruli from the 4 animal groups. Consistent with this, glomerular GLUT-I 
protein expression was 80% greater in the DSH rats than in DSN rats (P=0.004) as 
assessed by Western blotting, whereas no difference was seen between SHR and 
WKY (Figure F9-4 and F9-5). 
9.3.5 TGF-, O I is UpLeMlated in isolated glomeruli from DSH Rat 
Immunoblotting with specific anti-TGF-BI antiserum in total cell lysate of isolated 
glorneruli from the 4 animal groups showed that TGF-131 expression was 2.7-fold 
higher in DSH rats compared with DSN rats. By contrast, expression of TGF-B I was 
virtually undetectable in both WKY and SHR rats, and there were no differences 
between the 2 groups (Figure F9-6 and F9-7). 
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Stretch Induces GLUT-I Protein Expression 
55KDa--> 40" 410 -qp, 
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Control IgG Anti TGF-111 IgG 
Figure F9-1: GLUT-1 protein expression in 33 hours stretched (black columns) and 
nonstretched (white columns) human mesangial cells in the presence or absence of 
an anti-TGF-131 neutralising antibody or control IgG. Data are expressed as 
percentage change over nonstretched cells (n=5). *11<0.05 for stretch control IgG vs 
other conditions. A representative immunoblot flor G I, IJT- I is shown in the insert. 
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RESULTS 
Figure 9-2: Basal glucose transport in 33 hours stretched (black columns) and 
nonstretched (white columns) human mesangial cells in the presencc or abscnce of 
an anti-TGF-BI neutralising antibody or control IgG. Data are expressed as 
percentage change over nonstretched cells (n--5). t P<0.01 for stretch control IgG vs 
other conditions. 
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GLUT-1 Immunoperoxidase Staining of Kidney Cortex from DSH, DSN, 
SHR, and WKY rats 
]Figure F9-3. Intense GLUT-I staining (brown) was seen in DSH rat glomeruli but 
not in DSN, SHR, or WKY rats (magnification x 40). 
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Figure F94 Upper panel shows a representative immunoblot; lower panel shows 
densitometry analysis for GLUT-] in WKY and SIM expressed as percentage 
change over control (WKY) (n=4 to 5 animals per group). ll=ns 
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Figure F9-5 Upper panel shows a representative immunoblot; lower panel shows 
densitometry analysis for GLUT- I in DSH and DSN expressed as percentage change 
over control (DSN) (n=4 to 5 animals per group) *P=0.004 DS II vs DSN. 
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Figure F9-6. Densitometry analysis of TGF-Bl protein expression in the glomcruli 
isolated from WKY and SHR rats. Data are expressed as percentage change over the 
WKY control. (n=4 animals per group). P=ns. 
190 
WKY SHR 
TGF-01 Protein Level in the Glomeruli Isolated from 










DSN 1) s ti 
Figure F9-7. The upper panel shows a representative immunoblot; the lower panel 
shows densitometry analysis of TGF-BI protein expression in the glomeruli isokited 
from DSN and DSH rats. Data are expressed as percentage change over the DSN 
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This study demonstrates that GLUT-1 is over-expressed both in vitro in 
mesangial cells exposed to stretch and in vivo in the glomeruli of the hypertensive 
DSH rat, an animal model of glomerular hypertension. 
Stretching of mesangial cells upregulated GLUT-I protein expression as well 
as basal glucose transport through a TGF-BI -dependent mechanism. In mesangial 
cells high glucose enhances glucose uptake by upregulating GLUT-I expression 
(114), and the present study demonstrates that this is also the case for mechanical 
stretch in normal ambient glucose concentration. 
Both stretch-induced GLUT-I expression and basal glucose uptake were 
mediated by TGF-PI as they were almost completely abolished by the addition of an 
anti-TGF-PI neutralising antibody. This is in line with previous results in mesangial 
cells showing TGF-PI release in response to stretch (see Chapter 7) as well as 
increased basal glucose transport and GLUT-I expression in response to TGF-01 
(131). 
TGF-01 also mediates, at least in part, high glucosc-induccd GLUT-I 
overexpression in mesangial. cells (131). Iberefore, TGF-Pl appears to bc a kcy 
mediator of the final common pathway that, activatcd by metabolic and 
haemodynamic abnonnalities, leads to increased glucose entry into mesangial cells. 
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In kinetic analysis of TGF-01-induced 2DOG uptake TGF-PI increases 
Vmax without affecting Km (131). Stretch, which operates via TGF-Pl, is thus 
likely to induce glucose uptake by enhancing the number of glucose transporters 
rather than GLUT- I affinity to glucose. 
The magnitude of stretch-induced basal glucose transport was similar to that 
reported in mesangial cells exposed to either high glucose (114) or TGF-P I at 
concentrations released by stretched mesangial cells (13 1). This increase in glucose 
uptake, although modest, is likely to become of relevance both in vitro in the 
presence of a high glucose concentration in the milieu and in vivo in a chronic 
condition characterised by persistent hyperglycaemia as diabetes. Indeed, in vitro in 
mesangial cells stretch and high glucose have a synergistic effect on collagen 
production (267). Furthermore, in vivo in humans the glomerular lesion 
characteristic of diabetic kidney disease does not develop solely in the presence of 
hypertension and the concomitant presence of hyperglycaemia is required for the 
glomerular injury to occur. 
These in vitro observations were supported by our findings in animal models 
of hypertension. In hypertensive DSII rats but not in similarly hypertensive SIIR 
there was 80% increase in glomerular GLUT-I both by immunohistochemistry and 
by Western blot, while GLUT-I levels in normotensive WKY and DSN were similar 
to those in SHR. 
These findings suggested that GLUT-1 upregulation might be a consequence 
of the haemodynamic stress imposed by glomerular hypertension. It has been 
previously shown that transmission of the elevated systemic blood pressure to the 
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glomerular circulation in the DSH rat (391,393) results in glomerular hypertension, 
mesangial matrix expansion, and development of glomerulosclerosis (389). In 
contrast, in the SHR, increased preglomerular resistances prevent glomerular 
capillary pressure from rising in response to systemic hypertension, and glomerular 
damage is modest and delayed (389,391,392). When the preglomerular resistances 
are reduced such as in uninephrectomised or in the diabetic SHR, the development of 
glomerular capillary hypertension is associated with the development of accelerated 
proteinuria and an increased mesangial expansion and glomerulosclerosis (381,394). 
Previous studies have reported an increased expression of TGF-BI in the 
glomeruli of hypertensive Dahl salt-sensitive rats treated with a high salt diet 
(387,395). In contrast, no differences have been observed in TGF-BI expression in 
SHR rats between 7 and 16 weeks of age when compared with normotensivc WKY 
rats (395,396). In this study, we confmned that TGF-BI is upregulatcd in isolated 
glomeruli of DSH rats, suggesting that the uprcgulation of TGF-B1 may account for 
the increase of GLUT- I expression that we have observed. 
These data are in line with previous observations. In DSII rats, reduction of 
intraglomerular pressure with an angiotensin Il antagonist prevents glomerular TGF- 
BI upregulation (397). Further, systemic treatment with anti-TGF-BI antibodies in 
hypertensive Dahl rats reduces blood pressure as well as protcinuria and the severity 
of glomerulosclerosis (398). Of interest diabetic animals with incipient diabetic 
nephropathy have increased urinary excretion of TGF-Bl, which is associated with 
greater abundance of renal cortical GLUT-1 protein (399). 
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Hypertension is a major risk factor in the progression of renal disease in 
general (400) and diabetic nephropathy in particular (231,401). It is known that 
agents that interrupt the RAS are particularly renoprotective (177,249,402). These 
agents reduce systemic as well as glomerular hypertension and, by downregulating 
TGF-B1 (282,283,397), are likely to interrupt the TGF-BI-GLUT-1 axis. 
Collectively, these findings suggest a possible mechanism of interaction 
between mechanical forces and glucose-mediated pathways in the pathogenesis of 
glomerular injury and bring together in a unitary model evidence supporting both the 
haemodynamic and the metabolic origin of diabetic glomerulopathy. 
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Both systemic and glomerular hypertension play a key role in the 
pathogenesis of diabetic glornerulopathy. 
Using an in vitro system mimicking the haemodynamic stress to which 
mesangial. cells are exposed in vivo in pathological conditions characterised by 
increased glomerular capillary pressure, we have provided evidence that glomerular 
hypertension may have important deleterious cellular effects. 
Our results demonstrate that stretch, angiotensin 11, and IGF-I induce VEGF 
expression in human mesangial cells and that the intracellular signalling molecules 
PKC and Src; are important mediators of this process. Although the specific role of 
VEGF in the pathogenesis of the glomerular alterations of diabetic ncphropathy 
remains to be clarified by in vivo studies, the demonstration, in experimental 
diabetes, that VEGF blockade prevents glomerular hypcrtrophy, glomerular 
hyperfiltration, and ameliorates proteinuria strongly suggests the in vivo rclevancc of 
these findings. 
In addition, the complex interaction between Ang 11 and mechanical insult on 
VEGF, shown in this work, suggests the interesting possibility that pre-existent 
intraglomerular pressure levels may modulate Ang 11 cffects on mesangial cells. 
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Hence, the deleterious effect of high intraglornerular pressure can results not only 
from a direct mechanical insult, but also from an enhanced response to Ang 11. 
We have also described a new intracellular mechanism by which in human 
mesangial cells a haemodynamic insult induces sustained fibronectin overproduction 
leading eventually to glomerulosclerosis. Our results have shovVn, for the first time, a 
key role for p38 MAP kinase in the regulation of matrix molecules expression and in 
the TGF-PI intracellular signalling cascade. This concept has been recently 
confirmed and strengthened by in vitro and in vivo findings from other groups. 
Finally, the demonstration both in vitro and in vivo that the haemodynamic 
insult of glomerular capillary hypcrtcnsion can magnify glucotoxicity by enhancing 
the expression of the glucose transporter GLUT-1 has high clinical relevance as it 
may explain the particular susceptibility of diabetic patients with high blood pressure 
to develop kidney damage. 
Identification of the intracellular mechanisms by which mechanical forces 
and glucose interact in the induction of the glomerular damage may help identify 
new targets for therapeutic intervention or prevention. 
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Cell Culture Reagents and Media 
AL] Reazents 
N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulphonic acid (IIEPES 1M): 59.6 g 
HEPES was dissolved in 250 ml ddH20 and stored at 4'C. 
Sodium bicarbonate (NaHC03 7.5% w/v): 37.5 g sodium bicarbonate was 
dissolved in 500ml ddH20 and stored at 4'C. 
Sodium hydroxide (NaOH 1M): 10 g of NaOH was dissolvcd in 250 ml dd1120 and 
stored at 4'C. 
RPMI 1640 with L-glutamine (without glucose): IL of RPMj 1640 was prepared 
by dissolving 8.4 g of RPMI-1640 powder in the solution reported in Table 1. 





ddH20 945 -- --------- 
IIEPES (I M) 25 25 mM 
NaIIC03 (7.5%) 26.7 0.2% 
NaOH (I M) 3.3 3.3 mM 
0.5M Mannitol: 22.7 g mannitol was dissolvcd in 250ml ddl 120 and storcd at 4'C 
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0.55M D-Glucose: 25 g of D-glucose was dissolved in 250ml ddH20 and stored at 
4'C 
Following preparation, all these reagents were sterilised by filtration through a 
membrane with a porosltE of 0.2 Mm (Nalgene Disposable Filter Unit, Nalgene 
Company. Rochester, USA). 
Penicillin/streptomycin solution (P/S): the solution, containing 20,000 units/ml 
penicillin and 20 mg/ml streptomycin was aliquoted. in 10 ml falcon tubes and stored 
-20'C. 
insulin transferrin selenium supplement solution (ITS) 100x: the 100x solution, 
containing lmg/ml insulin, 0.55 mg/ml human transferrin and 0.5 ýtg/rnl sodium 
selenite was stored at 4" C. 
Dulbecco's phosphate buffered saline (PBS) (PIl 7.5): 50 PBS tabicts wcrc 
dissolved in 5L ddH20 to obtain a solution Ix of PBS without calcium and 
magnesium. The solution was aliquoted, autoclaved at I 15*C then stored at 4*C. 
Foetal Calf Serum (FCS): 500 ml of FCS were aliquotcd in 50 ml Falcon tubes and 
stored at -200C 





A]. 2 Media 
Following their preparation, all media were sterilised. by filtration and stored at 4'C. 
A1.2.1 RPMI 1640 based culture medium (pH 7.4; Osmolarity 285-295 mosni/L): 
500 ml of mesangial cell culture medium was prepared by combining the reagents 
reported in Table 2. 




RPMI 1640 liquid Ix 370 ----------- 
0.55M Glucose 6.2 6.8 mM 
0.5M Mannitol 16.2 16.2 mM 
FCS 100 20% (v/v) 
P/S 2.5 100 IU/Ml & 100 pg/Ml 
ITS (insulin-transferrin-selenium) 100x 5 10 pg/ml insulin 
5.5 pg/ml transfcrrin 
5 ng/ml scicnium 
A1.2.2 Serum and insulin-free RPMI 1640-based culture medium (PIl 7.4; 
osmolarity 285-295 mosm/L): 300 ml of scnun- and insulin-frcc mesangial ccil 
medium was prepared as detailed in Table 3. 





RPMl 1640 Medium 261.5 -- --------- 
-6-lucosc 0.55 M 3.3 6 mM 
Mannitol 0.5 M 23.7 40 mM 
P/S 1.5 100 lU/Ml & 100 [Ig/Ml 





The pH of the media was adjusted to 7.35-7.45 and their osmolarity checked to be 
285-295 mOsm/L using a cryoscopic osmometer (Osmostat 300, Berlin, Germany). 









Ethidium bromide (10mg/ml): Ethidiurn bromidc solution was storcd at room 
temperature protected from the light. 
Ethylenediaminetetra acetic acid (EDTA 0.5M pH 8.0): 18.6 g of EDTA (di- 
sodium: 2H20) were dissolved in 80 ml H20. NaOH was used to adjust the p1l (pII 
8). Water was added to the final volume of 100 ml. The solution was aliquoted, 
autoclaved, then stored at room temperature. 
(DX174 DNA/Hae 111 (1: 20 working solution): the stock solution (lpg/ýtl) was 
diluted 1: 20 in molecular water to obtain a working solution of 50 ng/jtl. 
Primers: stock primers solution were stored at -800C. Stock solutions were diluted 
in molecular to obtain a final working stock solution of 20-25pM concentration and 
stored at -20'C. 
A 2.2 Solutions and recipes 
Tris Borate EDTA (TBE buffer 5x): 27 g of Tris basc, 13.75 g Boric acid and 10 
ml of EDTA 0.5 M (pH 8.0) were dissolved in 400 ml of water. Water was added to 
the final volume of 500 ml and the solution was aliquoted and stored in plastic 
bottles at room temperature. 
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Tris Acetic acid EDTA (TAE buffer 5x): 12.1 g of Tris base, 2.86 ml of acetic acid 
and 5 ml of EDTA 0.5 M (pH 8-0) were dissolved in 50 ml of water. Water was 
added to the final volume of 55 ml and the solution was aliquoted and autoclaved 
and stored at room temperature. 
Reverse transcription reaction recipe: I pg of total RNA was reverse transcribed in 
a 20 [d final volume of reverse transcription mix. The reverse transcription recipe is 
detailed in Table 4. 




in 20 pI solution 
Reverse transcriptase reaction buffer (I Ox) 2 1 X* 
M902 (25 mM) 4 5 mM 
dNDTs (10 rnM) 2 1 MM 
RnaGuard (22,100 U/ml) 0.56 618.8 U/ml 
AW (20 U/ILI) 0.75 0.75 U/gl 
poli-d(T)12-18 (IIL9/91) 
1 0.05 [Lg/[LI 
Total RNA -- I pg/20ýd 
Molecular water to a final volutne of 20 pI 
(*) final concentration reaction buffer reagents: lOmM Tris-11CI pil 8.8 at 25*C, 
50mM KCI and 0.1% Triton X-100 
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Table 5: Primer sequencesfor PCR amplification 
Amplicons Primer sequences Size (bp) 









Table 6. - Mulatedprimer sequences 






Table 7: PCR amplification parameters. 
Amplicons Thermalcycler Parameters CYcles 
Denaturation 94'C 7 minutes I 
VEGF Denaturation 94"C I minute 30 seconds 
Annealing 620C 2 minutes 26 
Elongation 72*C 2 minutes 
Denaturation 95'C 5 minutes 
GAPDH Annealing 60"C 5 minutes I 
Denaturation 940C 45 seconds 
Annealing 600C 45 seconds 15 
Elongation 720C 90 seconds 
Elongation 72*C 10 minutes I 
Table 8: PCR recipes (40 jdfinal volume) 
VEGF GAPDII 





buffer (I Ox) 
4 Ix 4 Ix 
MgC12 (25 mM) 2 1.25 mM 2.4 1.5 mM 
dNDTs (20 mM) 0.25 0.125 mM 0.25 0.125 mM 
Perfectmatch (I U/ml) 0.5 0.51LU/40gl 0.5 0.5 gUMOVI 
AmpliTAQ (5U/gl) 0.4 2U/401A 0.4 2U/401d 





Competitors were added to the reaction in serial twofold dilutions of deletion- 
mutated competitor cDNAs. H20 was added to the mix to reach a final volume of 40 
ýfl. 
Table 9: Recipesfor the agarose gel 
Reagent 1% 1.5% 2% 3% 
Agarose powder 0.45g 0.68g 0.9g 1.35g 
TAE/TBE buffer 5x 9ml 9ml 9ml 9ml 




ELISA Reagents and Solutions 
A3.1 Buffers and blockinz solutions 
Carbonate-bicarbonate buffer (coating buffer pH 9.6) : the content of one 
capsule of carbonate-bicarbonate buffer was dissolved in 100 ml of MID to have a 
solution 0.05 M of carbonate bicarbonate buffer pH 9.6. The solution was stored for 
one month at 4*C. 
Phosphate buffer solution (PBS Ix): I tablet of PBS without calcium and 
magnesium was dissolved in 200 ml of ddH20- Iffie solution was stored at 4'C. 
PBS-Triton X 0.1% washing buffer: Iml Triton X-100 was added to 999 ml PBS 
Ix buffer and mixed by stirring. 
PBS-0.1%Tween washing buffer: Iml Tween-20 added was added to 999 ml PBS 
Ix buffer and mixed by stirring. 
Bovine Serum Albumin solution in PBS (BSA 0.5%): O-5g of bovine serum 
albumin were dissolved in I 00ml of the PB SIx buffer. 
Bovine Serum Albumin solution in RPMI based medium (BSA 0.5%): 0.5g of 
bovine serum albumin were dissolved in I 00ml of RPM I medium. 
Protein matrix solution: 0.35g of gamma globulin and 5g of bovine senim albumin 
were dissolved in approximately 80ml of PBS on a magnctic stirrer. PBS was added 
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to a final volume of 100 ml. The stock solution was aliquoted and stored at -40'C. 
Prior to use the stock aliquots were further diluted (1: 5) in PBS Ix buffer. 
A3.2 Standards 
VEGF16! 5 human recombinant: lOgg of human recombinant VEGF165 Were 
reconstituted in 2ml of PBS containing 0.1% human serum albumin (I 19nM). This 
was further diluted (1: 119) in PBS containing 0.1% human serum albumin to obtain 
aI nM stock solution. 'Me stock solution was diluted (1: 25) in medium to obtain the 
top standard concentration of 40 pM. The standard curve was prepared by serial 
dilution (40,20,10,5,2,1,0.5,0 pM) of the top standard in experimental medium. 
Human fibronectin: fibronectin was dissolved in water to obtain a stock solution of 
0.5mg/ml. The solution was frozen in aliquots at -2011C. 20 til stock solution were 
diluted in 10ml coating buffer to obtain a Ing/pLI working solution used for plate 
coating. 2[LI stock solution were dissolved in I ml of 0.5%BSA in medium to obtain a 
pg/ml solution that was used to generate the standards by serial dilutions. 
Table 10: Recipefor the preparation ofthefibronectin standards 
Standard Fibronectin 0.5%BSA medium 
0.5ýlg/ml 5 00 ýd of I pg/Ml 500gl 
0.25pg/ml 500 gl Of 0.5gg/ml 500gl 
0.125pg/ml 500 ýd of 0.25pg/ml 500ýd 
0.0625lig/ml 500 jil of 0.125pg/ml 500gl 




Mouse monoclonal anti-human VEGF antibody (500pg/mi): SOOpg mouse anti- 
human VEGF monoclonal antibody (capture antibody) were reconstituted in I ml of 
sterile PBS to obtain a final concentration of 500pg/ml. The stock solution was 
aliquoted and stored at -40'C. 
Rabbit anti-VEGF polyclonal antibody (lmg/mi): O-Img mbbit anti-VEGF 
polyclonal antibody were reconstituted in 0.1ml of sterile distilled water to obtain a 
final concentration of I mg/ml. The stock solution was aliquoted and stored at -200C. 
Rabbit anti-human fibronectin antibody: the antibody was stored in aliquots at 
-20*C, then diluted 1: 9000 in 0.5% BSA in medium prior to use. 
Anti-rabbit IgG (whole molecule) horseradish peroxidase conjugated antibody: 
the antibody was diluted 1: 2000 in 0.5% BSA in PBS prior to use. 
A 3.4 Substrate and stop solutions 
Substrate solution: two tablets of phosphate citrate buffer with urea hydrogen 
peroxide were added to 22 ml of distilled water in a Falcon tube wrapped in silver 
foil to prevent exposure to light, then mixed on the rolling mixer until dissolved. 
Two tablets of 3,3', 5,5' - tetramethylbenzidine (TMB) were added to the solution 
few minutes before the use and mixed by gentle inversion. 
Sulphuric acid (2M): 11.1 ml of sulphuric acid were placed into a 100 ml graduated 
flask placed on ice in the fume cupboard; water was then added to obtain a final 
volume of 100 ml. 
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Reagents, Buffers, and Recipes for Protein Extraction, Protein Measurement, 
and Western Blotting 
A 4.1 Stock Solutions for Protein Extraction 
A4.1.1 Buffers 
Tris 50 (pH 7.4 50 mM) : 303 mg of Tris, base was dissolved in 100 ml dd1120. The 
pH was adjusted to 7.4 and the solution stored at room temperature. 
NaCI (150 mM): 1.75 g of NaCl was dissolved in 30 ml of Tris 50 mM (plI 7.4) 
Tris HCI (pH 7.6 50 mM): 303 mg of Tris base was dissolved in 100 ml dd1120, 
The pH was adjusted to 7.6 and the solution stored at room temperature. 
Tris 50 mM-l% Triton: I ml of Triton-XIOO was dissolved in 99 ml of Tris IICI 
50mM pH 7.6. 
A4.1.2 Protease Inhibitors 
Ethyleneglycostetra-acetic acid (EGTA 0.5 M): 4.7g of EGTA-Tctrasodium was 
dissolved in 20 ml ddH20 and stored at room temperature. 
Ethylenediaminetetra-acetic acid (EDTA 0.5 M): 7.16g of EDTA-Tri-sodium was 
dissolved in 40ml ddH20 and stored at room temperature. 
Phenylmethylsulfonyl fluoride (PMSF 0.1 M): 0.174g of PMSF was dissolved in 
I Oml of 95% ethanol and stored at room temperature. 
Lcupeptin (1mg/ml): 5mg of leupeptin was dissolved in 5 ml ddII20. Aliquots 
were stored at -20'C. 
213 
APPENDIX IV 
- =;;: -10, 
Aprotinin (1mg/mI): 5mg of aprotinin was dissolved in 5 ml ddH20. Aliquots were 
stored at -20'C. 
A4.1.3 Phosphalase Inhibitors 
Sodium Fluoride (NaF 5M): 4.2g of NaF was dissolved in 20 ml dd1120 at 60"C 
and stored at room temperature. 
Sodium Orthovanadate (Na3V04 IM): 3.68g of Na3V04 was dissolved in 20ml 
ddH20 at 60T. Aliquots were stored at -20T. 
Tetra-Na pyrophosphate decahydrate (0.5M): 8.9g of Tetm-Na pyrophosphate 
decahydrate_was dissolved in 40ml distilled water at 80'C. Aliquots were stored at - 
20T. 
A. 4.1.4 Detergents and Reducing Agents 
Sodium Dodecyl Sulphate (SDS 10% w/v): 109 of SDS was dissolved in 100ml of 
ddH20 and stored at room temperature. 
Dithiothreitol (DTT 2M): 3.084g of DTT was dissolved in 10ml of dd1120- 
Aliquots were stored at -200C. 
A 4.2 DC-Protein Assa 
A serial dilution of the 3.0mg/ml. stock produced five different albumin 
concentrations that were used to generate a standard curve. Dilutions were 
performed using the same lysis buffer used to obtain the samples. 
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Table H: Recipefor the preparation ofthe albumin standards 
Standards 
mg/ml 
Albumin Lysis buffer 
(PI) 
1.5 200 gl of 3.0 mgIml solution 200 
1.0 100 Id of 1.5 mg/mI solution 50 
0.75 100 pI of 1.5 mg/ml solution 100 
0.5 100 pl of 0.75mg/ml solution 50 
0.2 100 [d of 0.5 mg/ml solution 150 
A4.3 Lvsis Buffers 
The recipe for the preparation of the lysis buffer (p38 MAP kinase extraction) is 
detailed in Table 12. The PMSF was added 10 minutes prior to protein extraction 
and the pH was adjusted to pH7.6. 





til inlOml buffer 
Tris-HCI 
Triton 
--- Tris 5OmM 
Triton 1% 
9210 
EDTA 0.5M 2mM 40 
EGTA 0.5M 2mM 40 
NaF 5m 100mm 200 
Na-pyrophosphate 0.5M lomm 200 
Na-ortovanadate Im 2mM 20 
Leupeptin Img/mI loAg/ml 100 
Aprotinin ImgImI lopgtml 100 
PMSF O. IM Imm '100 
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The lysis buffer for AT-1, GLUT-1, and TGF-BI protein extraction comprised Tris- 
HCI (50mM, pH 7.6) and Triton (I/o), 2 mmol/L EDTA, I mmol/L dithiothreitol 
(DTT), I mmol/L phenylmethylsulfonil-fluoride (PMSF), and 100 mmol/L sodium 
chloride. A NP40/DOC Lysis Buffer was used for the TGF-P receptor analysis. Both 
deoxycolate- and SDS-based buffers were used for pericellular fibronectin analysis. 






Tris (pH 7-4) 50 MM 50 mM 7950 
NaCI IM 150 mM 1500 
Deoxycolate --- 0.25% (w/v) 0.025g 
NP40 ---- - --------- I% (v/v) 100 
EGTA 0.5 M 2 mM 40 
Lcupeptin I Mg/Ml (I OOX) 10 pg/Ml 100 
Aprotinin I mg/Ml (100x) 10 jig/Mi 100 
NaF IM 10 MM 100 
Na3V04 IM (50OX) 1 MM 10 
PMSF 0.1 M (I OOX) I MM 100 





SDS Buffer Final 
Concentration 
Tris HO (pH 8-8) 20 mM Tris I ICI (pI 18.8) 20 mM 
Deoxycolate 2% (w/v) SDS I% (W/V) 
EDTA 2 mM EDTA 2 mM 
iodocetic acid 2 mM lodocctic acid 2 mM 
N-ethyl-maleimide 2 mM N-ethyl-maleimide 2 mM 
PMSF 2 mM PMSF 2 mM 
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A4.4 Reagents and Buffers for SDS-PA GE 
SDS (10% w/v): lOg SDS was dissolved in 100ml distilled water, and stored at 
room tempemture. 
Tris HCI (pH 8.8 1.5M): 27.23g of Tris base was dissolved in 150 ml ddl-120. The 
pH was adjusted to 8.8 using 6N HCI and the solution stored at 4*C. 
Tris HCI (pH 6.8 0.5M): 6g of Tris base was dissolved in 100 ml ddII20. ne p1l 
was adjusted to 6.8 using 6N HCI and the solution stored at 40C. 
Ammonium Persulphate (APS 10% W/V): 0.19 of ammonium persulphate was 
dissolved in I ml of ddH20- The APS was freshly prepared for each SDS-PAGE. 
Separating Gel Monomer Solution: 10 ml of the sepamfing gel was prepared in a 
fume cupboard. The solution was degassed for over 15 minutes. Ammonium 
persulphate (APS) and TEMED were added to the degassed mixture immediately 
prior to casting. 
Table 15: Recipefor the preparation ofthe separating gel monomer solution 
Reagent 5% Gel 7.5% Gel 10% Gel 12% Gel 
dd H20 5.65 ml 4.85 ml 4.05 ml 3.35 ml 
Tris-HCI (1.5M) 2.5 ml 2.5 ml 2.5 ml 2.5 ml 
SDS (10% w/v) 100 ILI 100 gl 100 ttl 100 [LI 
Acrylainide/ 
Bisacrylainide (30%) 
1.7 ml 2.5 ml 3.3 ml 4 ml 
APS (10% w/v) 50 gl 50 P1 50 til 50 pI 
TEMED 5 ýd 5 [d 5 pl 5 tLI 
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Stacking Gel Monomer Solution (4%): the stacking gel monomer solution was 
prepared by combining all the reagents except APS and TEMED. The solution was 
degassed under vacuum for 15 minutes. APS and TEMED were added to the 
degassed monomer solution immediately prior to casting. 
Table 16. Recipefor the preparation of 
the stacking gel monomer solution 
Reagent Volume 
dd H20 6.1 ml 
Tris HC1 (0.5 M) 2.5 ml 
SDS (10% w/v) 100 tit 
Acrylamide/Bis(30%) 1.33 ml 
APS (10% w/v) 50 tLI 
TEMED 10 ILI 
Loading Buffer: loading buffer was prepared by combining the reagents reported in 
Table 17, adding the 2-mercaptoethanol immediately before use. 
Table 1Z Loading buffer recipe 
Reagent Volume 
ddH20 3.8 ml 
Tris-HCI (0.5 M, pH 6.8) 1.0 MI 
Glycerol 0.8 ml 
SDS (10% w/v) 1.6 ml 
bromophenol blue (1% w/v) 0.4 ml 
2-mercaptoethanol 0.4 ml 
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Running Buffer (pH 8.3): the reagents reported in Table 18 were dissolved in 
600ml of ddH20 to give a 5x solution of running buffer that was stored at 4'C. For 
each electrophoretic run, 100 ml of this solution was added to 400 ml dd1120 to 
obtain a final Ix solution. 
Table 18: Running buffer recipe 
Reagent Mass (g) 
Tris base 9 
Glycine 43.2 
SDS 3 
4.5 Reazents and Buffers for Immunoblo 
Blotting Buffer (pH 8.3): the blotting buffer was prepared accordingly to the recipe 
detailed in Table 19. pH was checked but not adjusted (if pil fell below 8.0, buffer 
was remade). The buffer was cooled to -20"C prior to use. 
Table 19: Blotting buffer recipe 
Reagent Volume 
Mass 
Final concentration in 
1000 ml 
Tris base 3g 25 mM 
Glycine 14.4g 192 mM 
SDS O. Ig 0.1% (w/v) 
Methanol 200 ml 20% (v/v) 
ddH20 800 ml 
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Tris-buffered Saline (pH7.6 TBS): 2.42g of Tris base, 8g of NaCI and 3.8 ml I ICI 
IM were dissolved in IL ddH20. The pH was adjusted to 7.6 using IM HCI and the 
solution stored at room temperature. 
TBS-Tween-20 (0.5%) : 2.5 ml of Tween-20 was added to 500ml of TBS, and 
stored at room temperature. 
5% milk in TBS: 0.4 g of non-fat dry milk was dissolved in 8ml TBS. 
5% milk in TBS-T: Ig of non-fat dry n-fflk was dissolved in 20ml TBS-Tween-20 
5%. 
A4.5Antibodies 
Table 20: Primary antibodiesfor immunoblotting 
Primary Antibodies Species 
Host 
Dilution 
Anti-Total P38 Goat 1: 100 
Anti-Phospho P38 Rabbit 1: 2000 
Anti-Fibronectin Rabbit 1: 50 
Anti-TGF-01 Rabbit 1: 6000 
Anti-GLUTI Rabbit 1: 2500 
Anti-ATI Rabbit 1: 100 
220 
APPENDIX IV 
A 4.6 Staining Solutions 
Coomassie Brilliant Blue Staining Solution (0.1%): The reagents below were 
made up to 100 ml in ddH20, filtered through Whatman 3M filter paper and stored at 
room tempemture. 





Coomassie Blue R-250 0.1 g 0.1% (w/v) 
Methanol 40 ml 40% (v/v) 
Acetic acid 10 Ml 10 (v/v) 
Destaining Solution: The reagents reported in Table 22 were made up to 1000 ml in 
ddH20 and the solution stored at room temperature. 
Table 22: Destaining Solution 
Reagent Volume Final 
Concentration 
Methanol 400 ml 40 % (vIv) 
Acetic acid 100 MI 10 % (v/v) 
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Ponceau S (0.5%): the reagents reported in Table 23 were made up to 100 ml in 
ddH20, filtered through Whatman 3M filter paper and stored at room temperature in 
the dark as light sensitive. 
Table 23: Ponceau S staining solution 
Reagent Mass/Volume Final 
Concentration 
Glacial acetic acid 5 ml 5% (v/v) 
Ponceau S 500 mg 0.5% (w/v) 




Inhibitors, Blocking Antibodies, and Cytokines. 
A5.1 Inhibitors 
H7 (1-(5-Isoquinolinesulfonyl)-2-methylpipirazine): Img H7 were dissolved I ml 
PBS to obtain a final concentration of 2.7mM. This stock solution was aliquoted and 
stored at +4'C in the dark as light sensitive. 
Calphostin C: 50 ttg of powder were dissolved 100 til DMSO to obtain a final 
concentration of 0.5 mg/mI (0.63 mM). This stock solution was aliquoted and stored 
at -20'C in the dark as light sensitive. 
PMA (Phorbol-12-myristate-13 acetate): 1mg of PMA powder was dissolved in 500 
gl. of DMSO to obtain a fmal. concentration of 2mg/ml. nis stock solution was 
stored at -20'C in the dark as light-sensitive. 
Genistein (4', 5,7-Trihydroxyisoflavone): 5mg of powder were dissolved in 5 ml of 
DMSO to obtain a final concentration of Img/ml. This stock solution was aliquoted 
and stored at -20*C in the dark as light sensitive. 
Herbimycin A: 100 gg of powder were dissolved in 100 pl of DMSO to obtain a 
final concentration of lmg/ml. This stock solution was aliquoted and storcd at -20'C 
in the dark as light sensitive. The stock solution was further dissolved in medium 
just prior to use. 
Peptide A (tyrosine kinase peptide inhibitor - pp60src residues 137-157): 500 gg of 
powder were dissolved in 500 ýd of acetic acid (5%) to obtain a final concentration 
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of lmg/ml (0.4 mM). This stock solution was subdivided in aliquots and stored at - 
20'C in the dark as light sensitive. 
PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine): 1 mg of 
powder were dissolved in 333 Itl of DMSO to obtain a final concentration of 10 mM. 
This stock solution was subdivided in aliquots. and stored at +40C in the dark as light 
sensitive. 
Wortmannin: I mg of powder were dissolved in 207.3 pl of DMSO to obtain a final 
concentration of 4.82mg/ml (10 mM). This stock solution was subdivided in aliquots 
and stored at -20'C in the dark as light sensitive. 
SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinynphenyl)-5-(4-pyridyl)imidazole: 
I ing of powder were dissolved in 300 gl of DMSO to obtain a final concentration of 
3.3 mg/ml (8.8mM). This stock solution was subdivided in aliquots and stored at - 
20'C in the dark as light sensitive. 
Losartan-DuP753: (2-n-butyl-4-chloro-5-hydroxymethyl-I -2-(l 11-tctrazoic) 
biphenyl4-hylmethyl) imidazole: 50 mg powder were diluted in 10 ml of PBS to 
obtain a fmal concentration of 5g/L or 11.8mM. This stock solution was stored at 
+4'C in the dark as light-sensitive. 
A 5.2 Neutralisinje Antibodies 
Monoclonal anti-IGF-I type I receptor antibody (0113): the antibody, received in 
a Iyophilised form, was reconstituted as a stock solution of 100 P9/mI %ith sterile 
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PBS at 4'C with occasional gentle mixing for 2 hours, subdivided in aliquots and 
stored at -20T. 
Pan-neutralising anti-TGF-P antibody: the polyclonal anti-human TGF-p 
neutralising antibody, received in a Iyophilised fonn, was reconstituted as a stock 
solution of 500mg/ml with sterile PBS, aliquoted and stored at -700C. 
Monoclonal anti-human TGF-P, neutralising antibody: the monoclonal anti- 
human TGF-P, neutralising antibody, received in a Iyophilised form, was 
reconstituted as a stock solution of 500ptg/ml with sterile PBS, aliquoted and stored 
at -700C. 
Mouse IgGI isotype control: mouse IgGI isotype was purchased in a Iyophilised 
fonn, reconstituted as a stock solution of 500pg/ml with sterile PBS, aliquoted. and 
stored at -70'C. 
A5.3 Human Recombinant Cvtokines 
Human recombinant TGF-PI: 2 [tg of Iyophilised human recombinant TGF-PI 
were reconstituted in 2 ml of 4 mM HCI containing Iml/ml BSA to obtain a final 
concentration of lmg/ml. This stock solution was subdivided in aliquots and stored 
at-200C. 
Angiotensin 11: 1 mg of powder were dissolved in I MI Of 1120 to obtain a final 
concentration of Img/mI (0.95 mM). This stock solution was subdivided in aliquots 
and stored at -20'C. 
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Human recombinant IGF-1: 50 jtg of Iyophilised human recombinant IGF-I were 




1. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. 
The Lancet 1998; 352: 213-219. 
2. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving 
HH, Steffes MW. Nephropathy in diabetes. American Diabetes Association. 
Diabetes Care. 2004; 27(Suppl 1): S79-S83. 
3. Ritz E, Tamg DC. Renal disease in type 2 diabetes. Nephrol Dial Transplant. 
2001; 16(Suppl 5): 11-18. 
4. Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients 
with diabetes and end-stage renal disease. J Am Soc Nephrol. 2004; 15(Suppl 
1): S25-S29. 
U. S. Renal Data System: USRDS 2001 Annual Data Report: Atlas of End- 
Stage Renal Disease in the United States. Bethesda, MD, National Institutes of 
Health, National Institute of Diabetes and Digestive and Kidney Diseases, 
2001. 
6. Gordois A, Scuffharn P, Shearer A, Oglesby A. The health care costs of 
diabetic nephropathy in the United States and the United Kingdom. J Diabctes 
Complications. 2004; 18: 18-26. 
7. Brandle M, Zhou H, Smith BF, Marriott D, Burke R, Tabaei BP, Brown MB, 
Herman WH. T'he direct medical cost of type 2 diabetes. Diabctes Care. 2003; 
26: 2300-2304. 
8. Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander 
CM, Cook JR, Keane WF, Brenner BM. Losartan reduces the costs associated 
with diabetic end-stage renal disease: the RENAAL study economic 
evaluation. Diabetes Care. 2003; 26: 683-687. 
9. Mogensen CE. Definition of diabetic renal disease in insulin-dependent 
diabetes mellitus based on renal fimcdon tests. in The kidney and hypertcnsion 
in diabetes mellitus. Edited by Mogensen CE. Kluwer Academic Publishers. 
1997; 2: 11-22. 
227 
REFERENCES 
10. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. 
Microalbiuninuria as a predictor of clinical nephropathy in insulin-dependent 
diabetes mellitus. Lancet. 1982; 1: 1430-1432. 
11. Mogensen CE, Cooper ME. Diabetic renal disease: from recent studies to 
improved clinical practice. Diabet Med. 2004; 21: 4-17. 
12. Christensen CK, Mogensen CE. The course of incipient diabetic nephropathy: 
Studies of albumin excretion and blood pressure. Diab Med. 1985; 2: 97-102. 
13. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict 
metabolic control on progression of incipient nephropathy in insulin-dependent 
diabetes. Lancet. 1986; 2: 1300-1304. 
14. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner 
BM; RENAAL Study Group. Effects of blood pressure level on progression of 
diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 
2003; 163: 1555-1565. 
15. Poulsen PL, Hansen KW, Mogensen CE. Ambulatory blood pressure in the 
transition from nonno- to microalbuminuria. A longitudinal study in IDDM 
patients. Diabetes. 1994; 43: 1248-1253. 
16. Mogensen CE, Christensen CK. Blood pressure changes and renal function in 
incipient and overt diabetic nephropathy. Hypertension. 1985; 7: 11-64-11-73. 
17. Jaap AJ, Shore AC, Tooke JE. Differences in microvascular fluid permeability 
between long-duration type I (insulin-dependent) diabetic patients with and 
without significant microangiopathy. Clin Sci (Lond). 1996; 90: 113-117. 
18. Feldt-Rasmussen B. Increased transcapillary escape rate of albumin in type I 
(insulin-dependent) diabetic patients with Microalbuminuria. Diabetologia. 
1986; 29: 282-286. 
19. Deckert T, Yokoyama H, Mathiensen E, Ronn B, Jcnscn T, Feldt-Rasmussen 
B, Borch-Johnsen K, Jensen JS. Cohort study of predictive value of urinary 
albumin excretion for atherosclerotic vascular disease in patients with insulin- 
dependent diabetes. BML 1996; 312: 871-874. 
20. Donnelly R, Ycung JM, Manning G. Microalbuminuria: a common, 
independent cardiovascular risk factor, especially but not exclusively in type 2 
diabetes. J Hypertens Suppl. 2003; 21(Suppl 1): S7-SI2. 
228 
REFERENCES 
21. Caramori ML, Pecis M, Azevedo MJ. Increase in nocturnal blood pressure and 
progression to microalbuminuria in diabetes. N Engl J Med. 2003; 348: 260- 
264. 
22. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. 
Kidney Int. 1999; 56: 393-405. 
23. Dalla Vestra, M, Saller A, Mauer M, Fioretto P. Role of mesangial expansion 
in the pathogenesis of diabetic nephropathy. J Nephrol. 2001; 14(Suppl 
4): S51-S57. 
24. Olsen S. Light microscopy of diabetic glomerulopathy: the classic lesion. In 
The Kidney and Hypertension in Diabetes Mellitus by Mogensen C. E, Kluwer 
Academic Publishers. 1997; 18: 173-184. 
25. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. 
Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984; 
74: 1143-1155. 
26. Fioretto P, Steffes MW, Sutherland DER, Mauer SM. Sequential renal biopsies 
in IDDM patients: structural factors associated with clinical progression. 
Kidney Int. 1995; 48: 1929-1935. 
27. Bangstad HJ, Rudberg S, Osterby R. Renal structural changes in patients with 
type I diabetes and microalbuminuria. In: The Kidney and Hypertension in 
Diabetes Mellitus by Mogensen CE, Kluwer Academic Publishers. 2000; 211 - 
225. 
28. Drummond K, Mauer M for the International Diabetic Nephropathy Study 
Group. The early natural history of nephropathy in type I diabetes. 1-11. Early 
renal structural changes in type I diabetes. Diabetes. 2002; 51: 1572-1587. 
29. Fioretto, P, Steffes MW, Mauer M. Glomerular structure in nonprotcinuric 
IDDM patients with various levels of albuminuria. Diabetes. 1994; 43: 1358- 
1364. 
30. Osterby R, Hartmann A, Nyengaard JR, Bangstad II-J. Development of renal 
structural lesions in type I diabetic patients with microalbuminuria. 
Observations by light microscopy in 8-ycar follow-up biopsies. Virchows 
Arch. 2002; 440: 94-101. 
229 
REFERENCES 
3 1. Kim Y, Kleppel M, Butkowski F, Mauer M, Wieslander J, Michel A. 
Differential expression of basement membrane collagcn chains in diabetic 
nephropathy. Am J Pathol. 199 1; 13 8: 413 420. 
32. Schleicher ED. Biochemical aspects of diabetic nephropathy. In: The Kidney 
and Hypertension in Diabetes Mellitus by Mogensen C. E. Kluwer Academic 
Publishers. 1997; 23: 223-233. 
33. Shimomura, H, Spiro RG. Studies on macromolecular components of human 
glomerular basement membrane and alterations in diabetes. Decreased levels 
of heparan sulfate proteoglycan and laminin. Diabetes. 1987; 36: 374-3 8 1. 
34. Mohan PS, Carter WG, Spiro RG. Occurrence of type VI collagen in 
extracellular matrix of renal glomeruli and its increase in diabetes. Diabetes. 
1990; 39: 31-37. 
35. Schaefer RM, Paczek L, Huang S, Teschner M, Schefer L, Heidland A. Role 
of glornerular proteinases in the evolution of glomerulosclerosis. Eur J Clin 
Biochem. 1992; 30: 641-646. 
36. Barisoni L, Mundel P. Podocyte biology and the emerging understanding of 
podocyte diseases. Am J Nephrol. 2003; 23: 353-360. 
37. Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P. Is 
podocyte injury relevant in diabetic nephropathy? Studies in patients with type 
2 diabetes. Diabetes. 2003; 52: 1031-1035. 
38. Powell HR. Relationship between proteinuria and epithelial cell changes in 
minimal lesion glornerulopathy. Nephron. 1976; 16: 310-317. 
39. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke 
FIG, Coplon NS, Meyer TW. Podocyte loss and progressive glomerular injury 
in type 2 diabetes. J Clin Invest. 1997; 99: 342-348. 
40. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term 
urinary albumin excretion in Pima Indians with type II diabetes and 
microalbuminuria. Diabetologia. 1999; 42: 1341-1344. 
41. Lemley KV, Abdullah 1, Myers BD, Meyer TW, Blouch K, Smith WE, Bennet 
PH, Nelson RG. Evolution of incipient nephropathy in type 2 diabetes 
mellitus. Kidney Int. 2000; 58: 1228-1237. 
230 
REFERENCES 
42. White KE, Bilous RW; Diabiopsies Study Group. Structural alterations to the 
podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial 
Transplant. 2004; 19: 1437-1440. 
43. Steffes MW, Schmidt D, McCrery P, Basgen JM. Glomerular cell number in 
nonnal subjects and in type I diabetic patients. Kidney Int. 2001; 59: 2104- 
2113. 
44. White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi G, Piras G, De 
Cosmo S, Viberti G. Podocyte number in normotensive type I diabetic patients 
with albuminuria. Diabetes. 2002; 51: 3083-3089. 
45. Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. 11. 
Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int. 1992; 
42: 148-160. 
46. Cooper ME, Mundel P, Boner G. Role of nephrin in renal disease including 
diabetic nephropathy. Semin Nephrol. 2002; 22: 393-398. 
47. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, 
Camussi G. Nephrin expression is reduced in human diabetic nephropathy: 
evidence for a distinct role for glycated albumin and angiotensin 11. Diabetes. 
2003; 52: 1023-1030. 
48. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan 
normalises the deficiency in glomerular nephrin expression in a model of 
diabetes and hypertension. Diabetologia. 2001; 44: 874-877. 
49. Bader R, Bader E, Grung KE, Markensen-Haen S, Christ 11, Bohle A. 
Structure and function of the kidney in diabetic glomerulosclcrosis: 
correlations between morphological and functional parameters. Pathol Res 
Pract. 1980; 167: 204-216. 
50. Lane PH, Steffes MW, Fioretto P, Mauer SM. Renal interstitial expansion in 
insulin-dependent diabetes mellitus. Kidney Int. 1993; 43: 661-667. 
51. Taft J, Nolan CJ, Yeung SP, Hewitson TD, Martin FIR. Clinical and 
histological correlations of decline in renal function in diabetic patients with 
proteinuria. Diabetes. 1994; 43: 1046-105 1. 
231 
REFERENCES 
52. Ueno M, Kawashima S, Nishi S, Shimada S, Shimada, N, Karasawa R, Suzuki 
Y, Muruyama Y, Arakawa M. Tubulointerstitial lesions in non-insulin 
dependent diabetes mellitus. Kidney Int. 1997; 52(Suppl 63): S 19 1 -S 194. 
53. Brito PL, Fioretto P, Drummond K, Kim Y, Steffes MW, Basgcn JM, Sisson- 
Ross S, Mauer M. Proximal tubular basement membrane width in insulin- 
dependent diabetes mellitus. Kidney Int. 1998; 53: 754-761. 
54. Wu K, Setty S, Mauer SM, Killen P, Nagase H, Michael AF, Tsilibary EC. 
Altered kidney matrix gene expression in early stages of experimental 
diabetes. Acta Anat. 1997; 158: 155-165. 
55. Yagame M, Kim Y, Zhu D, Suzuki D, Eguchi K, Nomoto Y, Sakai 11, 
Groppoli T, Steffes MW, Mauer SM. Differential distribution of type IV 
collagen chains in patients with diabetic nephropathy in non-insulin-dependcnt 
diabetes mellitus. Nephron. 1995; 70: 4248. 
56. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathics. N Engl 
J Med. 1998; 12: 1448-1456. 
57. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, I funsickcr LG, King 
AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, Protcinuria, and 
the progression of renal disease. The Modification of Dict in Renal Disease 
Study. Ann Intern Med. 1995; 123: 754-762. 
58. Fioretto P, Stchouwer CDA, Mauer M, Chiesuracorona M, Brocco E, Carraro 
A, Bortoloso E, Vanhinsbergh VWM, Crcpaldi G, Nosadini It I Ictcrogcncous 
nature of microalbuminuria in NIDDM: Studies of cndothclial function and 
renal structure. Diabetologia. 1998; 4: 233-236. 
59. Gilbert RE, Cooper ME. Ile tubulointerstitium in progressive diabetic kidney 
disease: more than an aftermath of glomerular injury? Kidney Int. 1999; 
56: 1627-1637. 
60. Quinn M, Angelico MC, Wan-am J11, Krolewski AS. Familial factors 
determine the development of diabetic nephropathy in patients with IDDM. 
Diabetologia. 1996; 39: 940-945. 
61. Canani LH, Gerchman F, Gross JL. Familial clustering of diabetic ncphropathy 
in Brazilian type 2 diabetic patients. Diabetes. 1999; 48: 909-913. 
232 
REFERENCES 
62. Freedman BI, Tuttle AB, Spray BJ. Familial predisposition to nephropathy in 
African-Americans with non-insulin-dependent diabetes mellitus. Am j 
Kidney Dis. 1995; 25: 710-713. 
63. Fava S, Azzopardi J, Hattersley AT, Watkins pj. Increased prevalence of 
proteinuria in diabetic sibs of proteinuric type 2 diabetic subjects. Am J 
Kidney Dis. 2000; 35: 708-712. 
64. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett P11, Knowler WC. Sib- 
pair linkage analysis for susceptibility genes for microvascular complications 
among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. 
Diabetes. 1998; 47: 821-830. 
65. Vardarli I, Baier IJ, Hanson RL, Akkoyun 1, Fischer C, Rohmeiss P, Basci A, 
Bartrarn CR, Van Der Woude, FJ, Janssen B. Gene for susceptibility to diabetic 
nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int. 2002; 
62: 2176-2183. 
66. Bowden DW, Sale M, Howard TD, Qadri A, Spray BJ, Rothschild CB, Akots 
G, Rich SS, Freedman BI. Linkage of genetic markers on human chromosomes 
20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic 
nephropathy. Diabetes. 1997; 46: 882-886. 
67. Mogensen CE. Genetics and diabetic renal disease: still a big black hole. 
Diabetes Care. 2003; 26: 1631-1632. 
68. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatcllicr G, Scrt C, Dussclicr 
L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann I I, Bauduccau 11, Blcd 
F, Passa P, Alhenc-Gelas F. Contribution of genetic Polyphormism in the 
renin-angiotcnsin system to the development of renal complications in insulin- 
dependent diabetes. J Clin Invest. 1997; 99: 1585-1595. 
69. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lcccrf L, Poiricr 
0, Danilov S, Parving HH. Lack of relationship between an inscrtion/dclction 
polymorphism in the angiotensin I-converting enzyme gcnc and diabctic 
nephropathy and prolifemtive retinopathy in IDDM patients. Diabctcs. 1995; 
44: 489494. 
70. Parving HH, Jacobsen P, Tamow L, Rossing P, Lecerf L, Poirier 0, Cambicn 
F. Effect of deletion polymorphism of angiotensin converting cnzyMC gene on 
233 
REFERENCES 
progression of diabetic nephropathy during inhibition of angiotensin 
converting enzyme: observational follow-up study. BMJ. 1996; 313: 591-594. 
71. Andersen S, Tamow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving 11. 
H. Long-tenn renoprotective effects of losartan, in diabetic nephropathy: 
interaction with ACE insertion/deletion genotype? Diabetes Care. 2003; 
26: 1501-1506. 
72. Heesom. AE, Hibberd ML, Millward A, Dernaine AG. Polymorphism in the 5'- 
end of the aldose reductase gene is strongly associated with the development of 
diabetic nephropathy in type I diabetes. Diabetes. 1997; 46: 287-291. 
73. Dernaine AG. Polymorphisms of the aldose reductase gene and susceptibility 
to diabetic microvascular complications. Curr Med Chem. 2003; 10: 1389- 
1398. 
74. Mathiesen ER, Ronn B, Jensen T, Storm B, Deckert T. Relationship between 
blood pressure and urinary albumin excretion in development of 
microalbuminuria. Diabetcs. 1990; 39: 245-249. 
75. The Microalburninuria Collaborative Study Group. Predictors of the 
development of microalbuminuria in patients with Type I diabetes mcllitus: a 
seven-year prospective study. Diabet Med. 1999; 16: 918-925. 
76. The Diabetes Control and Complications Trial Research Group. The cffcct of 
intensive treatment of diabetes on the development and progression of long. 
term complications in insulin-dependent diabetes mellitus. N Engl J Mcd 1993; 
329: 977-986. 
77. The Diabetes Control and Complications Trial Research Group. Effcct of 
intensive therapy on the development and progression of diabetic ncphropathy 
in the Diabetes Control and Complications Trial. The Diabetes Control and 
Complications (DCCT) Research Group. Kidney Int. 1995; 47: 1703-1720. 
78. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucosc 
control with sulphonylureas or insulin compared with conventional treatment 
and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancct. 
1998; 12: 352: 837-853. 
234 
REFERENCES 
79. Lee CS, Mauer SM, Brown DM, Sutherland DE, Michael AF, Najarian JS. 
Renal transplantation in diabetes mellitus in rats. J Exp Med. 1974; 139: 793- 
800. 
80. Mauer SM, Steffes MW, Sutherland DE, Najarian-S, Michael AF, Brown DM. 
Studies of the rate of regression of the glomerular lesions in diabetic rats 
treated with pancreatic islet transplantation. Diabetes. 1975; 24: 280-285. 
81. Rasch R- Prevention of diabetic glomerulopathy in streptozotocin diabetic rats. 
Albumin excretion. Diabetologia 1980; 18: 413416. 
82. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of 
lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 
1998; 339: 69-75. 
83. Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end 
products: a Nephrologist's perspective. Am J Kidney Dis. 2000; 35: 365-380. 
84. Brownlee M. Biochemistry and molecular cell biology of diabetic 
complications. Nature. 2001; 414: 813-820. 
85. Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto 11, Ota 
Z, Araki N, Horiuchi S. Ultrastructure of nonenzymatically glycated mcsangial 
matrix in diabetic nephropathy. Kidney Int. 1995; 48: 517-526. 
86. Vlassara H, Striker U, Teichberg S, Fuh 11, Li YM, Stcffcs M. Advanced 
glycation end products induce glomerular sclerosis and alburninuria in normal 
rats. Proc Natl Acad Sci USA. 1994; 91: 11704-11708. 
87. Soulis T, Cooper ME, Vranes D, Bucala P, Jcrums G. Effects of 
aminoguanidine in preventing experimental diabetic ncphropathy arc rclatcd to 
the duration of treatment. Kidney Int. 1996; 50: 627-634. 
88. Lee HB, Cha MK, Song KI, Klm JII, Lee EY, Kim SI, Kim J, Yoo M11. 
Pathogenic role of advanced glycosylation end products in diabctic 
nephropathy. Kidney Int Suppl. 1997; 60: S60-65. 
89. Soulis T, Mallas V, Youssef S, Gilbert RE, MeWilliam BG, Murray-McIntosh 
RP, Cooper ME. Advanced glycation end products and their rcccptors co- 
localise in rat organs susceptible to diabetic microvascular injUry. 
Diabctologia. 1997; 40: 619-628. 
235 
REFERENCES 
90. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker IJ. Receptor- 
specific increase in extracellular matrix production in mouse mesangial cells 
by advanced glycosylation end products is mediated via platelet-derived 
growth factor. Proc Nad Acad Sci USA. 1992; 89: 2873-2877. 
91. Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Giannini S, Cresci B, 
Galli G, Rotella, CM, Vlassara, H, Di Mario U. Upregulation of mesangial 
growth factor and extracellular matrix synthesis by advanced glycation end 
products via a receptor-mediatcd mechanism. Diabetes. 1997; 46: 1881-1887. 
92. Twigg SM, Cao Z, MCLennan SV, Bums WC, Brammar G, Forbes JM, 
Cooper ME. Renal connective tissue growth factor induction in experimental 
diabetes is prevented by aminoguanidine. Endocrinology. 2002; 143: 4907- 
4915. 
93. Yamamoto Y, Kato 1, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe 
T, Yamagishi S, Sakurai S, Takasawa S, Okamoto 11, Yamamoto 11. 
Development and prevention of advanced diabetic nephropathy in RAGE- 
overexpressing mice. J Clin Invest. 200 1; 108: 261-268. 
94. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas 
V, Atkins RC, Osicka. T, Jerums G, Cooper ME. Advanced glycation end 
products cause epithelial-myofibroblast transdifferentiation via the receptor for 
advanced glycation end products (RAGE). J Clin Invest. 2001; 108: 1853-1863. 
95. Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen 
J, Wagle D, Shih D, Terlecky 1, Bucala R, Cerami A, Egan J, Ulrich P. An 
agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature. 
1996; 382: 275-278. 
96. Schwedler SB, Verbeke P, Bakala H, Weiss MF, Vilar J, Depreux P, 
Fourmaintraux E, Striker IJ, Striker GE. N-phenacylthiazoliurn bromide 
decreases renal and increases urinary advanced glycation end products 
excretion without ameliorating diabetic nephropathy in C57BIJ6 mice. 
Diabetes Obes Metab. 2001; 3: 230-239. 
97. Forbes JM, Soulis T, Tballas V, Panagiotopoulos S, Long DM, Vasan S, 
Wagle D, Jerums G, Cooper ME. Renoprotective effects of a novel inhibitor of 
advanced glycation. Diabetologia. 2001; 44: 108-114. 
236 
REFERENCES 
98. Cogan DG, Kinoshita JH, Kador PF, Robison G, Datilis MB, Cobo LM, 
Kupfer C. NIH conference. Aldose reductase and complications of diabetes. 
Ann Intem Med. 1984; 101: 82-91. 
99. Kador PF, Robison WG Jr, Kinoshita JH. The pharmacology of aldose 
reductase inhibitors. Annu Rev Pharmacol Toxicol. 1985; 25: 691-714. 
100. Pugliese G, Tilton RG, Speedy A, Santarelli E, Eades DM, Province MA, Kilo 
C, Sherman WR, Williamson JR. Modulation of hemodynamic and vascular 
filtration changes in diabetic rats by dietary myo-inositol. Diabetes. 1990; 
39: 312-322. 
101. Olgemoller B, Schwaabe S, Schleicher ED, Gerbitz KD. Upregulation of myo- 
inositol transport compensates for competitive inhibition by glucose. An 
explanation for the inositol paradox? Diabetes. 1993; 42: 1119-1125. 
102. Goldfarb S, Ziyadeh FN, Kem EF, Simmons DA. Effects of polyol-pathway 
inhibition and dietary myo-inositol on glomerular hemodynamic function in 
experimental diabetes mellitus in rats. Diabetes. 1991; 40: 465-471. 
103. Hamada, Y, Araki N, Horiuchi S, Hotta N. Role of polyol pathway in 
nonenzymatic glycation. Nephrol Dial Transplant. 1996; 11 (Suppl 5): 95-98. 
104. Gruden G, Viberti GC. Pathogenesis of Diabetic Nephropathy. In Joslin's 
Diabetes Mellitus by RC Kahn 14th Edition LWW 2004; (in press). 
105. Weigert C, Brodbeck K, Lehmann R, Haring IIU, Schleicher ED. 
Overexpression of glutamine: fructose-6-phosphate-amidotransferase induces 
transforming growth factor-PI synthesis in NIII-3T3 fibroblasts. FEBS Lett. 
2001; 488: 95-99. 
106. Burt DJ, Gruden G, Thomas SM, Tutt P, Dell'Anna C, Viberti GC, Gnudi L. 
P38 mitogen-activated protein kinase mediates hexosamine-induced TGFPI 
mRNA expression in human mesangial cells. Diabetologia. 2003; 46: 531-537. 
107. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High glucose- 
induced transforming growth factor 01 production is mediated by the 
hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest. 
1998; 101: 160-169. 
108. Nerlich AG, Sauer U, Kolm-Litty V, Wagner E, Koch M, Schleichcr ED. 
Expression of glutamine: fructose-6-phosphate amidotransferase in human 
237 
REFERENCES 
tissues: evidence for high variability and distinct regulation in diabetes. 
Diabetes. 1998; 47: 170-178. 
109. James LR, Ingram A, Ly H, Thai K, Cal L, Scholey JW. Angiotensin 11 
activates the GFAT promoter in mesangial cells. Am J Physiol Renal Physiol. 
2001; 281: FI51-162. 
110. Larkins RG, Dunlop ME. The link between hyperglycaemia, and diabetic 
nephropathy. Diabetologia 1992; 35: 499-504. 
1. Ayo SH, Radnik RA, Garoni JA, Glass WIF 2nd, Kreisberg JI. High glucose 
causes an increase in extracellular matrix proteins in cultured mesangial cells. 
Am J Pathol. 1990; 136: 1339-1348. 
112. Birkedal-Hansen H. Proteolytic remodelling of extracellular matrix. Curr Opin 
Cell Biol. 1995; 7: 728-735. 
113. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. 
Overexpression of glucose transporters in rat mesangial cells cultured in a 
normal glucose milieu mimics the diabetic phenotype. J Clin Invest. 1995; 
96: 1802-1814. 
114. Heilig CW, Liu Y, England RL, Freytag SO, Gilbert JD, Heilig KO, Zhu M, 
Concepcion LA, Brosius FC 3rd. D-glucose stimulates mesangial cell GLUTI 
expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: 
implications for diabetic nephropathy. Diabetes. 1997; 46: 1030-1039. 
115. Heilig CW, Kreisberg JI, Freytag S, Murakami T, Ebina Y, Guo L, Ilcilig K, 
Loberg R, Qu X, Jin Y, Henry D, Brosius FC 3rd. Antisensc GLUT-1 protects 
mesangial cells from glucose induction of GLUT-1 and fibronectin expression. 
Am J Physiol Renal Physiol. 2001; 280: F657-F666. 
116. DuX, MatsumuraT, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brovvnicc 
M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates 
three major pathways of hyperglycernic damage in endothelial cclls. J Clin 
Invest. 2003; 112: 1049-1057. 
117. Border WA, Noble NA. Transfortning Growth Factor-P in tissue fibrosis. N 
Engl J Med. 1994; 331: 1286-1292. 
118. Ziyadeh FN, Han DC. Involvement of TGF-P and its receptors in the 
pathogenesis of diabetic ncphropathy. Kidney Int. 1997; 52(Suppl 60) S7-S 11. 
238 
REFERENCES 
119. Cheng, J, Grande JP. Transforming Growth Factor-P Signal Transduction and 
Progressive Renal Disease. Exp Biol Med (Maywood). 2002; 227: 943-956. 
120. Terrell TG, Working PK, Chow CP, Green JD. Pathology of recombinant 
human TGF-01 in rats and rabbits. Int Rev Exp Pathol. 1993; 34B: 43-67. 
121. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. 
Glomerulosclerosis induced by in vivo transfection of transforming growth 
factor-P or platelet-derived growth factor gene into the rat kidney. J Clin 
Invest. 1993; 92: 2597-2601. 
122. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger EP, Klotman 
PE, Thorgeirsson SS. Transgenic mice with increased plasma levels of TGF-P I 
develop progressive renal disease. Lab Invest. 1996; 74: 991-1003. 
123. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression 
of transforming growth factor 0 is elevated in human and experimental diabetic 
nephropathy. Proc Natl Acad Sei USA. 1993; 90: 1814-1818. 
124. Iwano, M, Kubo A, Nishino, T, Sato H, Nishioka 11, Akai Y, Kurioka 11, Fujii 
Y, Kanauchi M, Shiiki H, Dohi K. Quantification of glomcrular TGF-01 
mRNA in patients with diabetes mellitus. Kidney Int. 1996; 49: 1120-1126. 
125. Hill C, Flyvbjerg A, Gronbaek H, Petrik J, Hill DJ, T'homas CR, Sheppard 
MC, Logan A. The renal expression of transforming growth factor-O isoforms 
and their receptors in acute and chronic experimental diabetes in rats. 
Endocrinology. 2000; 141: 1196-1208. 
126. Sharma K, An Y, Guo J, Ziyadeh FN. Neutralization of TGF-P by anti-TGF-P 
antibody attenuates kidney hypertrophy and the enhanced cxtracellular matrix 
gene expression in STZ-induced diabetic mice. Diabetes. 1996; 45: 522-530. 
127. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, 
Isono M, Chen S, McGowan TA, Sharma K. Long-term prevention of rcnal 
insufficiency, excess matrix gene expression, and glomerular mcsangial matrix 
expansion by treatment with monoclonal antitransforming growth factor-P 




128. Yevdokimova N, Wahab NA, Mason RM. Thrombospondin-I is the key 
activator of TGF-01 in human mesangial, cells exposed to high glucose. J Am 
Soc Nephrol. 2001; 12: 703-712. 
129. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene 
expression and protein synthesis in murine mesangial cells by high glucose is 
mediated by autocrine activation of transforming growth factor-P. J Clin 
Invest. 1994; 93: 536-542. 
130. Isono M, Mogyorosi A, Han DC, Hoffman BB, Ziyadch FN. Stimulation of 
TGF-P type II receptor by high glucose in mouse mesangial cells and in 
diabetic kidney. Am J Physiol Renal Physiol. 2000; 278: F830-F838. 
131. Inoki K, Haneda M, Maeda S, Koya D, Kikkawa P, TGF-P I stimulates 
glucose uptake by enhancing GLUTI expression in mesangial, cells. Kidney 
Int. 1999; 55: 1704-1712. 
132. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker U. Advanced 
glycation end products up-regulate gene expression found in diabetic 
glomerular disease. Proc Natt Acad Sci USA. 1994; 91: 9436-9440. 
133. Iglesias-de la Cruz MC, Ziyadeh FN, Isono, M, Kouahou M, Ilan DC, Kalluri 
P., Mundel P, Chen S. Effects of high glucose and TGF-P I on the expression of 
collagcn IV and vascular endothelial. growth factor in mouse podocytes. 
Kidney Int. 2002; 62: 901-913. 
134. van Det NF, Verhagen NA, Tainsma JT, Berden J11, Bruijn JA, Daha MR, van 
der Woude FJ. Regulation of glornerular epithelial cell production of 
fibronectin and transforming growth factor-P by high glucose, not by 
angiotensin 11. Diabetes. 1997; 46: 834-840. 
135. Goldschmeding R, Aten J, Ito Y, Blom 1, Rabelink T, Weening JJ. Connective 
tissue growth factor: just another factor in renal fibrosis? Ncphrol Dial 
Transplant. 2000; 15: 296-299. 
136. Murphy M, Godson C, Cannon S, Kato S, Mackenzie IIS, Martin F, Brady 
HF, Suppression subtractive hybridization identifies high glucose levels as a 
stimulus for expression of connective tissue growth factor and other genes in 
human mesangial cells. J Biol Chem. 1999; 274: 5830-5834. 
240 
REFERENCES 
137. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG. 
Regulation of connective tissue growth factor activity in cultured rat mesangial 
cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc 
Nephrol. 2000; 11: 25-38. 
138. Wahab NA, Yevdokimova N, Weston BS, Roberts T, Li XJ, Brinkman 11, 
Mason RM. Role of connective tissue growth factor in the pathogenesis of 
diabetic nephropathy. Biochem J. 2001; 359: 77-87. 
139. McLennan SV, Wang XY, Moreno V, Yue DK, Twigg SM. Connective tissue 
growth factor mediates high glucose effects on matrix degradation through 
tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic 
nephropathy. Endocrinology. 2004 (Epub ahead of print). 
140. Duncan MR, Frazier KS, Abramson S, Williams S, Mapper 11, Huang X, 
Grotendorst GR. Connective tissue growth factor mediates transforming 
growth factor P-induced collagen synthesis: down-regulation by cAMP. 
FASEB J. 1999; 13: 1774-1786. 
141. Abdel-Wahab N, Weston BS, Roberts T, Mason RM. Connective tissue 
growth factor and regulation of the mesangial cell cycle: role in cellular 
hypertrophy. J Am Soc Nephrol. 2002; 13: 2437-2445. 
142. Inoki 1, Shiomi T, Hashimoto G, Enomoto 11, Nakamura 11, Makino K, Ikeda 
E, Takata S, Kobayashi K, Okada Y. Connective tissue growth factor binds 
vascular endothelial growth factor (VEGF) and inhibits VEGF-induccd 
angiogenesis. FASEB J. 2002; 16: 219-221. 
143. Wang S, Denichilo M, Brubaker C, Hirschberg R. Connective tissue growth 
factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int. 2001; 
60: 96-105. 
144. Gore-Hyer E, Shegogue D, Markiewicz M, Lo S, Ilawn-Martin D, Grccne EL, 
Grotendorst G, Trojanowska M. TGF-P and CTGF have overlapping and 
distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol. 
2002; 283: F707-F716. 
145. Veelken R, Hilgers KF, Hartner A, Haas A, Bohmer KP, Sterzel RB. Nitric 
oxide synthase isofonns and glomerular hyperfiltration in early diabetic 
nephropathy. J Am Soc Nephrol. 2000; 11: 71-79. 
241 
REFERENCES 
146. De Vriese AS, Stoenoiu MS, Elger M, Devuyst 0, Vanholder R, Kriz W, 
Larneire NH. Diabetes-induced microvascular dysfunction in the 
hydronephrotic kidney: role of nitric oxide. Kidney Int. 2001; 60: 202-210. 
147. Goligorsky MS, Chen J, Brodsky S. Workshop: endothelial cell dysfunction 
leading to diabetic nephropathy : focus on nitric oxide. Hypertension. 2001; 
37: 744-748. 
148. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines 
in experimental diabetic kidney disease. Diabetologia. 2000; 43: 1205-1223. 
149. Chestnut RE, Quarmby V. Evaluation of total IGF-I assay methods using 
samples from Type I and Type 11 diabetic patients. J Immunol Methods. 2002; 
259: 11-24. 
150. Doi T, Striker LJ, Gibson CC, Agodoa LY, Brinster RL, Striker GE. 
Glomerular lesions in mice transgenic for growth hormone and insulinlike 
growth factor-1. Relationship between increased glornerular size and mesangial 
sclerosis. Am J Pathol. 1990; 137: 541-552. 
151. Giordano M, DeFronzo RA. Acute effect of human recombinant insulin-like 
growth factor I on renal ftinction in humans. Nephron. 1995; 7 1: 10-1 S. 
152. Landau D, Segev Y, Afargan M, Silbergeld A, Katchko L, Podshyvalov A, 
Phillip M. A novel somatostatin analogue prevents early renal complications in 
the nonobese diabetic mouse. Kidney Int. 2001; 60: 505-512. 
153. TsukAm H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct 
demonstration of insulin-like growth factor-l-induced nitric oxide production 
by endothelial cells. Kidney Int. 1994; 45: 598-604. 
154. Schreiber 1313, Hughes ML, Groggel GC. Insulin-like growth factor stimulates 
production of mesangial. cell matrix components. Clin Nephrol. 1995; 43: 368- 
374. 
155. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. 
Endocr Rev. 1997; 18: 4-25. 
156. Plate KH, Breier G, Weich IIA, Risau W. Vascular endothelial growth factor is 
a potential turnour angiogenesis factor in vivo. Nature 1992; 359: 845-847. 
157. Aiello LP, Avery R, Arrigg R, Key B, Jampel 11, Shah S, Paquale L, Thierne 
H, Iwamoto M, Park JE, Nguyen 11, Aiello LM, Ferrara N, King GL. Vascular 
242 
REFERENCES 
endothelial growth factor in ocular fluid of patients with diabetic retinopathy 
and other retinal disorders. N Engl J Med. 1994; 331: 1480-1487. 
158. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. 
Hypoxic induction of human vascular endothelial growth factor expression 
through c-Src activation. Nature. 1995; 375: 577-581. 
159. Chen J, Bract F, Brodsky S, Weinstein T, Romanov V, Noiri E, Goligorsky 
MS. VEGF-induced mobilization of caveolae and increase in permeability of 
endothelial cells. Am J Physiol Cell Physiol. 2002; 282: C I 053-C 1063. 
160. Roberts WG, Palade GE. Increased vascular permeability and endothelial 
fenetration induced by vascular endothelial growth factor. J Cell Sci. 1995; 
108: 2369-2379. 
161. Khamaisi M, Schrijvers BF, De Vriese AS, Raz 1, Flyvbjerg A. The emerging 
role of VEGF in diabetic kidney disease. Nephrol Dial Transplant. 2003; 
18: 1427-1430. 
162. Tbomas S, Vanuystel J, Gruden G, Rodriguez V, Burt D, Gnudi L, Hartley B, 
Viberti G. Vascular endothelial growth factor receptors in human mesangiurn 
in vitro and in glomerular disease. J Am Soc Nephrol. 2000; 11: 123 6-1243. 
163. Foster RR, Hole R, Anderson K, Satchell SC, Coward RJ, Mathieson PW, 
Gillatt DA, Saleem M, Bates DO, Harper SJ. Functional evidence that 
vascular endothelial growth factor may act as an autocrine factor on human 
podocytes. Am J Physiol Renal Physiol. 2003; 284: FI263-FI273. 
164. Kim NH, Jung HH, Cha DR, Choi DS. Expression of vascular cndothelial 
growth factor in response to high glucose in rat mesangial cells. J Endocrinol. 
2000; 165: 617-624. 
165. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita 
Z. Advanced glycation end product-induced apoptosis and overcxprcssion of 
vascular endothelial. growth factor and monocytc chcrnoattractant protcin-I in 
human-cultured mesangial cells. J Biol Chem. 2002; 277: 20309-20315. 
166. Iijima K, Yoshikawa N, Connolly DT, Nakamura 11. Human mesangial ccIls 
and peripheral blood mononuclear cells produce vascular permcability factor. 
Kidney Int. 1993; 44: 959-966. 
243 
REFERENCES 
167. Hoshi S, Nomoto K, Kuromitsu. J, Tomari S, Nagata M. High glucose induced 
VEGF expression via PKC and ERK in glomerular podocytes. Biochem 
Biophys Res Connnun. 2002; 290: 177-184. 
168. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, 
Bach LA, Kelly DJ, Gilbert RE. Increased renal expression of vascular 
endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental 
diabetes. Diabetes. 1999; 48: 2229-2239. 
169. Bortoloso E, Del Prete D, Gwnbaro G, Dalla Vestra M, Sailer A, Baggio B, 
Antonucci F, Fioretto P, Anglani F. Vascular endothelial growth factor 
(VEGF) and VEGF receptors in diabetic nephropathy: expression studies in 
biopsies of type 2 diabetic patients. Ren Fail. 2001; 23: 483493. 
170. Hovind P, Tarnow L, Oestergaard PB, Parving HH. Elevated vascular 
endothelial growth factor in type I diabetic patients with diabetic nephropathy. 
Kidney Int Suppl. 2000; 75: S56-S61 
171. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Larneire NIL 
Antibodies against vascular cndothelial. growth factor improve early renal 
dysfunction in experimental diabetes. J Am Soc Ncphrol. 200 1; 12: 993 -1000. 
172. Flyvbjerg A, Dagnaes-Hansen F, Dc Vriese AS, Schrijvers. BF, Tilton RG, 
Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic 
mice by a neutralizing vascular endothelial growth factor antibody. Diabetes. 
2002; 51: 3090-3094. 
173. Hood JD, Meininger CJ, Ziche M, Gmnger IIJ. VEGF upregulates ecNOS 
message, protein, and NO production in human endothelial cells. Am J 
Physiol. 1998; 274: HI054-HI058. 
174. Dzau VJ, Ingelfinger JR. Molecular biology and pathophysiology of the 
intrarenal renin-angiotensin system. J Hypertens. 1989; 7(Suppl 7): S3-S8. 
175. Anderson S, Jung F, Ingelfinger J. Renal renin-angiotensin system in diabetes: 
ftinctional, immunochemical and biological coffelations. Am J Physiol. 1993; 
265: F477-F486. 
176. Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Bums KD. Early 
streptozotocin-diabetes mellitus downregulates rat kidney AI2 receptors. Am J 
Physiol Renal Physiol. 2001; 280: F254-F265. 
244 
REFERENCES 
177. Bohlen L, de Courten M, Weidmann. P. Comparative study of the effect of 
ACE-inhibitors and other antihypertensive agents on proteinuria, in diabetic 
patients. Am J Hypertension. 1994; 7: 84S-92S. 
178. Chansel D, Czekalski S, Pham P, Ardaillou P, Characterization of angiotensin 
II receptor subtypes in human glomeruli and mesangial cells. Am J Physiol. 
1992; 262: F432-F441. 
179. Wolf G, Ziyadeh FN. The role of Angiotensin Il in diabetic nephropathy: 
emphasis on non-hemodynamic mechanisms. Am J Kidney Dis. 1997; 29: 153- 
163. 
180. Gilbert RE, Krum H, Wilkinson-Berka J,. Kelly DJ. T'he renin-angiotensin 
system and the long-term complications of diabetes: pathophysiological and 
therapeutic considerations Diabet Med. 2003; 20: 607-621. 
181. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates 
extracellular matrix protein synthesis through induction of transforming 
growth factor-O expression in rat glomerular mesangial cells. J Clin Invest. 
1994; 93: 2431-2437. 
182. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic 
nephropathy. Kidney Int. 2000; 77 (Suppi): S93-S98. 
183. Ding G, Reddy K, Kapasi AA, Fmnki N, Gibbons N, Kasinath BS, Singhal 
PC. Angiotensin Il induces apoptosis in rat glomerular epithelial cells. Am J 
Physiol Renal Physiol. 2002; 283: 17 1 73-F 180. 
184. Abbate M, Zoja C, Morigi M, Rottoli D, Angioletti S, Tomasoni S, Zanchi C, 
Longaretti L, Donadelli F, Remuzzi G. Transforming growth factor-ol is up- 
regulated by podocytes in response to excess intraglomerular passage of 
proteins: a central pathway in progressive glomerulosclcrosis. Am J Pathol. 
2002; 161: 2179-2193. 
185. Benio A, Remuzzi G. How renal cytokines and growth factors contribute to 
renal disease progression. Am J Kidney Dis. 200 1; 37(l Suppl 2): S21 -S24. 
186. Bohrer MP, Deen WM, Robertson CR, Brenner BM. Mechanism of 




187. Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Rernuzzi G. 
Angiotensin 11 modulates glomerular capillary permselectivity in rat isolated 
perfused kidney. J Am Soc Nephrol. 1996; 7: 653-660. 
188. Williarns B, Baker AQ, Gallacher B, Lodwick D. Angiotensin Il increases 
vascular permeability factor gene by human vascular smooth muscle cells. 
Hypertension. 1995; 25: 913-917. 
189. Ingram AJ Scholey JW. Protooncogene expression and diabetic kidney injury. 
Kidney Int. 1997; 52 (Suppl 60): S70-S76. 
190. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, 
Roberts AB. Autoinduction of transforming growth factor 01 is mediated by 
the AP- I complex. Mol Cell Biol. 1990; 10: 1492-1497. 
191. Dean DC, McQuillan JJ, Weintraub S. Serum stimulation of fibronectin gene 
expression appears to result from rapid serum-induced binding of nuclear 
proteins to a cAMP response element. J Biol Chem. 1990; 265: 3522-3527. 
192. Shankland SJ, Scholey JW. Expression of growth related protooncogenes 
during renal hypertrophy. Kidney Int. 1995; 47: 782-788. 
193. Kreisberg JI, Radnik RA, Ayo SH, Garoni J, Saikumar P. Ifigh glucose 
elevates c-fos and c-jun transcripts and proteins in mesangial cell cultures. 
Kidney Int. 1994; 46: 105-112. 
194. Kreisberg JI, Kreisberg SH. High glucose activates PKC and stimulates 
fibronectin gene expression by enhancing a cAMP responsive clement. Kidney 
Int. 1995; 48: S3-S 11. 
195. Nishizuka Y. Intracellular signalling by hydrolysis of phospholipids and 
activation of PKC. Science. 1992; 258: 607-614. 
196. King GL, Ishii H, Koya, D. Diabetic vascular dysfunction: a model of 
excessive activation of protein kinasc C. Kidney Int. 1997; 52: (Suppl 60) S77- 
S85. 
197. Messina JL, Standaert ML, Ishizuka, T, Weinstock RS, Farese RV. Role of 
protein kinase C in insulins regulation of c-fos transcription. J Biol Chcm. 
1992; 267: 9223-9228. 
246 
REFERENCES 
198. Zhang J, Wang L, Petrin J, Bishop WR, Bond RW. Characterization of site- 
specific mutants altered at protein kinase C01 isozyme autophosphorylation 
sites. Proc Nad Acad Sci USA. 1993; 90: 6130-6134. 
199. Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from 
streptozotcin diabetic rats. J Clin Invest. 1989; 83: 1667-1675. 
200. Craven PA, Davidson C, DeRubertis F. Increase in DAG mass in isolated 
glomeruli by high glucose from de novo synthesis of glycerolipids Diabetes. 
1990; 39: 667-674. 
201. Ayo SH, Radnik I, Garoni JA, Troyer DA, Kreisberg JI. High glucose 
increases diacylglycerol mass and activates protein kinase C in mesangial cell 
cultures. Am J Physiol. 199 1; 26 1: F57 I -F577. 
202. Xia P, Inoguchi T, Kem TS, Engerman RL, Oates PJ, King GL. 
Characterization of the mechanism for the chronic activation of diacylglycerol- 
protein kinase C pathway in diabetes and hypergalactosemia. Diabetes. 1994; 
43: 1122-1129. 
203. Koya D, King GL. Protein kinase C activation and the development of diabetic 
complications. Diabetes. 1998; 47: 859-866. 
204. Singh LP, Andy J, Anyamale V, Greene K, Alexander M, Crook ED. 
Hexosamine-induced fibronectin protein synthesis in mesangial cells is 
associated with increases in cAMP responsive element binding (CREB) 
phosphorylation and nuclear CREB: the involvement of protein kinases A and 
C. Diabetes. 2001; 50: 2355-2362. 
205. Studer RK, Craven PA, DeRubertis FR. Role for protein kinase C in the 
mediation of increased fibronectin accumulation by mesangial cells grown in 
high-glucose medium. Diabetes. 1993; 42: 118-126. 
206. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization 
of protein kinase CP isoform activation on the gene expression of 
transforming growth factor-0, extraccliular matrix components, and 
prostanoids in the glomeruli of diabetic rats. J Clin Invest. 1997; 100: 115-126. 
207. Koya D, Haneda M, Nakagawa 11, Isshiki K, Sato 11, Maeda S, Sugimoto T, 
Yasuda 11, Kashiwagi A, Ways DK, King GL, Kikkawa R. Amelioration of 
accelerated diabetic mesangial expansion by treatment with a PKC 0 inhibitor 
247 
REFERENCES 
in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000; 
14: 439-447. 
208. Ishii H, Jirousek MF, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern 
TS, Ballas LM, Heath VvT, Stramm LE, Feener EP, King GL. Amelioration of 
vascular dysfunctions in diabetic rats by an oral PKC P inhibitor. Science. 
1996; 272: 728-731. 
209. Menne J, Park JK, Boehne M, Elger M, Lindschau C, Kirsch T, Meier M, 
Gueler F, Fiebeler A, BahImann FH, Leitges M, Haller H. Diminished loss of 
proteoglycans and lack of albuminuria, in protein kinase C-a-dericient diabetic 
mice. Diabetes. 2004; 53: 2101-2109. 
210. Seger R, Krebs EG. The MAPK signalling cascade. FASEB J. 1995; 9: 726- 
798. 
211. Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R. Mitogen- 
activated protein kinase cascade is activated in glomeruli of diabetic rats and 
glornerular mesangial cells cultured under high glucose conditions. Diabetes. 
1997; 46: 847-853. 
212. Dunlop ME, Muggli EE. Small heat shock protein alteration provides a 
mechanism to reduce mesangial cell contractility in diabetes and oxidativc 
stress. Kidney Int. 2000; 57: 464-475. 
213. Li JH, Huang XF, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, 
Lan HY. Advanced glycation. end products activate Smad signaling via TGF-P- 
dependent and independent mechanisms: implications for diabetic renal and 
vascular disease. FASEB 12004; 18: 176-178. 
214. Wilmer WA, Dixon CL, Hebert C. Chronic exposure of human mesangial cells 
to high glucose environments activates the p38 MAPK pathway. Kidney Int. 
2001; 60: 858-871. 
215. Chang PC, Chen TH, Chang CJ, Hou CC, Chan P, Lee 11M. Advanced 
glycosylation end products induce inducible nitric oxide synthase (NOS) 
expression via a p38 MAPK-dependent pathway. Kidney Int. 2004; 65: 1664- 
1675. 
216. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N. 
Angiotensin II induces thrombospondin-I production in human mesangial cclls 
248 
REFERENCES 
via p38 MAPK and JNK: a mechanism for activation of latent TGF-p I. Am J 
Physiol Renal Physiol. 2004; 286: F278-F287. 
217. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Bottinger 
EP. Apoptosis in podocytes induced by TGF-D and Smad7. J Clin Invest. 2001; 
108: 807-816. 
218. Kimmelsteil P, Wilson C. Intercapillary lesions in the glorneruli in the kidney. 
Am J Pathol. 1936; 12: 83-97. 
219. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin- 
converting-enzyme inhibition on diabetic nephropathy. The Collaborative 
Study Group. N Engl J Med. 1993; 329: 1456-1462. 
220. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on 
progression to clinical proteinuria in patients with insulin-dependent diabetes 
mellitus and microalburninuria. European Microalburninuria Captopril Study 
Group. JAMA. 1994; 271: 275-279. 
221. Mogensen CE. Long term antihypertensive treatment inhibiting progression of 
diabetic nephropathy. Br Med J. 1982; 285: 685-688. 
222. The Microalbuminuria Captopril Study Group. Captopril reduces the risk of 
nephropathy in IDDM patients with microalbuminuria. Diabetologia. 1996; 
39: 587-593. 
223. Ravid M, Savin H, Jutrin 1, Bental T, Katz B, Lishner M. Long-tcrm 
stabilizing effect of angiotensin-converting enzyme inihibitors on plasma 
creatinine and on proteinuria in normotensive type 11 diabetic patients. Ann Int 
Med. 1993; 118: 577-581. 
224. Deferrari G, Cheli V, Robaudo C. Treatment of diabetic ncphropathy in its 
early stages. Diabetes Metab Rev. 1997; 13: 51-61. 
225. CooPer ME, Allen TJ, O'Brien RC, Macmillan PA, Clarke B, Jcrums G, Doyle 
AE. Effects of genetic hypertension on diabetic ncphropathy in the mt-- 
functional and structural characteristics. J Hypertens. 1988; 6: 1009-1016. 
226. Cooper ME, Allen TJ, O'Brien RC, Papazoglou D, Clarke BE, Jcnuns G, 
Doyle AE. Nephropathy in model combining genetic hypertension with 
experimental diabetes. Enalapril versus hydralazine and mctoprolol thcrapy. 
Diabetes. 1990; 39: 1575-1579. 
249 
REFERENCES 
227. Kvetny J, Gregersen G, Pedersen RS. Randomized placebo-controlled trial of 
perindopril in normotensive, normoalburninuric patients with type I diabetes 
mellitus. QJM. 200 1; 94: 89-94. 
228. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani F- Main risk factors 
for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean 
blood pressure, and hypcrglycemia. Arch Intern Med. 1998; 158: 998-1004. 
229. Nelson RG, Pettitt DJ, Baird HR, Charles MA, Liu QZ, Bennett P11, Knowler 
WC. Pre-diabetic blood pressure predicts urinary albumin excretion after the 
onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. 
Diabetologia. 1993; 36: 998-1001. 
230. Viberti GC, Keen H, Wiseman MJ. Raised arterial pressure in parents of 
proteinuric insulin dependent diabetics. BMJ 1987; 295: 515-517. 
231. Krolewski AS, Canessa M, Waffam JH, Laffel LM, Christlieb AR, Knowler 
WC, Rand U. Predisposition to hypertension and susceptibility to renal 
disease in insulin-dependent diabetes mellitus. N Engl J Med. 1988; 318: 140- 
145. 
232. Fogarty DG, Rich SS, Hanna L, Warram J11, Krolewski AS. Urinary albumin 
excretion in families with type 2 diabetes is heritable and genetically correlated 
to blood pressure. Kidney Int. 2000; 57: 250-257. 
233. Mangili R, Bending JJ, Scott G, Li LK, Gupta A, Viberti G. Increased sodium- 
lithium countertransport activity in red cells of patients with insulin-depcndent 
diabetes and nephropathy. N Engl J Med. 1988; 318: 146-150. 
234. Zerbini G, Gabcllini D, Ruggicri D, Maestroni A. Increased sodium-lithium 
countertransport activity: a cellular dysfunction common to essential 
hypertension and diabetic nephropathy. J Am Soc Nephrol. 2004; 15(Suppl 
1): S81-84. 
235. Trevisan F, Li LK, Messent J, Tariq T, Earle K, Walker JD, Viberti G. 
Na+/H+ antiport activity and cell growth in cultured skin fibroblasts of IDDM 
patients with nephropathy. Diabetes. 1992; 41: 1239-1246. 
236. Ng LL, Davies JE, Siczkowski M, Sweeney FP, Quinn PA, Krolcwski B, 
Krolewski AS. Abnonnal Na+/Ii+ antiportcr phcnotypc and tumovcr of 
250 
REFERENCES 
immortalized lymphoblasts from type I diabetic patients with nephropathy. J 
Clin Invest. 1994; 93: 2750-2757. 
237. Koren W, Koldanov R, Pronin VS, Postnov IY, Peleg E, Rosenthal T, Berezin 
M, Postnov YV. Enhanced erythrocyte Na+/H+ exchange predicts diabetic 
nephropathy in patients with IDDM. Diabetologia. 1998; 41: 201-205. 
238. Viberti GC. Why do we have to invoke genetic susceptibility for diabetic 
nephropathy. Kidney Int. 1999; 55: 2526-2527. 
239. Hostetter TH, Rennke H, Brenner BM. The case for intra-renal hypertension in 
the initiation and progression of diabetic and other glomerulopathies. Am J 
Med. 1982; 72: 375-380. 
240. Brenner BM. Hemodynamically mediated glomerular injury and the 
progressive nature of kidney disease. Kidney Int. 1983; 23: 647-655. 
241. Zatz R, Dunn BR, Meyer TW, Anderson-S, -Rennke-IIG, Brenner BM. 
Prevention of diabetic glomerulopathy by pharmacological amelioration of 
glornerular capillary hypertension. J Clin Invest. 1986; 77: 1925-1930. 
242. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic 
rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. 
Proc Natl Acad Sci USA. 1985; 82: 5963-5967. 
243. Mauer SM, Steffes MW, Azar S, Sandberg SK, Brown DM. Tle effects of 
Goldblatt hypertension on development of the glomerular lesions of diabetes 
mellitus in the rat. Diabetes. 1978; 27: 73 8-744. 
244. Anderson S, Rennke H, Brenner B. Therapeutic advantages of converting 
enzyme inhibitors in arresting progressive renal disease associated with 
systemic hypertension in the mt. J Clin Invest. 1986; 77: 1993-2000. 
245. Thomsen OF, Andersen AR, Christiansen JS, Deckcrt T. Renal changes in 
long-term type I (insulin-dependent) diabetic patients with and without clinical 
nephropathy: a light microscopic, morphometric study of autopsy matcrial. 
Diabetologia. 1984; 26: 361-365. 
246. Christensen PK, Hansen HP, Parving 1111. Impaired autoregulation of 
glomerular filtration rate in non insulin dependent diabetic patients with 
diabetic nephropathy. Kidney Int. 1997; 52: 1369-1374. 
251 
REFERENCES 
247. Fegan PG, Tooke JE, Gooding KM, Tullett JM, MacLeod KM, Shore AC. 
Capillary pressure in subjects with type 2 diabetes and hypertension and the 
effect of antihypertensive therapy. Hypertension. 2003; 41: 1111-1117. 
248. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, 
Raffaele J, Tsalamandris C. Long-term comparison between perindopril and 
nifedipine in normotensive, patients with type I diabetes and microalbuminuria. 
Am J Kidney Dis. 2001; 37: 890-899. 
249. Lewis EJ, Hunsicker LG, Clarke WP, Berl T, Pohl MA, Lewis JB, Ritz E, 
Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect 
of the angiotensin-receptor antagonist irbcsartan in patients with nephropathy 
due to type 2 diabetes. N Engl J Med. 2001; 345: 851-860. 
250. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving 1111, 
Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study 
Investigators. Effects of losartan on renal and cardiovascular outcomes in 
patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861- 
869. 
251. Cortes P, Riser BL, Zhao X, Narins RG. Glomerular volume expansion and 
mesangial cell mechanical strain: mediators of glomerular pressure injury. 
Kidney Int. 1994; 45(Suppl 45): S II -S 16. 
252. Cortes P, Zhao, X, Riser BL, Narins RG. Regulation of glomcrular volume in 
normal and partially nephrectomized rats. Am J Physiol. 1996; 363: 17356- 
F370. 
253. Cortes P, Zhao X, Riser BL, Narins RG. Role of glomerular mechanical strain 
in the pathogenesis of diabetic nephropathy. Kidney Int. 1997; 51: 57-68. 
254. Kriz W, Elger M, Lemley K, Sakai T. Structure of the glomcrular mcsangium. 
A biornechanical interpretation. Kidney Int. 1990; 38(Suppl 30): S2-S9. 
255. Baskin L, Howard PS, Macarak E. Effect of mcchainical forces on 
extracellular matrix synthesis by bovine urethral fibroblasts in vitro. J Urol. 
1993; 150: 637-641. 
256. Kollros PR, Bates SR, Mathews MB, Horwitz AL, Glagov S. Cyclic AMP 
inhibits increased collagen production by cyclically stretched smooth muscle 
cells. Lab Invest. 1987; 56: 410417. 
252 
REFERENCES 
257. Persson K, Sando JJ, Tuttle JB, Steers WD. Protein kinase C in cyclic stretch- 
induced nerve growth factor production by urinary tract smooth muscle cells. 
Am J Physiol. 1995; 269: C 10 1 8-C 1024. 
258. Komuro 1, Kaida T, Shibazaki Y, Kurabayashi M, Katoh Y, Hoh E, Takaku F, 
Yazaki Y. Stretching cardiac myocytes stimulates protooncogene expression. J 
Biol Chem. 1990; 265: 3595-3598. 
259. Komuro I, Kurabayashi M, Takaku F, Yazaki Y. Expression of cellular 
oncogenes in the myocardiurn during the developmental stage and pressure- 
overloaded hypertrophy of the rat heart. Circ Res. 1988; 62: 1075-1079. 
260. Komuro 1, Katoh Y, Kaida T, Shibazaki Y, Kurabayashi M, Iloh E, Takaku F, 
Yazaki Y. Mechanical loading stimulates cell hypertrophy and specific gene 
expression in cultured rat cardiac myocytes. Possible role of protein kinase C 
activation. J Biol Chem. 1991; 266: 1265-1268. 
261. Lammerding J, Kamm RD, Lee RT. Mechanotransduction in cardiac 
myocytes. Ann NY Acad Sci. 2004; 10 15: 53 -70. 
262. Kojima M, Shiojima 1, Yamazaki T, Komuro, 1, Zou Z, Wang Y, Mizuno T, 
Ueki K, Tobe K, Kadowaki T, Nagai R, Yazaki Y. Angiotensin 11 receptor 
antagonist TCV-116 induces regression of hypertensive left ventricular 
hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch- 
mediated cardiornyocyte hypertrophy in vitro. Circulation. 1994; 89: 2204- 
2211. 
263. Harris RC, Haralson MA, Badr KF. Continous strctch-rclaxation in culture 
alters rat mesangial cell morphology, growth characteristics, and metabolic 
activity. Lab Invest. 1992; 66: 548-554. 
264. Makino H, Kashihara N, Sugiyarna H, Kanao K, Sekikawa T, Okamoto K, 
Maeshima, Y, Ota Z, Nagai R. Phenotypic modulation of the mesangium 
reflected by contractile proteins in diabetes. Diabetes. 1996; 45: 488-495. 
265. Riser BL, Cortes P, Zhao X, Bernstein J, Durnier F, Narins RG. 
Intraglomerular pressure and mesangial stretching stimulate extracellular 
matrix formation in the mt. J Clin invest. 1992; 90: 1932-1943. 
253 
REFERENCES 
266. Yasuda T, Kondo S, Homma T, Harris RC. Regulation of extracellular matrix 
by mechanical stress in rat glomerular mesangial cells. J Clin Invest. 1996; 
98: 1991-2000. 
267. Riser BL, Cortes P, Yee J, Sharba AK, Asano K, Rodriguez-Barbero A, Narins 
RG. Mechanical strain- and high glucose-induced alterations in mesangial cells 
collagen metabolism: role of TGF-01. J Am Soc Nephrol. 1998; 9: 827-836. 
268. Riser BL, Cortes P, Heilig C, Grondin J, Ladson-Wofford S, Patterson D, 
Narins RG. Cyclic stretching force selectively up-regulates transforming 
growth factor-P isoforms in cultured rat mesangial cells. Am J Pathol. 1996; 
148: 1915-1923. 
269. Riser BL, Ladson-Wofford S, Sharba A, Cortes P, Drake K, Guerin CJ, Yee J, 
Choi ME, Segarini PR, Narins RG. TGF-P receptor expression and binding in 
rat mesangial cells: modulation by glucose and cyclic mechanical strain. 
Kidney Int. 1999; 56: 428-439. 
270. Hirakata M, Kanarne S, Chung UG, Joki N, Hori Y, Noda M, Takuwa Y, 
Okazaki T, Fujita T, Katoh T, Kurokawa K. Tyrosine kinasc dependent 
expression of TGF-P induced by stretch in mesangial cells. Kidney Int. 1997; 
51: 1028-1036. 
271. Akai Y, Homma T, Bums KD, Yasuda T, Badr KF, Harris RC. Mechanical 
stretch/relaxation of cultured rat mesangial cells induces protooncogenes and 
cyclooxygenase. Am J Physiol. 1994; 267: C482-C490. 
272. Homma T, Akai Y, Bums KD, Harris RC. Activation of S6 kinasc by 
repeatred cycles of stretching and relaxation in rat glomerular mesangial cells. 
Evidence for involvement of protein kinase C. J Biol Chem. 1992; 
267: 32: 23129-23135. 
273. Yasuda T, Akai Y, Kondo S, Becker BN, flomma T, Owada S, Ishida M, 
Harris RC. Alteration of cellular function in rat mcsangial cclis in response to 
mechanical stretch relaxation. In: Physical forces and Remodelling by 
Ichikawa KH. Progression of Chronic Renal Diseases. Contrib Nephrol Basel 
Karger 1996; 118: 222-228. 
254 
REFERENCES 
274. Ishida T, Haneda M, Maeda S, Koya D, Kikkawa R. Stretch-induced 
overproduction of fibronectin in mesangial. cells is mediated by the activation 
of mitogen-activated protein kinase. Diabetes. 1999; 48: 595-602. 
275. Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, Mundel P, Endlich K. 
Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol. 2001; 
12: 413-422. 
276. C. Dessapt, A. Dei Cas, M. O. Baradez, A. Hayward, R. Hargreaves, G. C. 
Viberti, L. Gnudi. Modulation of 001 integrin expression and cell adhesion in 
murine glomendar visceral epithelial cells by high glucose and mechanical 
stretch in vitro. EDSNG Congress, Bergamo, Italy, 2004. 
277. Endlich N, Sunohara M, Nietfeld W, Wolski EW, Schiwek D, Kranzlin B, 
Gretz N, Kriz W, Eickhoff 11, Endlich K. Analysis of differential gene 
expression in stretched podocytes: osteopontin enhances adaptation of 
podocytes to mechanical stress. FASEB J. 2002; 16: 1850-1852. 
278. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, 
Pichler P, Griffin S, Couser WG, Shankland SJ. Activation of a local tissue 
angiotensin system in podocytes by mechanical strain. Kidney Int. 2004; 
65: 30-39. 
279. Striker GE, Striker U. Glomerular cell culture. Lab Invest 1985; 53: 122 -13 1. 
280. Sacks S, Zhou W, Campbell RD, Martin J. C3 and C4 gene expression and 
interferon-gamma-mediated regulation in human glomcrular mesangial ccils. 
Clin Exp Immunol. 1993; 93: 411417. 
281. Morocutti A, Sethi M, Hayward A, Lee A, Vibcrti G. Glutathione reverses the 
growth abnormalities of skin fibroblasts from insulin-dcpcndent diabctic 
patients with nephropathy. J Am Soc Nephrol. 1998; 9: 1060-1066. 
282. Banes AJ, Gilbert J, Taylor D, Monbureau. 0. A new vacuum-operated stress- 
providing instruments that applies static or variable duration cycling tcnsion or 
compression to cells in vitro. J Cell Sci. 1985; 75: 35-42. 
283. Drumond MC, Deen WM. Analysis of pulsatile pressures and flows in 
glornerular filtration. Am J Physiol. 199 1; 26 IT409-419. 
284. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, 
Abraham JA. The human gene for vascular endothelial growth factor. Multiple 
255 
REFERENCES 
protein forms are encoded through alternative exon splicing. J Biol Chem. 
1991; 266: 11947-11954. 
285. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Feffara N. Vascular 
endothelial growth factor is a secreted angiogenic mitogen. Science. 1989; 
246: 1306-1309. 
286. Tso JY, Sun XH, Kao TH, Reece KS, Wu R. Isolation and characterization of 
rat and human glyceraldehyde-3 -phosphate dehydrogenase cDNAs: genomic 
complexity and molecular evolution of the gene. Nucleic Acids Res. 1985; 
13: 2485-2502. 
287. Maier JA, Voulalas P, Roeder D, Maciag T. Extension of the life-span of 
human endothelial cells by an interleukin-I a antisense oligomer. Science. 
1990; 249: 1570-1574. 
288. Gilliland G, Perrin S, Blanchard K, Bunn HE Analysis of cy-tokine mRNA and 
DNA: detection and quantitation by competittive polymerase chain reaction. 
Proc. Nad. Acad. Sci. USA. 1990; 87: 2725-2729. 
289. Celi FS, Zenilman ME, Shuldiner AR. A rapid and versatile method to 
synthesize internal standards for competitive PCR. Nucleic Acid Research. 
1993; 21: 1047. 
290. Rennard SI, Berg R, Martin GR, Foidart JM, Robey PG. Enzyme-linkcd 
Immunoassay (ELISA) for connetive tissue components. Annal Biochcm. 
1980; 104: 205-214. 
291. Choi MG, Hyncs RO. Biosynthesis and proccssing of fibronectin in NIL. 8 
hamster cells. J Biol Chem. 1979; 254: 12050-12055. 
292. Gnudi L, Frevert EU, Houseknecht KL, Erhardt P, Kahn BB. Adenovirus. 
mediated gene transfer of dominant negative ras(asnl7) in 3T3LI adipocytcs 
does not alter insulin-stimulated P13-kinase activity or glucose transport. Mot 
Endocrinol. 1997; 11: 67-76. 
293. Osterby R, Parving HH, Hommel E, Jorgensen IIE, Lokkcgaard 11. Glomerular 
structure and ftmction in diabetic nephropathy. Early to advanced stages. 
Diabetes. 1990; 39: 1057-1063. 
256 
REFERENCES 
294. Uchida K, Uchida S, Nitta K, Yumura W, Marumo F, Nihei, H. Glomerular 
endothelial cells in culture express and secrete vascular endothelial growth 
factor. Am J Physiol. 1994; 266: F81-F88. 
295. Sato K, Miki S, Tachibana, H, Hayashi F, Akiyarna T, Fukarni Y. A synthetic 
peptide corresponding to residues 137 to 157 of p60v-src inhibits tyrosine- 
specific protein kinases. Bioch Bioph Res Com. 1990; 171: 1152-1159. 
296. Fukazawa, H, Li PM, Yamamoto C, Murakami Y, Mizuno S, Uehara Y. 
Specific inhibition of cytoplasmatic protein tyrosinc kinases by herbimycin A 
in vitro. Bioch Phannacol. 199 1; 42: 1661-167 1. 
297. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D. The von Hippel-Lindau 
gene product inhibits vascular permeability factor/vascular endothelial growth 
factor expression in renal cell carcinoma by blocking protein kinase C 
pathways J Biol Chem. 1997; 272: 27509-27512. 
298. Finkcnzeller G, Marme D, Weich HA, Hug H. Platclet-derived growth factor- 
induced transcription of the vascular endothelial growth factor gene is 
mediated by protein kinase C. Cancer Res. 1992; 52: 4821-4823. 
299. Harris RC, Akai Y, Yasuda, T, Homma, T. The role of physical forces in 
alterations of mesangial cell function. Kidney Int. 1994; 45(Suppl 45): SI7- 
S21. 
300. Pan J, Singh US, Takahashi T, Oka Y, Palm-Leis A, Iferbelin BS, Baker KM. 
PKC mediates cyclic stretch-induced cardiac hypertrophy through Rho family 
GTPases and mitogen-activated protein kinases in cardiornyocytcs. J Cell 
Physiol. 2004 [Epub ahead of print]. 
301. Yamazaki T, Tobe K, Hoh E, Maemura Y,, Kaida T, Komuro, I, Tamemoto 11, 
Kadowaki T, Nagai R, Yakaki Y. Mechanical loading activates mitogcn- 
activated protein kinase and S6 peptide kinase in cultured rat cardiac 
myocytes. J Biol Chem 1993; 268: 12069-12076. 
302. Liu M, Qin Y, Liu J, Tanswell AK, Post M. Mechanical strain induces pp60src 
activation and translocation. to cytoskeleton in fetal rat lung cclls. J Biol Chem 
1996; 271: 7066-7071. 
257 
REFERENCES 
303. Hashimoto Y, Ideura T, Yoshimura A, Koshikawa S. Autoregulation of renal 
blood flow in stretptozocin-induced diabetic rats. Diabetes. 1989; 38: 1109- 
1113. 
304. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II 
mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993; 
75: 977-984. 
305. Sudhir K, Wilson E, Chattedee K, Ives HE. Mechanical strain and collagen 
potentiate mitogenic activity of angiotensin Il in rat vascular smooth muscle 
cells. J Clin Invest. 1993; 92: 3003-3007. 
306. Sato K, Yamazaki K, Shizume K, Kanaji Y, Obara T, Ohsumi K, Demura 11, 
Yamaguchi S, Shibuya M. Stimulation by thyroid-stimulating hormone and 
Graves' immunoglobulin G of vascular endothelial growth factor mRNA 
expression in human thyroid follicles in vitro and flt mRNA expression in the 
rat thyroid in vivo. J Clin Invest. 1995; 96: 1295-1302. 
307. Miura. S, Saku K, Kamik SS. Molecular analysis of the structure and function 
of the angiotensin 11 type I receptor. Hypertens Res. 2003; 26: 93743. 
308. Dudley DT, Panek RL, Major TC, Lu GH, Bruns RF, Klinkefus BA, Hodges 
JC, Weishaar RE. Subclasses of angiotensin II binding sites and their 
functional significance. Mol Pharmacol. 1990; 38: 370-377. 
309. Wong PC, Hart SD, Zaspel AM, Chiu AT, Ardecky RJ, Smith RD, 
Timmermans PB. Functional studies of nonpeptide angiotensin 11 receptor 
subtype-specific ligands: DuP753 (All-1) and PD123177 (All-2). J Pharmacol 
Exp Ther. 1990; 255: 584-592. 
310. Wolf G, Haberstroh U, Neilson EG. Angiotensin 11 stimulates the proliferation 
and biosynthesis of type I collagen in cultured murine mesangial cells. Am J 
Pathol. 1992; 140: 95-107. 
311. Naitoh M, Suzuki H, Arakawa K, Matsumoto A, Ichihara A, Matsuda 11, 
Murakami M; Nakamoto 11, Saruta T. Role of kinin and rcnal angiotcnsin 11 
blockade in the effects of ACE inhibitors in low renin hypertension. Am J 
Physiol. 1997; 272: H679-H687. 
258 
REFERENCES 
312. Seikaly MG, Arant BS Jr, Seney FD Jr. Endogenous angiotensin 
concentrations in specific intrarenal fluid compartments of the rat. J Clin 
Invest. 1990; 86: 1352-1357. 
313. Garrido C, Saule S, Gospodarowicz D. Transcriptional regulation of vascular 
endothelial growth factor gene expression in ovarian bovine granulosa cells. 
Growth Factors. 1993; 8: 109-17. 
314. Iwai N, Yamano Y, Chaki S, Konishi F, Bardhan S, Tibbetts C, Sasaki K, 
Hasegawa M, Matsuda Y, Inagami T. Rat angiotensin II receptor: cDNA 
sequence and regulation of the gene expression. Biochem Biophys Res 
Commun. 1991; 177: 299-304. 
315. Oppermann M, Freedman NJ, Alexander RW, Lcfkowitz RJ. Phosphorylation 
of the type IA angiotensin II receptor by G protein-coupled receptor kinases 
and protein kinase C. J Biol Chem. 1996; 271: 13266-13272. 
316. Anderson PW, Zhang XY, Tian J, Correale JD, Xi XP, Yang D, Graf K, Law 
RE, Hsueh WA. Insulin and angiotensin II arc additive in stimulating TGF-01 
and matrix mRNAs in mesangial cells. Kidney Int. 1996; 50: 745-753. 
317. Anderson P, Do YS, Hsueh WA. Angiotensin 11 causes mesangial cell 
hypertrophy. Hypertension 1993; 21: 29-35. 
318. Ray PE, Bruggeman LA, Horikoshi S, Aguilera G, Kjotman PE. Angiotensin 
II stimulates human fetal mesangial cell proliferation and fibroncctin 
biosynthesis by binding to ATI receptors. Kidney Int. 1994; 45: 177-184. 
319. Koibuchi Y, Lee WS, Gibbons GI-1, Pratt RE. Role of transforming growth 
factor-P I in the cellular growth response to angiotcnsin 11.1 lypertension. 1993; 
21: 1046-1050. 
320. Itoh H, Mukoyama M, Pratt RE, Gibbons GII, Dzau VJ. Multiple autocrine 
growth factors modulate vascular smooth muscle cell growth response to 
angiotensin Il. i Clin invest 1993; 91: 2268-2274. 
321. Yamazaki T, Komuro 1, Kudoh S, Zou Y, Shiojima 1, Mizuno T, Takano 11, 
Hiroi Y, Ueki K, Tobe K, Kadowaki T, Nagai R, Yazaki Y. Angiotensin 11 
partly mediates mechanical stress-induccd cardiac hypertrophy. Circ Rcs. 
1995; 77: 258-265. 
259 
REFERENCES 
322. Flyvbjerg A. Role of growth hormone, insulin-like growth factors (IGFs) and 
IGF-binding proteins in the renal complications of diabetes. Kidney Int. 1997; 
52(Suppl 60): SI2-SI9. 
323. Flyvbjerg A, Bennett WF, Rasch R, Kopchick JJ, Scarlett JA. Inhibitory effect 
of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, 
glomerular hypertrophy, and urinary albumin excretion in experimental 
diabetes in mice. Diabetes. 1999; 48: 377-382. 
324. Sugimoto H, Shikata K, Makino, H, Ota K, Ota Z. Increased gene expression of 
insulin-like growth factor-I receptor in experimental diabetic rat glomeruli. 
Nephron. 1996; 72: 648-653. 
325. Landau D, Chin E, Bondy C, Domene H, Roberts CT Jr, Gronbaek 11, 
Flyvbjerg A, LeRoith D. Expression of insulin-like growth factor binding 
proteins in the rat kidney: Effects of long-term diabetes. Endocrinology. 1995; 
136: 1835-1842. 
326. Conti FG, Striker IJ, Lesniak MA, MacKay K, Roth J, Striker GE. Studies on 
binding and mitogenic effect of insulin and insulin-like growth factor I in 
glomerular mesangial cells. Endocrinology. 1988; 122: 2788-2795. 
327. Nissley P, Lopaczynski W. Insulin-like growth factor receptors. Growth 
Factors. 1991; 5: 2943. 
328. Li YM, Schacher DH, Liu Q, Arkins S, Rebeiz N, McCusker R11 Jr, Dantzcr 
R, Kelley KW. Regulation of myeloid growth and differentiation by the 
insulin-like growth factor I receptor. Endocrinology. 1997; 138: 362-368. 
329. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB. Induction of vascular 
endothelial growth factor by insulin-like growth factor I in colorectal 
carcinoma. J Biol Chem. 1996; 271: 29483-29488. 
330. Kaliman P, Canicio J, Shepherd PF, Beeton CA, Testar X, Palacin M, Zorzano 
A. Insulin-like growth factors require phosphatidylinositol 3-kinase to signal 
myogenesis: dominant negative p85 expression blocks differentiation of 1,6139 
muscle cells. Mol Endocrinol. 1998; 12: 66-77. 
331. Duan C, Bauchat JR, Hsieh T. Phosphatidylinositol 3-kinase is required for 
insulin-like growth factor-l-induced vascular smooth muscle cell proliferation 
and migration. Circ Res. 2000; 86: 15-23. 
260 
REFERENCES 
332. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, 
Pollok BA, Connelly PA. Discovery of a novel, potent, and Src family- 
selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell 
activation. J Biol Chem. 1996; 271: 695-701. 
333. Pricci F, Pugliese G, Romano G, Romeo G, Locuratolo N, Pugliese F, Mene, P, 
Galli G, Casini A, Rotella CM, Di Mario U. Insulin-like growth factors I and 11 
stimulate extracellular matrix production in human glomerular mesangial cells. 
Comparison with transforming growth factor-P. Endocrinology. 1996; 
137: 879-885. 
334. Conti FG, Striker LJ, Elliot SJ, Andreani D, Striker GE. Synthesis and release 
of insulin-like growth factor I by mesangial cells in culture. Am J Physiol. 
1988; 255: FI214-FI219. 
335. Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K, Levy AP, Levy 
NS, Goldberg MA, D'Amato RJ, Adamis AP. Regulation of vascular 
endothelial growth factor expression by insulin-like growth factor I. Diabetes. 
1997; 46: 1619-1626. 
336. Bermont L, Lamielle F, Fauconnet S, Esumi H, Weisz A, Adessi GL. 
Regulation of vascular endothelial growth factor expression by insulin-like 
growth factor-I in endometrial adenocarcinorna cells. Int J Cancer. 2000; 
85: 117-123. 
337. Abrass CK, Raugi GJ, Gabourel. LS, Lovett DII. Insulin and insulin-likc 
growth factor I binding to cultured rat glornerular mesangial cells. 
Endocrinology. 1988; 123: 2432-2439. 
338. Gao N, Shen L, Zhang Z, Leonard SS, He H, Zhang XG, Shi X, Jiang B11. 
Arsenite induces HIF-la and VEGF through P13K, Akt and reactive oxygen 
species in DU145 human prostate carcinoma cells. Mol Cell Biochem. 2004; 
255: 33-45. 
339. Mazure NM, Chen EY, Laderoute KF, Giaccia AJ. Induction of vascular 
endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3- 
kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia 
inducible factor- I transcriptional element. Blood. 1997; 90: 3322-333 1. 
261 
REFERENCES 
340. Goad DL, Rubin J, Wang H, Tashjian AH Jr, Patterson C. Enhanced 
expression of vascular endothelial growth factor in human SaOS-2 osteoblast- 
like cells and murine osteoblasts induced by insulin-like growth factor I. 
Endocrinology. 1996; 137: 2262-2268. 
341. Miele C, Rochford JJ, Filippa N, Giorgctti-Pcraidi S, Van Obbcrghcn E. 
Insulin and insulin-like growth. factor-I induce vascular endothelial growth 
factor mRNA expression via different signaling pathways. J Biol Chem. 2000; 
275: 21695-21702. 
342. Fredriksson JM, Lindquist JM, Bronnikov GE, Nedergaard J. Norepinephrine 
induces vascular endothelial growth factor gene expression in brown 
adipocytes through a 0-adrenoreceptor/cAMP/protein kinase A pathway 
involving Src but independently of Erkl/2. J Biol Chem. 2000; 275: 13802- 
13811. 
343. Urso B, Cope DL, Kalloo-Hosein HE, Hayward AC, %itehead JP, O'Rahilly 
S, Siddle K. Differences in signaling properties of the cytoplasmic domains of 
the insulin receptor and insulin-like growth factor receptor in 3T3-LI 
adipocytes. J Biol Chem. 1999; 274: 30864-30873. 
344. Hirschberg R, Kopple JD, Blantz RC, Tucker BL Effects of recombinant 
human insulin-like growth factor I on glomerular dynamics in the mt. J Clin 
Invest. 1991; 87: 1200-1206. 
345. Oemar BS, Foellmer HG, Hodgdon-Anandant L, Rosenzweig SA. Regulation 
of insulin-like growth factor I receptors in diabetic mesangial cells. J Biol 
Chem. 1991; 266: 2369-2373. 
346. Hiragushi K, Sugimoto H, Shikata Ir, Yamashita T, Mi yatake N, Shikata Y, 
Wada J, Kumagai 1, Fukushima M, Makino 11. Nitric oxide system is involved 
in glomerular hyperfiltration in Japanese norTno- and micro-albuminuric 
patients with type 2 diabetes. Diabetes Res Clin Pract. 2001; 53: 149-159. 
347. Gifford SM, Grummer MA, Pierre SA, Austin JL, Zheng J, Bird IM. 
Functional characterization of IIUVEC-CS: Ca(++) signaling, ERK 1/2 




348. Tonshoff B, Kaskel FJ, Moore LC. Effects of insulin-like growth factor I on 
the renal juxtarnedullary microvasculature. Am J Physiol. 1998; 274TI20- 
F128. 
349. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Caballero S, Chegini N, Guy J. 
Insulin-like growth factor I as an angiogenic agent. In vivo and in vitro studies. 
Ann NY Acad Sci. 1993; 692: 230-242. 
350. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in 
ocular neovascularization and proliferative diabetic retinopathy. Diabetes 
Metab Rev. 1997; 13: 3 7-5 0. 
351. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver 
S, Bischoff J, Zhang B, Schaeffer JM, Senger DR. Regulation of vascular 
endothelial growth factor-dependent retinal neovascularization by insulin-like 
growth factor-I receptor. Nat Med. 1999; 5: 1390-1395. 
352. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albcrtsson- 
Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith 
LE. Low IGF-l suppresses VEGF-survival signaling in retinal endothelial 
cells: Direct correlation with clinical retinopathy of prematurity. Proc Natl 
Acad Sci USA. 2001; 98: 5804-5808. 
353. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE. Secreted protein 
acidic and rich in cysteine expression after subtotal nephrectomy and blockade 
of the renin-angiotensin system. J Am Soc Nephrol. 1997; 8: 1373-1382. 
354. Kleeff J, Korc M. Up-regulation of transforming growth factor (TGF)-P 
receptors by TGF-P I in COLO-357 cells. J Biol Chem. 1998; 273: 7495-7500. 
355. Lee LK, Meyer TW, Pollock AS, Lovett DII. Endothelial cell injury initiates 
glomerular sclerosis in the rat remnant kidney. J Clin Invest. 1995; 96: 953- 
964. 
356. Raingeaud J, Gupta S, Rogers J, Dickens M, Ilan J, Ulevitch RJ, Davis Ri. 
Pro-inflammatory cytokines and environmental stress cause p38 MAP kinase 
activation by dual phosphorylation on tyrosinc and thrconine. J Biol Chem. 
1995; 270: 7420-7426. 
357. Han J, Lec JD, Bibbs L, Ulevitch. A MAP kinase targctcd by cndotoxin and 
hyperosmolarity in mammalian cells. Science. 1995; 265: 808-811. 
263 
REFERENCES 
358. Hannigan M, Zhan L, Ai Y, Huang CK. The role of p38 MAP kinase in TGF- 
01-induced signal transduction in human neutrophils. Biochern Biophys Res 
Commun. 1998; 246: 55-58. 
359. Adhikary L, Chow F, Nikolic-Paterson DJ, Starnbe C, Dowling J, Atkins RC, 
Tesch GH. Abnormal p38 mitogen-activated protein kinase signalling in 
human and experimental diabetic nephropathy. Diabctologia. 2004; 47: 1210- 
1222. 
360. Janknecht R, Hunter T. Convergence of MAP kinase pathways on the ternary 
complex factor SAP-1 a. EMBO J. 1997; 16: 1620-1627. 
361. Kletsas D, Basdra EK, Papavassiliou AG. Effect of protein kinase inhibitors on 
the stretch-elicited c-Fos and c-Jun up-regulation in human PDL ostcoblast- 
like cells. J Cell Physiol. 2002; 190: 313-321. 
362. Gupta S. Campbell D. Derijard B. Davis RJ. Transcription factor ATF2 
regulation by the JNK signal transduction pathway. Science. 1995; 267: 389- 
393. 
363. Furukawa F, Matsuzaki K, Mori S, Tahashi Y, Yoshida K, Sugano y, 
Yamagata H, Matsushita M, Seki T, Inagaki Y, Nishizawa M, Fujisawa J, 
Inoue K. p38 MAPK mediates fibrogenic signal through Smad3 
phosphorylation in rat myofibroblasts. Ilepatology. 2003; 38: 879-889. 
364. Kim SJ, Denhez F, Kim KY, Holt JT, Sporn MB, Roberts AB. Activation of 
the second promoter of the transforming growth factor-Ol gene by 
transfonning growth factor-PI and phorbol ester occurs through the same 
target sequences. J Biol Chem. 1985; 264: 19373-19378. 
365. Muro AF, Bernath VA, Komblihtt AR. Interaction of the 170 cyclic AMP 
response element with the adjacent CCAAT box in the human fibronectin gene 
promoter. J Biol Chem. 1992; 267: 12767-12774. 
366. Sassone-Corsi P, Ransone IJ, Verma IM. Cross-talk in signal transduction: 
TTA-inducible factorjun/AP-1 activates cAMP-rcsponsive enhancer elements. 
Oncogene. 1990; 5: 427-431. 
367. Ingram AJ, Ly H, Thai K, Kang M, Scholey JW. Activation of mcsangial ccil 




368. Tong L, Pav S, White DM, Rogers S, Crane KM, Cywin CL, Brown ML, 
Pargellis CA. A highly specific inhibitor of human p38 MAP kinase binds in 
the ATP pocket. Nat Struct Biol. 1997; 4: 311-316. 
369. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, 
Lee JC. SB203580 is a specific inhibitor of a MAP kinase homologue which is 
stimulated by cellular stresses and interleukin-1. FEBS Letters. 1995; 364: 229- 
233. 
370. Rausch 0, Marshall CJ. Cooperation of p38 and extracellular signal-regulated 
kinase mitogen-activated protein kinase pathways during granulocyte colony- 
stimulating factor-induced hemopoietic cell proliferation. J Biol Chem. 1999; 
274: 4096-4105. 
371. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, 
McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, 
McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, 
Young PR. A protein kinase involved in the regulation of inflammatory 
cytokine biosynthesis. Nature. 1994; 372: 739-746. 
372. Wbitmarsh AJ, Yang SH, Su MS, Sharrocks ADv Davis RJ. Role of p38 and 
JNK mitogen-activated protein kinases in the activation of ternary complex 
factors. Mol Cell Biol. 1997; 17: 2360-2371. 
373. Igarashi M, Wakasaki H, Takahara. N, Ishii H, Jiang ZY, Yamauchi T, Kuboki 
K, Meier M, Rhodes CJ, King GL- Glucose or diabetes activates p38 mitogen- 
activated protein kinase via different pathways. J Clin Invest. 1999; 103: 185- 
195. 
374. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi 1, Ueno N, Taniguchi T, 
Nishida, E, Matsumoto K. Identification of a member of the MAPKKK family. 
as a potential mediator of TGF-P1 signal transduction. Science. 1995; 
270: 2008-2011. 
375. Kusuhara M, Takahashi E, Peterson TE, Abe J, Ishida M, Ilan J, Ulevitch R, 
Berk BC. p38 Kinase is a negative regulator of angiotensin 11 signal 
transduction in vascular smooth muscle cells: effects on Na+/I I+ exchange and 
ERKI/2. Circ Res. 1998; 83: 824-83 1. 
265 
REFERENCES 
376. Choukroun G, Haijar R, Kyriakis JM, Bonventre JV, Rosenzweig A, Force T. 
Role of the stress-activated protein kinase in endothelin-induced 
cardiornyocytes hypertrophy. J Clin Invest. 1998; 102: 1311-1320. 
377. Kawata Y. Mizukami Y. Fujii Z. Sakumura T. Yoshida K. Matsuzaki M. 
Applied pressure enhances cell proliferation through mitogen-activated protein 
kinase activation in mesangial cells. J Biol Chem. 1998; 273: 16905-16912. 
378. Nernoto S, Sheng Z, Lin A. Opposing effects of Jun kinase and p38 mitogen- 
activated protein kinases on cardiornyocyte hypertrophy. Mol Cell Biol. 1998; 
18: 3518-3526. 
379. Rai L. Nitric oxide in hypertension: relationship with renal injury and left i 
ventricular hypertrophy. Hypertension. 1998; 31: 189-193. 
380. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and 
progressive glomerular damage in Dahl rats. Kidney Int. 1984; 26: 137-143. 
381. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating 
experimental diabetic nephropathy. Diabetologia. 2001; 44: 1957-1972. 
382. Cao Z, Cooper ME, Wu LL, Cox AJ, Jandeleit-Dahm K, Kelly DJ, Gilbert RE. 
Blockade of the renin-angiotensin and endothelin systems on progressive renal 
injury. Hypertension. 2000; 36: 561-568. 
383. Perico N, Rernuzzi G. Angiotensin II receptor antagonists and treatment of 
hypertension and renal disease. Curr Opin Ncphrol Hypcrtens. 1998; 7: 571- 
578. 
384. Wakisaka M, He Q, Spiro MJ, Spiro RG. Glucose entry into rat mcsangial 
cells is mediated by both Na(+)-coupled and facilitative transporters. 
Diabetologia. 1995; 38: 291-297. 
385. Mueckler M. Facilitative glucose transporters. Eur J Biochcm. 1994; 219: 713- 
725. 
386. Heilig CW, Brosius FC 3rd, Henry DN. Glucose transporters of the glomcrulus 
and the implications for diabetic nephropathy. Kidney Int. 1997; 52: S91-S99, 
387. Tamaki K, Okuda S, Nakayama M, Yanagida T, Fujishima M. Transforming 
growth factor-01 in hypertensive renal injury in Dahl salt-scnsitivc rats. J Am 
Soc Nephrol. 1996; 7: 2578-2589. 
266 
REFERENCES 
388. Hayakawa H, Raij L. Nitric oxide synthase activity and renal injury in genetic 
hypertension. Hypertension. 1998; 31: 266-270. 
389. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury 
in experimental salt-sensitive hypertension: effects of antihypertensive therapy. 
Circulation. 1997; 96: 2407-2413. 
390. Rapp JP. Dahl salt-susceptible and salt-resistant rats. Hypertension. 1982; 
4: 753-763. 
391. Azar S, Limas C, Iway J, Weller D. Single nephron dynamics during high 
sodium intake and early hypertension in Dahl rats. Jpn Heart J. 1979; 20(Suppl 
1): 138-140. 
392. Arendshorst WJ, Beierwaltes WH. Renal and nephron hemodynamics in 
spontaneously hypertensive rats. Am J Physiol. 1979; 236: F246-F25 1. 
393. Takenaka T, Forster H, De Micheli A, Epstein M. Impaired myogenic 
responsiveness of renal microvessels in Dahl salt-sensitive rats. Circ Res. 
1992; 71: 471-480. 
394. Dworkin LD, Feiner HD. Glomerular injury in uninephrectornized 
spontaneously hypertensive rats: a consequence of glomerular capillary 
hypertension. J Clin Invest. 1986; 77: 797-809. 
395. Nagase M, Kaname S, Nagase T, Wang G, Ando K, Sawamura T, Fujita T. 
Expression of LOX-1, an oxidized low-density lipoprotein receptor, in 
experimental hypertensive glomerulosclcrosis. J Am Soc Nephrol. 2000; 
11: 1826-1836. 
396. Yamauchi T, Ogura T, Oishi T, Omiya T, Ota Z. The angiotensin 1-converting 
enzyme inhibitor, cilazapril inhibits the platelet-derived growth factor B chain 
expression in glomeruli of spontaneously hypertensive rats. Ren Physiol 
Biochern. 1995; 18: 237-245. 
397. otsuka F, Yamauchi T, Kataoka H, Mimura Y, Ogura T, Makino 11. Effects of 
chronic inhibition of ACE and ATI receptors on glomerular injury in Dahl 
salt-sensitive rats. Am J Physiol. 1998; 274: 111 797-R 1806. 
398. Dahly AJ, Hoagland KM, Flasch AK, iha S, Ledbetter SR, Roman RJ. 
Antihypertensive effects of chronic anti-TGF-0 antibody therapy in Dahl S 
rats. Am J Physiol Regul Integr Comp Physiol. 2002; 283: 11757-11767. 
267 
REFERENCES 
399. D'Agord Schaan B, Lacchini S, Bertoluci MC, Irigoyen MC, Machado UF, 
Schmid H. Increased renal GLUTI abundance and urinary TGF-P1 in 
streptozotocin-induced diabetic rats: implications for the development of 
nephropathy complicating diabetes. Horrn Metab Res. 2001; 33: 664-669. 
400. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of 
chronic renal diseases. Lancet. 2001; 357: 1601-1608. 
401. Fagerudd JA, Tarnow L, Jacobsen P, Stenman S, Nielsen FS, Pettersson- 
Fernholm. KJ, Gronhagen-Riska C, Parving HH, Groop PH. Predisposition to 
essential hypertension and development of diabetic nephropathy in IDDM 
patients. Diabetes. 1998; 47: 439-444. 
402. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from 
ACEI to angiotensin II antagonists. Kidney Int. 2000; 57: 1803-1817. 
268 
